Technologies for oligonucleotide preparation

JP2024105256A5Pending Publication Date: 2024-11-06WAVE LIFE SCI LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024063134
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-09-18
Filing Date
2024-04-10
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Natural oligonucleotides suffer from low stability and activity, which limits their effectiveness as therapeutic agents, and conventional synthesis methods lead to high impurity levels and reduced yield due to uncontrolled stereochemistry and reactive functional groups.

Method used

Implementing a modified capping strategy in oligonucleotide synthesis that includes pre- and post-modification capping steps with reduced nucleophile levels and selective amidation conditions to control stereochemistry, reducing impurities and improving yield and purity.

Benefits of technology

The method achieves crude purity of over 70% for stereocontrolled oligonucleotides, significantly higher than conventional methods, with improved efficiency and reduced manufacturing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.SOLUTION: The present invention provides a method comprising the following steps: a) a coupling step; b) a pre-modification capping step; c) a modification step; d) a post-modification capping step; e) optionally a de-blocking step; and f) optionally repeating steps b) through e) a number of times.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 560,169, filed September 18, 2017, which is incorporated herein by reference in its entirety. [Background technology]

[0002] Oligonucleotides can contain a variety of modifications. Certain modifications, such as phosphorothioate internucleotide linkages, can introduce novel chiral centers into the oligonucleotide. Summary of the Invention

[0003] Oligonucleotides are useful for many purposes, however, natural oligonucleotides are known to have drawbacks, such as low stability and low activity, which can reduce or negate their usefulness as therapeutic agents.

[0004] Certain techniques have been developed that can improve the properties and utility of oligonucleotides. For example, certain modifications, such as modifications to nucleobases, sugars, and / or internucleotide linkages, that can improve the properties and utility of oligonucleotides have been described. Furthermore, techniques that allow for the preparation of stereochemically controlled and / or stereocontrolled oligonucleotides have been demonstrated to provide particularly useful and effective oligonucleotide compositions. Specific useful exemplary techniques are described in, for example, one or more of U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, etc. (each of which is incorporated herein by reference).

[0005] In particular, given the demonstrated desirability and utility of stereocontrolled oligonucleotide compositions, Applicant has realized that it would be of great benefit to develop techniques that could improve or expedite the manufacture of oligonucleotide compositions, particularly stereocontrolled oligonucleotide compositions. The present disclosure describes certain such developments and provides techniques relating to oligonucleotide compositions, particularly stereocontrolled oligonucleotide compositions. The provided techniques may be particularly useful, for example, with respect to therapeutic oligonucleotides.

[0006] Among other things, the present disclosure encompasses the recognition that certain conditions and / or sequences of steps utilized in the preparation of oligonucleotides, particularly stereocontrolled (e.g., stereopure) oligonucleotide compositions, can be associated with the occurrence of certain impurities. In some embodiments, the present disclosure therefore identifies the source of the problem in strategies utilizing such conditions and / or steps; the present disclosure provides techniques, including methods, utilizing certain conditions and / or sequences of steps that are described and demonstrated to dramatically improve crude product purity and yield, in some embodiments, significantly improve efficiency and / or reduce production costs. For example, as demonstrated in the Examples, in some embodiments, the provided techniques can provide chirally controlled oligonucleotide compositions with crude purity (full-length product purity) of greater than 70%, far greater than reference techniques (where full-length product crude purity may be about 30% or less).

[0007] Oligonucleotide synthesis typically utilizes highly efficient chemical transformations in its steps. However, despite this high efficiency, the product of one or more steps may contain one or more reactive functional groups that, in the absence of capping, can introduce significant amounts of impurities, such as an unreacted 5'-OH group for coupling products and / or reactive groups (e.g., primary and / or secondary amino groups) newly formed when chiral auxiliaries are used in chiral-controlled oligonucleotide synthesis. Often, such reactive functional groups are capped during oligonucleotide synthesis to reduce the impurities resulting therefrom. In some embodiments, the present disclosure encompasses the recognition of the source of the problem that capping steps, such as those typically used in conventional phosphoramidite-based oligonucleotide synthesis, can lead to the generation of significant amounts of by-products, particularly for many chiral-controlled (stereocontrolled, stereoselective) oligonucleotide synthesis processes. Among other things, the present disclosure provides techniques that address these issues.

[0008] In some embodiments, the present disclosure provides methods that include a post-modification capping step, e.g., after the modification step but before the subsequent deblocking and / or coupling step. In some embodiments, the post-modification capping step is after the modification step that provides a chiral-controlled internucleotide linkage but before the subsequent deblocking and / or coupling step.

[0009] In some embodiments, the present disclosure provides methods that include a capping step with a different chemistry strategy compared to a reference capping step in conventional oligonucleotide synthesis. For example, in some embodiments, the present disclosure provides methods that include one or more capping steps, each of which selectively caps amino groups over hydroxyl groups (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis). In some embodiments, the provided capping step is selective for amidation over esterification. In some embodiments, the capping reagent system for the capping step contains no or reduced levels of strong nucleophiles and / or esterification catalysts (or reagents that can provide them when contacted with the composition to be capped) (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis), such as no or reduced levels of DMAP, NMI, etc. In some embodiments, the present disclosure provides methods that include a capping step that can efficiently cap both amino groups and hydroxyl groups, e.g., a capping step that is equivalent or identical to a reference capping step in conventional oligonucleotide synthesis.

[0010] In some embodiments, the present disclosure provides methods for achieving oligonucleotide synthesis that include capping steps with the same or different chemistry strategies and can provide various advantages, such as improved crude purity and improved yield, particularly for chiral (stereocontrolled, stereoselective) oligonucleotide synthesis. In some embodiments, the present disclosure provides methods with a pre-modification capping step (after a coupling step but before the next modification step) and a post-modification capping step (after a modification step but before the next deblocking and / or coupling step). In some embodiments, the pre-modification capping step and the post-modification capping step are different. In some embodiments, the pre-modification capping step and the post-modification capping step have different chemistry strategies. In some embodiments, the pre-modification capping step selectively caps amino groups over hydroxyl groups (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis). In some embodiments, the post-modification capping step can cap both amino and hydroxyl groups (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis). In some embodiments, the pre-modification capping step selectively caps amino groups over hydroxyl groups (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis). In some embodiments, the pre-modification capping step can cap both amino and hydroxyl groups (e.g., compared to a reference capping reagent system in conventional oligonucleotide synthesis).

[0011] In some embodiments, provided methods include two or more capping steps in an oligonucleotide synthesis cycle. In some embodiments, provided methods include two capping steps in an oligonucleotide synthesis cycle, wherein the two steps are separated by a modification step, e.g., oxidation, sulfurization, etc. In some embodiments, provided methods include a step in which a chiral modified internucleotide linkage containing a chiral linked phosphorus is favorably formed in either the Rp or Sp configuration with a stereoselectivity of at least 80:20, 85:15, 90:10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2, or 99:1.

[0012] In some embodiments, the present disclosure provides: providing a chiral nucleoside phosphoramidite containing a chiral atom which is not a phosphorus atom or a sugar carbon atom; and A capping step immediately following the sulfurization or oxidation step The present invention provides a method comprising:

[0013] In some embodiments, the present disclosure provides: providing a chiral nucleoside phosphoramidite containing a chiral atom which is not a phosphorus atom and which is not an atom of a nucleoside unit; and A capping step immediately following the sulfurization or oxidation step The present invention provides a method comprising:

[0014] In some embodiments, the present disclosure provides: providing an oligonucleotide intermediate comprising a chiral linking phosphorus atom linked to a chiral unit that does not comprise a nucleoside unit or portion thereof; and A capping step immediately following the sulfurization or oxidation step The present invention provides a method comprising:

[0015] In some embodiments, the present disclosure provides: providing an oligonucleotide intermediate containing a chiral linking phosphorus atom linked to a chiral unit that does not contain an atom of a nucleoside unit; and A capping step immediately following the sulfurization or oxidation step The present invention provides a method comprising:

[0016] In some embodiments, the present disclosure provides a method for preparing a composition comprising a plurality of oligonucleotides, the method comprising: a) a coupling step, contacting a deblocked composition (deblocked oligonucleotide composition) comprising a plurality of deblocked oligonucleotides or nucleosides, each independently deblocked in that it contains a free hydroxyl group, with a coupling reagent system comprising a partner compound comprising a nucleoside unit; and Coupling a partner compound to the free hydroxyl groups of multiple deblocked oligonucleotides or nucleosides. Includes; a coupling step, providing a coupling product composition comprising a plurality of coupling product oligonucleotides, each independently comprising an internucleotide bond linking a hydroxyl group of the deblocked oligonucleotide to a nucleoside unit of a partner compound; b) optionally a pre-modification capping step, contacting the coupling product composition with a pre-modification capping reagent system; and Capping one or more functional groups of the coupling product composition Includes; a pre-modification capping step to provide a pre-modification capping product composition comprising a plurality of pre-modification capping product oligonucleotides; c) a modification step, contacting the coupling product composition with a modification reagent system comprising a modification reagent and modifying one or more internucleotide linkages of one or more coupling product oligonucleotides; or contacting the pre-modified capping product composition with a modification reagent system and modifying one or more bonds of one or more pre-modified capping product oligonucleotides; Includes; a modifying step providing a modified product composition comprising a plurality of modified product oligonucleotides; d) optionally a post-modification capping step, contacting the modified product composition with a post-modification capping reagent system; and Capping one or more functional groups of a plurality of oligonucleotides of the modified product composition Includes; a post-modification capping step to provide a post-modification capping product composition comprising a plurality of post-modification capping product oligonucleotides; e) optionally a deblocking step, contacting the modified product composition or the modified post-capping product composition with a deblocking reagent system Includes; a deblocking step to provide a deblocked product composition comprising a plurality of deblocked product oligonucleotides, each independently comprising a free hydroxyl group; and f) Optionally, repeating steps b) through e) multiple times. Includes.

[0017] In some embodiments, the provided methods include one or more pre-modification capping steps. In some embodiments, the provided methods include one or more post-modification capping steps. In some embodiments, the provided methods include one or more pre- and post-modification capping steps. In some embodiments, the provided methods include one or more deblocking steps.

[0018] In some embodiments, the disclosure provides a method of preparing a composition comprising a plurality of oligonucleotides, the method comprising one or more cycles, each cycle independently comprising: a) a coupling step, contacting a deblocked composition (deblocked oligonucleotide composition) comprising a plurality of deblocked oligonucleotides or nucleosides, each independently deblocked in that it contains a free hydroxyl group, with a coupling reagent system comprising a partner compound comprising a nucleoside unit; and Coupling a partner compound to the free hydroxyl groups of multiple deblocked oligonucleotides or nucleosides. Includes; a coupling step, providing a coupling product composition comprising a plurality of coupling product oligonucleotides, each independently comprising an internucleotide bond linking a hydroxyl group of the deblocked oligonucleotide to a nucleoside unit of a partner compound; b) optionally a pre-modification capping step, contacting the coupling product composition with a pre-modification capping reagent system; and Capping one or more functional groups of the coupling product composition Includes; a pre-modification capping step to provide a pre-modification capping product composition comprising a plurality of pre-modification capping product oligonucleotides; c) a modification step, contacting the coupling product composition with a modification reagent system comprising a modification reagent and modifying one or more internucleotide linkages of one or more coupling product oligonucleotides; or contacting the pre-modified capping product composition with a modification reagent system and modifying one or more bonds of one or more pre-modified capping product oligonucleotides; Includes; a modifying step providing a modified product composition comprising a plurality of modified product oligonucleotides; d) optionally a post-modification capping step, contacting the modified product composition with a post-modification capping reagent system; and Capping one or more functional groups of a plurality of oligonucleotides of the modified product composition Includes; a post-modification capping step to provide a post-modification capping product composition comprising a plurality of post-modification capping product oligonucleotides; e) optionally a deblocking step, contacting the modified product composition or the modified post-capping product composition with a deblocking reagent system Includes; a deblocking step to provide a deblocked product composition comprising a plurality of deblocked product oligonucleotides, each independently comprising a free hydroxyl group; Includes.

[0019] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, the method comprising one or more cycles, each of the cycles independently comprising the steps of: (1) Coupling step; (2) optionally, a pre-modification capping step; (3) modification step; (4) optionally, a post-modification capping step; and (5) Deblocking step Includes.

[0020] In some embodiments, the cycle includes one or more pre-modification capping steps. In some embodiments, the cycle includes one or more post-modification capping steps. In some embodiments, the cycle includes one or more pre- and post-modification capping steps. In some embodiments, the cycle includes one or more deblocking steps.

[0021] In some embodiments, the present disclosure encompasses the recognition that conventional capping conditions, when used as is in conventional oligonucleotide synthesis, can be a significant source of problems under certain circumstances and can contribute to the formation of one or more by-products (impurities) and significantly lower crude oligonucleotide purity and yield, particularly for the stereoselective preparation of oligonucleotides containing one or more chiral internucleotide linkages. Among other things, the present disclosure provides techniques that include capping strategies that can result in surprisingly high crude impurities and yields compared to appropriate reference techniques, for example, by using a designed capping strategy in combination with other steps in oligonucleotide synthesis.

[0022] In some embodiments, the referenced techniques use conventional capping conditions as in conventional phosphoramidite-based oligonucleotide synthesis to contact an oligonucleotide and cap hydroxyl groups (e.g., unreacted 5'-OH groups), which are typically or include esterification conditions to acylate hydroxyl groups, for example, by using a mixture including an acylating agent (e.g., acetic anhydride), a base (e.g., 2,6-lutidine), and a catalyst (e.g., N-methylimidazole, DMAP, etc.). Conventional capping conditions typically employ substantial amounts of acylating agent, base, and catalyst for capping, generally each independently, about 5% to 15% by volume and / or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 equivalents relative to the initial nucleoside incorporated into the oligonucleotide (prior to any cycle that forms an internucleotide bond) or the oligonucleotide loading capacity of the support (e.g., the loading capacity of a support used to prepare an oligonucleotide can be calculated by multiplying the unit loading capacity of the support (e.g., umol / g) by the amount of support (g)). In some embodiments, as used in conventional oligonucleotide synthesis, each synthesis cycle of the reference technology includes a single capping step. In some embodiments, the referenced technique includes only one capping step in each of its synthesis cycles, where capping is performed using esterification conditions including, for example, an acylating agent (e.g., acetic anhydride), a base (e.g., 2,6-lutidine), and a catalyst (e.g., N-methylimidazole (NMI), DMAP, etc.) (each independently at about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% by volume or more of the capping reagent solution and / or the catalyst at about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.5, or 2 equivalents or more relative to the acylating agent and / or base).

[0023] In some embodiments, the present disclosure provides techniques that include one or more capping steps, e.g., a pre-modification capping step, a post-modification capping step, etc., each independently equivalent or identical to a reference capping step in conventional oligonucleotide synthesis, e.g., based on phosphoramidite chemistry. In some embodiments, the present disclosure strategically positions (or timings) capping steps in the oligonucleotide synthesis method and / or cycle to reduce by-products that may be formed in such capping steps. In some embodiments, such capping steps are positioned after amino groups (typically primary and secondary) have often been selectively capped (over free hydroxyl groups, particularly the 5'-OH), either as a separate, discrete capping step or in combination with other capping steps (e.g., capping amino groups, often preferentially the 5'-OH).

[0024] In some embodiments, the present disclosure provides techniques that include one or more capping steps, each independently comprising conditions selective or specific for amidation over esterification. In some embodiments, the present disclosure provides techniques that include one or more capping steps using amidation conditions that are not efficient and / or typical esterification conditions. As those skilled in the art will readily appreciate, esterification and amidation have been extensively studied, and various conditions selective or specific for amidation over esterification and various methods for assessing the selectivity and / or specificity of amidation over esterification are widely known in the art and can be utilized in the present disclosure. For example, typical conditions selective or specific for amidation over esterification are anhydride and base (e.g., AcO and 2,6-lutidine) without a catalyst, while corresponding efficient esterification conditions typically require anhydride, base, and catalyst (e.g., AcO, 2,6-lutidine, and NMI) as in conventional capping conditions. In some embodiments, the present disclosure provides techniques comprising one or more synthesis cycles each independently comprising a coupling step, a modification step (e.g., oxidation, sulfurization, etc.), and one or more capping steps, wherein each capping step after the coupling step and before the modification step comprises amidation conditions but not esterification conditions. In some embodiments, the amidation conditions comprise no more than 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, or 5% by volume of an esterification catalyst relative to the acylating agent and / or under corresponding conditions appropriate for the oligonucleotide loading capacity of the support (with the same acylating agent and base), and / or no more than about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, or 1.2 equivalents of an esterification catalyst relative to the acylating agent and / or under corresponding conditions appropriate for the oligonucleotide loading capacity of the support (with the same acylating agent and base). In some embodiments, the acylating agent is an anhydride. In some embodiments, the acylating agent is Ac2O. In some embodiments, the catalyst is NMI. In some embodiments, the catalyst is DMAP. In some embodiments, the catalyst is a nucleophilic nitrogen base.

[0025] Without intending to be bound by any theory, in some embodiments, the present disclosure encompasses the recognition of a source of problems in oligonucleotide synthesis, in that nucleophiles, particularly when used in a capping step after a coupling step and before a modification step in stereoselective oligonucleotide preparation, can contribute to the generation of by-products and overall poor preparation efficiency and / or crude purity by, for example, degrading the oligonucleotide, reducing the performance of other steps, etc. Accordingly, in some embodiments, the present disclosure provides capping techniques that contain only significantly reduced levels or no strong nucleophiles, such as DMAP and NMI, used in typical capping conditions, in contrast to conventional capping conditions that may contain large amounts of nucleophilic catalysts (e.g., in some cases 5% to 15% by volume of NMI in the capping solution). In some embodiments, each of the one or more capping steps after the coupling step and before the modification step within an oligonucleotide preparation cycle independently contains only significantly reduced levels or no strong nucleophiles. In some embodiments, the reduced level is no more than 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, or 5% by volume of the capping reagent solution. In some embodiments, the reduced level is no more than about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, or 1.2 equivalents relative to the acylating agent. In some embodiments, the reduced level is no more than about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, or 1.2 equivalents relative to the oligonucleotide loading capacity of the support.

[0026] In some embodiments, the strong nucleophile is a nucleophilic base. In some embodiments, the nucleophilic base is a nitrogenous base. In some embodiments, the nucleophilic base is a nitrogenous base, where the basic nitrogen atom (e.g., =N- or -N(-)-) does not have an alpha substituent. In some embodiments, the nucleophilic base is a nitrogenous base, where the basic nitrogen atom (e.g., =N- or -N(-)-) does not have an alpha substituent that is not part of a ring. In some embodiments, the nucleophilic base is an optionally substituted 5-10 membered heteroaryl compound containing a basic nitrogen atom =N-, where the nitrogen atom has less than two or no alpha substituents. In some embodiments, the nucleophilic base is a nucleophilic nitrogenous base. In some embodiments, the nucleophilic nitrogenous base has the formula BI: N(R N )3 BI wherein each R N is independently R, and the three R groups together with the nitrogen atom form a bicyclic or polycyclic ring optionally substituted as described for R groups (and groups can be R) in this disclosure, wherein: The nitrogen (underlined) in JPEG2024105256000002.jpg777 is a tertiary nitrogen, and there is no substitution at any of the positions alpha to the nitrogen atom. In some embodiments, the ring formed is saturated. In some embodiments, the nucleophilic base is DABCO (1,4-diazabicyclo[2.2.2]octane). In some embodiments, the ring formed contains one or more unsaturations.

[0027] In some embodiments, the nucleophilic nitrogen base is a base comprising =N-, wherein there is no substitution at any of the positions alpha to the nitrogen atom. In some embodiments, the nucleophilic nitrogen base is a base comprising an aromatic moiety comprising =N-, wherein there is no substitution at any of the positions alpha to the nitrogen atom. In some embodiments, the nucleophilic nitrogen base is represented by Formula B-II: R N -CH=N-CH=CH-R N , B-II wherein each R N is independently R, and two R groups taken together with their intervening atoms form an optionally substituted ring as described in this disclosure, where the compound comprises -CH=N-CH=. In some embodiments, the ring formed is an optionally substituted C5- 30 In some embodiments, the ring formed is a heteroaryl ring. In some embodiments, the ring formed is an optionally substituted 5-membered heteroaryl ring. In some embodiments, the ring formed is a substituted 5-membered heteroaryl ring. In some embodiments, the ring formed is a substituted imidazolyl ring. In some embodiments, the nucleophilic base is a substituted imidazole. In some embodiments, the nucleophilic nitrogenous base is NMI. In some embodiments, the ring formed is an optionally substituted 6-membered heteroaryl ring. In some embodiments, the ring formed is a substituted 6-membered heteroaryl ring. In some embodiments, the ring formed is a substituted pyridinyl ring. In some embodiments, the nucleophilic base is a substituted pyridine. In some embodiments, the nucleophilic nitrogenous base is DMAP.

[0028] As one skilled in the art will understand, nucleophilicity, e.g., the nucleophilicity of a basic nitrogen atom in a base, is related to several factors, such as steric hindrance, electron density, etc. Techniques for assessing nucleophilicity are widely known in the art and can be utilized in the present disclosure. Additionally or alternatively, bases with various levels of nucleophilicity are well known and can be evaluated and / or utilized in the present disclosure. In some embodiments, a base that can efficiently catalyze an esterification reaction, e.g., a base that can be used in conventional oligonucleotide synthesis in conjunction with anhydrides and 2,6-lutidine to efficiently cap unreacted 5'-OH (e.g., DMAP, NMI, etc.), is a strong nucleophilic base and should be avoided or used at reduced levels in capping steps that contain only significantly reduced levels or no strong nucleophiles, e.g., any capping step after the coupling step and before the modification step. In some embodiments, a strong nucleophilic base is a base that can effectively replace DMAP or NMI in esterification. In some embodiments, a strong nucleophilic base is one that can effectively replace DMAP or NMI in the capping step of conventional oligonucleotide synthesis (which typically uses phosphoramidite chemistry, does not use a chiral auxiliary, and is considered non-stereoselective / stereocontrolled).

[0029] In some embodiments, the provided methods include a capping step, which includes no more than 0.1, 0.2, 0.3, 0.4, 0.5, 0.5, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 equivalents of a strong nucleophilic base relative to the loading capacity of the oligonucleotide or support. In some embodiments, the capping step immediately precedes the uncapping step. In some embodiments, the capping step immediately follows the uncapping step. In some embodiments, the capping step immediately precedes and follows the uncapping step. In some embodiments, the uncapping step is a coupling step. In some embodiments, the uncapping step immediately precedes the capping step is a modification step. In some embodiments, the uncapping step immediately preceding the capping step is a coupling-modification step.

[0030] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) either does not contain a strong nucleophile, or, if it contains one or more strong nucleophiles, the level of each of the one or more strong nucleophiles is independently reduced compared to an appropriate reference capping condition.

[0031] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) does not contain a strong nucleophile, or if it contains one or more strong nucleophiles, the level of each of the one or more strong nucleophiles is independently less than or equal to about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, or 1 equivalent relative to the first incorporated nucleoside of the oligonucleotide.

[0032] In some embodiments, the first nucleoside incorporated into the oligonucleotide is the first nucleoside loaded onto the support before the first cycle of forming an internucleotide bond. In some embodiments, the equivalent of the first nucleoside incorporated into the oligonucleotide relative to the oligonucleotide loading capacity of the support used to prepare the oligonucleotide is 1.

[0033] In some embodiments, the strong nucleophilic agent is a strong nucleophilic base as described in the present disclosure. In some embodiments, the strong nucleophilic base is a compound of formula BI. In some embodiments, the strong nucleophilic base is a compound of formula BI, and can be used for efficient capping in conventional phosphoramidite-based oligonucleotide synthesis. In some embodiments, the strong nucleophilic base is a compound of formula B-II. In some embodiments, the strong nucleophilic base is a compound of formula B-II, and can be used for efficient capping in conventional phosphoramidite-based oligonucleotide synthesis. In some embodiments, the strong nucleophilic base is DMAP. In some embodiments, the strong nucleophilic base in NMI.

[0034] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) does not contain a catalyst that promotes capping of the 5'-OH as in the appropriate reference capping conditions, or if it contains one or more such catalysts, the level of each of the one or more such catalysts is independently reduced compared to the appropriate reference capping conditions.

[0035] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) does not contain a catalyst that promotes capping of the 5'-OH as in the appropriate reference capping conditions, or if it contains one or more such catalysts, the level of each of the one or more such catalysts is independently 0.01, 0.02, 0.05, 0.1, 0.2, 0.5 or 1 equivalent or less relative to the first incorporated nucleoside of the oligonucleotide.

[0036] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) does not include an esterification catalyst, or if it includes one or more esterification catalysts, the level of each of such one or more catalysts is independently reduced compared to the appropriate reference capping conditions.

[0037] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) does not contain an esterification catalyst, or if it contains one or more esterification catalysts, the level of each of such one or more catalysts is independently 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, or 1 equivalent or less relative to the first incorporated nucleoside of the oligonucleotide.

[0038] In some embodiments, the catalyst, e.g., a catalyst for esterification, which promotes capping of 5'-OH in oligonucleotide synthesis, is a compound of formula BI. In some embodiments, the catalyst is a compound of formula BI and can be used for efficient capping in conventional phosphoramidite-based oligonucleotide synthesis. In some embodiments, the catalyst is a compound of formula B-II. In some embodiments, the catalyst is a compound of formula B-II and can be used for efficient capping in conventional phosphoramidite-based oligonucleotide synthesis. In some embodiments, the catalyst is DMAP. In some embodiments, it is a strong nucleophilic base in NMI.

[0039] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) contains conditions that are selective for amidation over esterification.

[0040] In some embodiments, the present disclosure provides a method of preparing an oligonucleotide, comprising one or more cycles, wherein: Each cycle independently forms an internucleotide bond; Each cycle independently includes a coupling step, one or more capping steps, and a modification step, where the coupling step forms an internucleotide bond and the modification step modifies the internucleotide bond formed in the coupling step; Each capping step between the coupling step and the modification step (pre-modification capping step) includes conditions that are selective for amidation over esterification and do not include conditions that are identical or equivalent to the appropriate reference conditions.

[0041] In some embodiments, conditions selective for amidation over esterification include reduced levels or no esterification catalyst, e.g., no DMAP, no NMI, etc. In some embodiments, conditions identical or equivalent to appropriate reference conditions can be used to replace capping conditions in conventional phosphoramidite-based oligonucleotide synthesis without a significant decrease in efficiency, crude purity, and / or yield (or by no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%).

[0042] In some embodiments, the provided methods include a second capping step after the modification step in one or more cycles. In some embodiments, the provided methods include a second capping step after the modification step and before the deblocking step (which unblocks the blocked hydroxyl group) in one or more cycles. In some embodiments, the second capping step includes a strong nucleophile. In some embodiments, the second capping step includes a level of strong nucleophile equivalent to the reference capping conditions. In some embodiments, the second capping step includes an esterification catalyst. In some embodiments, the second capping step includes a level of esterification catalyst equivalent to the reference capping conditions. In some embodiments, the second capping step includes esterification conditions. In some embodiments, the second capping step includes esterification conditions that are the same or equivalent to the reference capping conditions, for example, in terms of capping unreacted 5'-OH in oligonucleotide synthesis. In some embodiments, the strong nucleophile is DMAP or NMI. In some embodiments, the strong nucleophile is DMAP. In some embodiments, the strong nucleophile is NMI. In some embodiments, the esterification catalyst is DMAP or NMI. In some embodiments, the esterification catalyst is DMAP. In some embodiments, the esterification catalyst is NMI.

[0043] In some embodiments, the present disclosure provides: (1) Coupling step; (2) the first capping step; (3) modification step; (4) second capping step; (5) Deblocking step The present invention provides a method for preparing an oligonucleotide, the method comprising a cycle comprising the steps of: The cycle includes steps (2)-(3)-(4) in this order; The cycle is repeated until the length of the oligonucleotide is achieved.

[0044] In some embodiments, the present disclosure provides: (1) Coupling step; (2) the first capping step; (3) modification step; (4) second capping step; (5) Deblocking step The present invention provides a method for preparing an oligonucleotide, the method comprising a cycle comprising the steps of: The cycle includes steps (2)-(4)-(3) in this order; The cycle is repeated until the length of the oligonucleotide is achieved.

[0045] In some embodiments, the first capping step does not include any strong nucleophiles as described herein, or if included, only at reduced levels. In some embodiments, the first capping step does not include any esterification catalysts, or if included, only at reduced levels. In some embodiments, the first capping step includes conditions that are selective for amidation over esterification. In some embodiments, the first capping step does not include conditions that are the same as or equivalent to appropriate reference conditions.

[0046] In some embodiments, the first capping step is the pre-modification capping step as described in the present disclosure.In some embodiments, the first capping step utilizes a capping reagent system that is a pre-modification capping reagent system.In some embodiments, the second capping step is the post-modification capping step as described in the present disclosure.In some embodiments, the second capping step utilizes a capping reagent system that is a post-modification capping reagent system.

[0047] In some embodiments, suitable reference capping conditions are those of conventional oligonucleotide synthesis based on phosphoramidite chemistry. An exemplary cycle of conventional phosphoramidite-based oligonucleotide synthesis is described below. JPEG2024105256000003.jpg4777

[0048] In some embodiments, the first capping step contains only a reduced level of a strong nucleophilic base or no strong nucleophilic base at all. In some embodiments, the first capping step contains only a reduced level of NMI. In some embodiments, the first capping step contains no NMI at all. In some embodiments, the first capping step contains only a reduced level of DMAP. In some embodiments, the first capping step contains no DMAP at all.

[0049] In some embodiments, an exemplary cycle of the provided technology is shown below (DPSE auxiliary for binding phosphorus of various configurations, JPEG2024105256000004.jpg1177), where each R LP are independently -XL as described in this disclosure. s -R 5 and BA, W and R 2s are independently as described herein. In some embodiments, capping-2 is performed after modification. In some embodiments, capping-1 is a pre-modification capping step. In some embodiments, capping-2 is a post-modification capping step. In some embodiments, the cycle end is after deblocking and before the next coupling. JPEG2024105256000005.jpg6777

[0050] In some embodiments, the reduced level of the present disclosure is less than or equal to a certain percentage, such as 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, etc., based on the volume of the capping reagent solution. In some embodiments, the percentage is 0.01%. In some embodiments, the percentage is 0.02%. In some embodiments, the percentage is 0.05%. In some embodiments, the percentage is 0.1%. In some embodiments, the percentage is 0.2%. In some embodiments, the percentage is 0.5%. In some embodiments, the percentage is 1%. In some embodiments, the percentage is 2%. In some embodiments, the percentage is 3%. In some embodiments, the percentage is 4%. In some embodiments, the percentage is 5%.

[0051] In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, or 1.2 equivalents or less compared to the reference agent. In some embodiments, the reference agent is an acylating agent. In some embodiments, the reference agent is a support (oligonucleotide loading capacity units). In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, or 1.2 equivalents or less compared to the acylating agent. In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 100 equivalents or less compared to the oligonucleotide. In some embodiments, the reduced level is no more than about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 100 equivalents relative to the initial nucleoside incorporated into the oligonucleotide. Often, the equivalents of the initial nucleoside incorporated into the oligonucleotide relative to the oligonucleotide loading capacity of the support used to prepare the oligonucleotide is 1. In some embodiments, the reduced level is no more than about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 100 equivalents relative to the oligonucleotide loading capacity of the support. In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, or 10 equivalents or less relative to the oligonucleotide loading capacity of the support. In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, or 5 equivalents or less relative to the oligonucleotide loading capacity of the support.In some embodiments, the reduced level is about 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, or 1 equivalent or less relative to the oligonucleotide loading capacity of the support. In some embodiments, the reduced level is about 0.01 equivalent or less. In some embodiments, the reduced level is about 0.02 equivalents or less. In some embodiments, the reduced level is about 0.05 equivalents or less. In some embodiments, the reduced level is about 0.1 equivalents or less. In some embodiments, the reduced level is about 0.2 equivalents or less. In some embodiments, the reduced level is about 0.5 equivalents or less. In some embodiments, the reduced level is about 1 equivalent or less. In some embodiments, the reduced level is about 1.1 equivalents or less. In some embodiments, the reduced level is about 1.2 equivalents or less.

[0052] In particular, provided techniques are particularly useful for preparing chiral-controlled oligonucleotide compositions.In some embodiments, provided techniques comprise the formation of one or more chiral internucleotide linkages, each of which independently comprises a chiral linking phosphorus, wherein each chiral center of the chiral linking phosphorus is independently formed as described in the present disclosure, for example, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% stereoselectivity.

[0053] In some embodiments, provided techniques involve stereoselectively forming one or more chiral-controlled internucleotide linkages using one or more chiral auxiliaries. In some embodiments, provided techniques involve providing a monomeric phosphoramidite as described herein, e.g., of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% diastereomeric purity. In many embodiments, the provided diastereomeric-purity phosphoramidites include a chiral auxiliary moiety. In some embodiments, conventional oligonucleotide synthesis phosphoramidites are utilized for non-chiral and / or non-chiral internucleotide linkages. Chiral auxiliaries and phosphoramidites suitable for chiral controlled oligonucleotide synthesis that can be utilized in the present disclosure include those described in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, and International Publication No. WO 2017 / 015555. Nos. WO 2017 / 015575, WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, and WO 2018 / 098264 (each of which chiral auxiliaries and phosphoramidites are independently incorporated herein by reference).In some embodiments, the chiral auxiliary is of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or a salt thereof, as described herein. In some embodiments, the phosphoramidite has the structure of Formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, IVa-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e, as described herein.

[0054] In some embodiments, the provided techniques involve forming an internucleotide linkage having the structure of Formula VII, as described in this disclosure.

[0055] In some embodiments, the provided techniques provide oligonucleotides as intermediates and / or products. In some embodiments, the provided oligonucleotides are of Formula VIII, as described in this disclosure, or salts thereof. In some embodiments, the provided oligonucleotides are those described in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9,744,183, U.S. Patent No. 9,605,019, U.S. Patent No. 9,394,333, U.S. Patent No. 8,859,755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8,470,987, U.S. Patent No. 8,822,671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862 (each of which oligonucleotides is independently incorporated herein by reference). In some embodiments, the provided intermediates and / or products are chiral controlled oligonucleotide compositions. In some embodiments, the intermediates and / or products provided are chiral controlled oligonucleotide compositions of a plurality of oligonucleotides of Formula VIII or salts thereof.In some embodiments, the provided intermediates and / or products are selected from the group consisting of U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 0155 and WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, and WO 2018 / 098264 (each of which oligonucleotide compositions is independently incorporated herein by reference).

[0056] In some embodiments, the present disclosure provides a composition comprising: the plurality of oligonucleotides comprises a plurality of oligonucleotides of the modified product composition; The reagent system is a pre- or post-modification capping reagent system; and A post-modification capping reagent system is contacted with the plurality of oligonucleotides.

[0057] In some embodiments, the present disclosure provides: a capping reagent system comprising a first compound having the structure of formula BI or B-II; a plurality of oligonucleotides each containing at least one internucleotide linkage containing a -C(O)-N(-)- or -PS- moiety; providing a composition comprising: The first compound is at a level of at least 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 50 or 100 equivalents relative to the plurality of oligonucleotides.

[0058] In some embodiments, the present disclosure provides: a capping reagent system comprising a first compound having the structure of formula BI or B-II; a plurality of oligonucleotides, wherein each internucleotide linkage of the plurality of oligonucleotides is independently an internucleotide linkage comprising a -C(O)-N(-)- moiety and a tetravalent linking phosphorus; providing a composition comprising: The first compound is at a level of at least 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 50 or 100 equivalents relative to the plurality of oligonucleotides.

[0059] In some embodiments, the plurality of oligonucleotides is a plurality of oligonucleotides of a modified product composition. The oligonucleotides share the same base sequence; The oligonucleotides share the same backbone linkage pattern; and the plurality of oligonucleotides comprise at least one chiral controlled internucleotide linkage, the internucleotide linkage being chiral controlled in that the plurality of oligonucleotides share the same stereochemical configuration at the chiral linking phosphorus of the internucleotide linkage; At least ((DS)) of all oligonucleotides sharing the same base sequence in the crude composition Nc × 100)% are a plurality of oligonucleotides, where DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and Nc is the number of chiral internucleotide linkages.

[0060] In some embodiments, the first compound is of formula BI. In some embodiments, the first compound is of formula B-II. In some embodiments, the first compound is a strong nucleophile as described herein. In some embodiments, the first compound is an esterification catalyst as described herein. In some embodiments, the first compound is of formula BI. In some embodiments, the first compound is of formula B-II. In some embodiments, the first compound is a base comprising =N-, wherein there is no substitution at any α-position relative to the nitrogen of =N-. In some embodiments, the first compound is a base comprising a heteroaryl moiety, wherein the heteroaryl moiety comprises =N-, wherein there is no substitution at any α-position relative to the nitrogen of =N-.

[0061] In some embodiments, the first compound is NMI. In some embodiments, the first compound is DMAP.

[0062] In some embodiments, the plurality of oligonucleotides is attached to a support, such as a solid support used to prepare the oligonucleotides. In some embodiments, the molar amount of the plurality of oligonucleotides is equal to the loading capacity of the solid support to which it is attached.

[0063] In some embodiments, a plurality of oligonucleotides share 1) a common base sequence, 2) a common backbone linkage pattern, and 3) a common backbone phosphorus modification pattern, wherein the plurality of oligonucleotides share the same stereochemistry at one or more chiral internucleotide linkages. In some embodiments, a plurality of oligonucleotides share the same stereochemistry at at least one internucleotide linkage comprising a -C(O)-N(-)- moiety or a -PS- moiety. In some embodiments, about 0.1% to 100% (e.g., about 1% to 100%, 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%, or about 100% to 100% of all oligonucleotides in a chiral controlled oligonucleotide composition that share a common base sequence, a common backbone linkage pattern, and a common backbone phosphorus modification pattern. 00%, 50% to 90% or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% is a plurality of oligonucleotides.

[0064] In some embodiments, the plurality of oligonucleotides each have the structure of Formula VIII or a salt thereof. In some embodiments, the plurality of oligonucleotides are selected from the group consisting of U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 201 and WO 2017 / 098264 (each of which oligonucleotides is independently incorporated by reference).

[0065] In some embodiments, the levels of the present disclosure are at least 0.1 equivalents. In some embodiments, the levels are at least 0.2 equivalents. In some embodiments, the levels are at least 0.5 equivalents. In some embodiments, the levels are at least 1 equivalent. In some embodiments, the levels are at least 2 equivalents. In some embodiments, the levels are at least 3 equivalents. In some embodiments, the levels are at least 4 equivalents. In some embodiments, the levels are at least 5 equivalents. In some embodiments, the levels are at least 6 equivalents. In some embodiments, the levels are at least 7 equivalents. In some embodiments, the levels are at least 8 equivalents. In some embodiments, the levels are at least 9 equivalents. In some embodiments, the levels are at least 10 equivalents. In some embodiments, the levels are at least 20 equivalents. In some embodiments, the levels are at least 50 equivalents. In some embodiments, the levels are at least 100 equivalents.

[0066] In some embodiments, -C(O)-N(-)- is part of a capped amino group in a chiral auxiliary moiety attached to the bound phosphorus, where the corresponding chiral auxiliary (in which the bond to -C(O)- of -C(O)-N(-)- is replaced with -H and the bond to the bound phosphorus is replaced with -H) is a compound of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, or a salt thereof.

[0067] In particular, the present disclosure provides oligonucleotide compositions of high crude purity. In some embodiments, the present disclosure provides chiral-controlled crude oligonucleotide compositions comprising a plurality of oligonucleotides, wherein: The oligonucleotides share the same base sequence; The oligonucleotides share the same backbone linkage pattern; and the plurality of oligonucleotides comprise at least one chiral controlled internucleotide linkage, the internucleotide linkage being chiral controlled in that the plurality of oligonucleotides share the same stereochemical configuration at the chiral linking phosphorus of the internucleotide linkage; At least ((DS)) of all oligonucleotides sharing the same base sequence in the crude composition Nc × 100)% are a plurality of oligonucleotides, where DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and Nc is the number of chiral internucleotide linkages.

[0068] In some embodiments, the present disclosure provides a chiral controlled crude oligonucleotide composition comprising a plurality of oligonucleotides, wherein: The oligonucleotides share the same composition; and the plurality of oligonucleotides comprise at least one chiral controlled internucleotide linkage, the internucleotide linkage being chiral controlled in that the plurality of oligonucleotides share the same stereochemical configuration at the chiral linking phosphorus of the internucleotide linkage; At least ((DS)) of all oligonucleotides sharing the same base sequence in the crude composition Nc × 100)% are a plurality of oligonucleotides, where DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and Nc is the number of chiral internucleotide linkages.

[0069] In some embodiments, the chirality-controlled crude oligonucleotide compositions provided have a crude purity of at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%. In some embodiments, the chirality-controlled crude oligonucleotide compositions are cleaved from the support and before any further purification. In some embodiments, the chirality-controlled crude oligonucleotide compositions are cleaved after desalting from the support and before any further purification. In some embodiments, the chirality-controlled crude oligonucleotide compositions are cleaved before any chromatographic or gel purification. In some embodiments, the crude purity is the % full-length product. In some embodiments, the crude purity is the % full-length product as assessed by LC-UV observed at UV 260 nm.

[0070] In some embodiments, the DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the DS is at least 85%. In some embodiments, the DS is at least 90%. In some embodiments, the DS is at least 92%. In some embodiments, the DS is at least 95%. In some embodiments, the DS is at least 96%. In some embodiments, the DS is at least 97%. In some embodiments, the DS is at least 98%. In some embodiments, the DS is at least 99%. In some embodiments, the DS is the diastereoselectivity and / or diastereopurity at the chiral linking phosphorus of the chiral-controlled internucleotide linkage.

[0071] In some embodiments, the diastereoselectivity at the chiral linkage phosphorus of a chiral internucleotide linkage in an oligonucleotide and / or its diastereopurity can be measured or expressed through a model reaction, such as the formation of a dimer under essentially the same or equivalent conditions, where the dimer has the same internucleotide linkage as the chiral internucleotide linkage, the 5'-nucleoside of the dimer is the same as the nucleoside to the 5'-terminus of the chiral internucleotide linkage, and the 3'-nucleoside of the dimer is the same as the nucleoside to the 3'-terminus of the chiral internucleotide linkage. For example, The diastereomeric purity of the underlined bond in JPEG2024105256000006.jpg777 can be assessed from coupling of two G moieties under the same or equivalent conditions, e.g., monomers, chiral auxiliaries, solvents, activators, temperatures, etc. In some embodiments, the dimer The diastereopurity (and / or diastereoselectivity) of the bond JPEG2024105256000007.jpg677 is determined by the oligonucleotide JPEG2024105256000008.jpg777 is used as the diastereomeric purity (and / or diastereoselectivity) of the corresponding bond in JPEG2024105256000008.jpg777. In some embodiments, the diastereomeric purity of a compound containing multiple chiral elements is the product of the diastereomeric purities of all of its chiral elements. In some embodiments, the diastereomeric purity (i.e., diastereomeric purity) of a provided oligonucleotide is the product of the diastereomeric purities of all of its chiral linkage phosphorus in its chiral internucleotide linkage.

[0072] In some embodiments, Nc is the number of chirality-controlled internucleotide bonds and is 1 to 100. In some embodiments, Nc is 1 to 50. In some embodiments, Nc is 1 to 40. In some embodiments, Nc is 1 to 30. In some embodiments, Nc is 1 to 25. In some embodiments, Nc is 1 to 24. In some embodiments, Nc is 1 to 23. In some embodiments, Nc is 1 to 22. In some embodiments, Nc is 1 to 21. In some embodiments, Nc is 1 to 20. In some embodiments, Nc is 1 to 19. In some embodiments, Nc is 1 to 18. In some embodiments, Nc is 1 to 17. In some embodiments, Nc is 1 to 16. In some embodiments, Nc is 1 to 15. In some embodiments, Nc is 1 to 14. In some embodiments, Nc is 1 to 13. In some embodiments, Nc is 1 to 12. In some embodiments, Nc is 1 to 11. In some embodiments, Nc is 1 to 10. In some embodiments, Nc is 1 to 9. In some embodiments, Nc is 1 to 8. In some embodiments, Nc is 1 to 7. In some embodiments, Nc is 1 to 6. In some embodiments, Nc is 1 to 5. In some embodiments, Nc is 1. In some embodiments, Nc is 2. In some embodiments, Nc is 3. In some embodiments, Nc is 4. In some embodiments, Nc is 5. In some embodiments, Nc is 6. In some embodiments, Nc is 7. In some embodiments, Nc is 8. In some embodiments, Nc is 9. In some embodiments, Nc is 10. In some embodiments, Nc is 11. In some embodiments, Nc is 12. In some embodiments, Nc is 13. In some embodiments, Nc is 14. In some embodiments, Nc is 15. In some embodiments, Nc is 16. In some embodiments, Nc is 17.In some embodiments, Nc is 18. In some embodiments, Nc is 19. In some embodiments, Nc is 20. In some embodiments, Nc is 21. In some embodiments, Nc is 22. In some embodiments, Nc is 23. In some embodiments, Nc is 24. In some embodiments, Nc is 25.

[0073] In some embodiments, the provided techniques include one or more modification steps that independently include or are sulfurization (thiolation). In some embodiments, the provided intermediates and / or products include one or more phosphorothioate internucleotide linkages or precursors thereof (which can be converted to phosphorothioate internucleotide linkages upon deprotection / cleavage), optionally with chirality control. In some embodiments, the provided techniques include one or more modification steps that independently include or are oxidation. In some embodiments, the provided intermediates and / or products include one or more native phosphate linkages or precursors thereof (which can be converted to native phosphate linkages upon deprotection / cleavage). In some embodiments, the provided intermediates and / or products include one or more native phosphate linkages and one or more phosphorothioate internucleotide linkages.

[0074] In this disclosure, various supports, such as those described in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015556, WO 2017 / 015557, WO 2017 / 015558, WO 2017 / 015559 ... Those described in International Publication No. 017 / 015575, International Publication No. 2017 / 062862, U.S. Patent No. 9,403,865, International Publication No. 2017 / 160741, International Publication No. 2017 / 192664, International Publication No. 2017 / 192679, International Publication No. 2017 / 210647, International Publication No. 2018 / 022473, International Publication No. 2018 / 067973, International Publication No. 2018 / 098264, etc., can be used. In some embodiments, the support is a polymer. In some embodiments, the support is a solid support. In some embodiments, the solid support is a polymer, for example, polystyrene. In some embodiments, the solid support is Primer Support (e.g., Primer Support 5G, Primer Support 200, etc.). In some embodiments, the solid support is a NittoPhase support (e.g., NittoPhase HL, NittoPhase UnyLinker, etc.). In some embodiments, the solid support is controlled pore glass (CPG). In some embodiments, the volume of the solid support, e.g., certain polystyrene-based solid supports, changes during oligonucleotide synthesis, e.g., at different synthesis stages and / or upon contact with different solvent systems and / or reagents. In some embodiments, the volume of the solid support, e.g., many CPG supports, changes by less than 25%, 20%, 15%, 10%, or 5%, or remains substantially the same during oligonucleotide synthesis.In some embodiments, the present disclosure encompasses the recognition that volume changes of solid supports during synthesis can cause deviations from planned reaction conditions, e.g., solvent systems, reagent concentrations, contact times, etc., and can negatively impact synthesis efficiency, crude purity, and / or yield. In some embodiments, solid supports whose volume does not change significantly or remains substantially the same during oligonucleotide synthesis can provide advantages, such as reduced deviations from planned reaction conditions, higher crude purity, and higher yield. Supports can have any number of chemical modifications for nucleoside loading and can have a variety of unit loading capacities (e.g., umol / g).

[0075] In the oligonucleotide synthesis using support, typically, oligonucleotide is bound to support via linker.In the present disclosure, several linkers can be used, for example, those described in US Patent Application Publication No. 2015100197, US Patent No. 9744183, US Patent No. 9605019, US Patent No. 9394333, US Patent No. 8859755, US Patent Application Publication No. 20130178612, US Patent No. 8470987, US Patent No. 8822671, US Patent Application Publication No. 20150211006, US Patent Application Publication No. 20170037399, International Publication No. 2017 / 015555, International Publication No. 2017 / 015575, International Publication No. 2017 / 062862, US Patent No. 9403865 etc. In some embodiments, the present disclosure provides designed linkers.

[0076] In some embodiments, the support is functionalized with an amino group. In some embodiments, the support is functionalized with an amino group. n In some embodiments, the first linker is functionalized with -CH2-NH2, where the -CH2- terminus is linked to a support, such as a CPG. In some embodiments, the first linker is -CH2-(CH2) n-CH2-NH-, where the -CH2- terminus is linked to a support, e.g., CPG, and -NH- is linked to a nucleoside, e.g., the 3'-OH, via a second linker, e.g., -C(O)-CH2-CH2-C(O)-, where n is as described herein. In some embodiments, n is 1. In some embodiments, n is 7.

[0077] In some embodiments, the first linker is -CH2-(CH2) n -CH2-NH-C(O)-X-(CH2) m In some embodiments, the first linker is -NH-, where each variable is independently as described in this disclosure. In some embodiments, the first linker is -CH-(CH) n -CH2-NH-C(O)-X-(CH2) m -NH-C(O)-X-(CH2) p In some embodiments, the first linker is -NH-, where each variable is independently as described in this disclosure. In some embodiments, the first linker is -CH-(CH) n -CH2-NH-C(O)-X-CH2-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-CH2-NH-, where each variable is independently as described in this disclosure. In some embodiments, the first linker is -CH2-(CH2) n -CH2-NH-C(O)-X-CH2-CH2-O-CH2-CH2-O-(CH2-CH2-O)m-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-, where each variable is independently as described in this disclosure. In some embodiments, the first linker is -CH2-(CH2) n-CH2-NH-C(O)-X-CH2-CH2-CH2-O-CH2-CH2-CH2-O-(CH2-CH2-CH2-O)m-CH2-CH2-CH2-O-CH2-CH2-CH2-NH-, where each variable is independently as described in this disclosure. In some embodiments, the -CH2- terminus is linked to a support, e.g., a CPG, and the -NH- is linked to a nucleoside, e.g., the 3'-OH, via a second linker, e.g., -C(O)-CH2-CH2-C(O)-.

[0078] In some embodiments, not all available amino moieties are loaded with nucleosides, for example, via the second linker -C(O)-CH-CH-C(O)-. In some embodiments, some available amino moieties are capped with an acyl group, for example, -C(O)-R, to form -CH-(CH) n -CH2-NH-C(O)-R, -CH2-(CH2) n -CH2-NH-C(O)-X-(CH2) m -NH-C(O)-R, -CH2-(CH2) n -CH2-NH-C(O)-X-(CH2) m -NH-C(O)-X-(CH2) p -NH-C(O)-R, -CH2-(CH2) n -CH2-NH-C(O)-X-CH2-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-CH2-NH-C(O)-R, -CH2-(CH2) n -CH2-NH-C(O)-X-CH2-CH2-O-CH2-CH2-O-(CH2-CH2-O)m-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-C(O)-R or -CH2-(CH2) n-CH2-NH-C(O)-X-CH2-CH2-CH2-O-CH2-CH2-CH2-O-(CH2-CH2-CH2-O)m-CH2-CH2-CH2-O-CH2-CH2-CH2-NH-C(O)-R, where each variable is independently as described in this disclosure, can be formed, thereby adjusting the unit loading capacity of the support. In some embodiments, R is -(CH2)o-, where o is 0 to 20.

[0079] In some embodiments, o is 0-12. In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, o is 4. In some embodiments, o is 5. In some embodiments, o is 6. In some embodiments, o is 7. In some embodiments, o is 8. In some embodiments, o is 9. In some embodiments, o is 10. In some embodiments, o is 11. In some embodiments, o is 12. In some embodiments, o is 13. In some embodiments, o is 14. In some embodiments, o is 15.

[0080] In some embodiments, the following structure: JPEG2024105256000009.jpg10177, wherein: w is a nucleoside moiety as described in this disclosure, In some embodiments, JPEG2024105256000010.jpg777 is a support as described herein, and each other variable is independently as described herein.

[0081] In some embodiments, X is -O-, -S-, -NH-, -CH2-, m is 3 to 15, n is 1 or 7, o is 0 to 12, and p is 3 to 15. In some embodiments, X is -O-, -S-, -NH-, -CH2-, m is 0 to 10, n is 1 or 7, o is 0 to 12, and p is 3 to 15.

[0082] In some embodiments, -OR w is a nucleoside moiety of formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, IVa-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e. W teeth, JPEG2024105256000011.jpg1177, where R 2s is as described herein. In some embodiments, R W teeth, JPEG2024105256000012.jpg1277, wherein each variable is as described herein. In some embodiments, BA is a protected nucleobase selected from A, T, C, U, G, and 5mC. In some embodiments, BA is C(N-4-Ac or Bz), 5-Me-C(N-4-Ac or Bz), U, T, A(N-6-Bz), or G(N-2-iBu), and R 2s is -OH, -H, -F, -OCH or -OCHCHOCH, Z is -O-, -S-, -CH-, and R s is -CH3, -OCH3 or -CH2CH3.

[0083] Oligonucleotide synthesis typically includes a deblocking step, which deblocks blocked hydroxyl groups for the next step, e.g., a coupling step, and keeps capped hydroxyl groups intact that should not be involved in the next step, e.g., a coupling step. In the present disclosure, U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575 Various deblocking conditions can be utilized, including those described in the following publications: International Publication No. WO 2017 / 062862, U.S. Patent No. 9,403,865, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, and WO 2018 / 098264. In some embodiments, deblocking removes the DMT group from the DMT-protected hydroxyl (detritylation). In some embodiments, deblocking is performed by contacting the oligonucleotide with an acid. In some embodiments, the acid is trichloroacetic acid or dichloroacetic acid. In some embodiments, the deblocking conditions are 2% trichloroacetic acid (TCA) or 3% dichloroacetic acid (DCA) in an inert solvent (eg, dichloromethane, toluene, etc.).

[0084] The coupling step forms an internucleotide linkage, which adds a nucleoside unit to an existing oligonucleotide. In some embodiments, the internucleotide linkage formed during the coupling step is a phosphite triester linkage. In some embodiments, the internucleotide linkage can be formed with chiral control, as in chiral controlled oligonucleotide synthesis using, for example, diastereomerically pure phosphoramidites, which typically contain a chiral auxiliary moiety. Coupling conditions have been widely reported and are included in this disclosure in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015556, WO 2017 / 015557, WO 2017 / 015558, WO 2017 / 015559 ... Many coupling reagent systems can be used, including those described in WO 2017 / 015575, WO 2017 / 062862, U.S. Pat. No. 9,403,865, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, and WO 2018 / 098264. In some embodiments, the coupling reagent system comprises a nucleoside phosphoramidite and an activating agent.The provided technology includes U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, International Publication No. 2017 / 015555, International Publication No. 2017 / 015575, International Publication No. 2017 / 062862, U.S. Patent No. 9403865, International Publication No. 2017 / 160741, International Publication No. 2017 / 19 A variety of phosphoramidites may be used, including those described in WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973 and WO 2018 / 098264, as well as those having the structure of formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, IVa-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d or VI-e, or a salt thereof, as described in this disclosure.Exemplary activators include those described in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, and U.S. Patent No. 9403865 (each of which activators is independently incorporated herein by reference). In some embodiments, the activator is CMPT. In some embodiments, the activating agent is CMIMT. In some embodiments, the activating agent is ETT. In some embodiments, conditions, such as phosphoramidite concentration, activating agent concentration, contact time, solvent, etc., can be optimized for each coupling to improve, for example, crude purity, yield, etc.

[0085] In some embodiments, one or more capping steps are performed after the coupling step and before the modification step. In some embodiments, each capping step after the coupling step and before the modification step is performed, as described herein, with, for example, reduced levels of strong nucleophiles or no nucleophiles, reduced levels of esterification catalysts or no nucleophiles, and / or under conditions selective or specific for amidation over esterification. In some embodiments, each capping step after the coupling step and before the modification step is performed to cap one or more amino groups, e.g., one or more amino groups formed after coupling on a chiral auxiliary moiety attached to the bound phosphorus atom.

[0086] In some embodiments, after one or more capping steps as described herein, a modification step is performed to modify the internucleotide linkage formed after coupling, which in some embodiments includes a linked phosphorus atom that is trivalent (e.g., as in a phosphite linkage). In some embodiments, the modification step is or includes oxidation, e.g., converting the phosphite linkage to a tetracoordinate phosphotriester linkage (introducing =O at the linked phosphorus). In some embodiments, the modification step is or includes sulfurization. In some embodiments, sulfurization converts the phosphite linkage to a tetracoordinate internucleotide linkage by introducing =S at the linked phosphorus. In some embodiments, sulfurization converts the phosphite linkage to a tetracoordinate phosphorothioate triester internucleotide linkage (e.g., -P(=O)(SL s -R 5 )-, in the formula, -L s -R 5 (is not hydrogen). Exemplary modifications and related techniques include U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015556, WO 2017 / 015557, WO 2017 / 015558, WO 2017 / 015559 ... Examples of such compounds include those described in International Publication No. 2017 / 015575, International Publication No. 2017 / 062862, U.S. Pat. No. 9,403,865, International Publication No. 2017 / 160741, International Publication No. 2017 / 192664, International Publication No. 2017 / 192679, International Publication No. 2017 / 210647, International Publication No. 2018 / 022473, International Publication No. 2018 / 067973, and International Publication No. 2018 / 098264.

[0087] In some embodiments, the provided techniques offer greater flexibility in the selection of modifying reagents, e.g., oxidation reagents, sulfurization reagents, etc. For example, reagents that tend to be unsuccessful in previously reported chiral controlled oligonucleotide syntheses can be utilized with the disclosed techniques to yield significantly improved and satisfactory results.

[0088] In some embodiments, another capping step is performed after the modification step. In some embodiments, the post-modification capping step is performed using a substantial amount of a strong nucleophile and / or an esterification catalyst (the strong nucleophile can be the same as the esterification catalyst) under esterification conditions equivalent to or identical to those used in conventional oligonucleotide synthesis. In some embodiments, the post-modification capping step caps free hydroxyl groups, such as hydroxyl groups remaining intact after the modification step as a result of incomplete coupling. After this capping step, the oligonucleotide is deblocked to expose the hydroxyl groups at the site of further chain elongation, allowing for another synthesis cycle.

[0089] After the desired chain length is achieved, the oligonucleotides can be fully deprotected and cleaved from the support for purification and / or further use. In this disclosure, U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575 Various cleavage and / or deprotection techniques can be utilized, including those described in WO 2017 / 062862, U.S. Pat. No. 9,403,865, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, and WO 2018 / 098264. As one of skill in the art will appreciate, cleavage and / or deprotection conditions can depend on the chemistry used during oligonucleotide synthesis, e.g., the nature of the linker connecting the oligonucleotide to the support, the nature of the base and / or sugar blocking groups, the nature of the chiral moiety, etc. In some embodiments, removal of the chiral auxiliary, e.g., a DPSE-type chiral auxiliary, involves the use of TEA-HF. In some embodiments, the present disclosure has surprisingly demonstrated that TEA-HF can be successfully utilized for oligonucleotide synthesis using a CPG support.

[0090] The technology provided in the present disclosure allows for the use of various sugars and nucleobases, including unnatural modified sugars and nucleobases, as described in, for example, U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO ... Sugars and nucleic acid bases described in International Publication Nos. WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973 and WO 2018 / 098264 can be used.

[0091] In some embodiments, the provided techniques are useful for large-scale preparation of oligonucleotides. In some embodiments, the scale is 100 g or greater. In some embodiments, the scale is 200 g or greater. In some embodiments, the scale is 500 g or greater. In some embodiments, the scale is at least 1000 g or greater.

[0092] In some embodiments, the composition of another step that is contacted in a step is the composition of the first step that precedes that step. In some embodiments, the composition of another step that is contacted in each step is the composition of the first step that precedes that step. For example, the deblocked composition contacted in the coupling step is the deblocked composition of the first deblocking step preceding the coupling step, the coupling product composition contacted in the pre-modification capping step is the coupling product composition of the first coupling step preceding the pre-modification capping step, the coupling product composition contacted in the modification step is the coupling product composition of the first coupling step preceding the modification step, the pre-modification capping product composition contacted in the modification step is the pre-modification capping product composition of the first pre-modification capping step preceding the modification step, the modified product composition contacted in the post-modification capping step is the modified product composition of the first modification step preceding the post-modification capping step, the modified product composition contacted in the deblocking step is the modified product composition of the first modification step preceding the deblocking step, and the post-modification capping product composition contacted in the deblocking step is the post-modification capping product composition of the first post-modification capping step preceding the deblocking step, etc.

[0093] In some embodiments, the techniques provided may be utilized for preparing other oligomeric compounds generally. In some embodiments, a method for preparing a composition comprising a plurality of oligomeric compounds comprises: a) a coupling step, contacting a deblocked composition comprising a plurality of deblocked compounds each independently comprising deblocked monomeric units, each deblocked in that each deblocked monomeric unit independently comprises a free linking group, with a coupling reagent system comprising a partner compound comprising a monomeric unit of an oligomeric compound; and By coupling a partner compound comprising a monomer unit of an oligomeric compound with the free linking groups of a plurality of deblocked compounds, a coupling product composition is provided comprising a plurality of coupling products, each of which independently comprises a bond connecting the linking group of the deblocked monomer unit to a monomer unit of the partner compound. a step including: b) optionally a pre-modification capping step, contacting the coupling product composition with a pre-modification capping reagent system; and Capping one or more functional groups of the coupling product composition to provide a pre-modified capped product composition comprising a plurality of pre-modified capped products. a step including: c) a modification step, contacting the coupling product composition and modifying one or more bonds of one or more of the coupling products to provide a modification step composition comprising a plurality of modified products; or contacting the pre-modification capping product composition and modifying one or more bonds of one or more pre-modification capping products to provide a modified product composition comprising a plurality of modified products. a step including: d) optionally a post-modification capping step, contacting the modified product composition with a post-modification capping reagent system; and Capping one or more functional groups of one or more compounds of the modified product composition to provide a modified capped product composition comprising a plurality of modified capped products. a step including: e) optionally a deblocking step, contacting the modified product composition or the modified post-capping product composition with a deblocking reagent system to provide a deblocked composition comprising a plurality of deblocked products, each independently comprising a deblocked monomer unit comprising a free linking group. Steps including Includes.

[0094] In some embodiments, the method optionally includes repeating steps b) through e) multiple times, for example, until a desired length is achieved. In some embodiments, the method includes both a pre-modification capping step and a post-modification capping step (wherein the pre-modification capping reagent system is optionally different from the post-modification reagent system), or a pre-modification capping step (wherein the pre-modification capping reagent system caps a plurality of non-linking groups of a plurality of coupling products), and a modification step including sulfurization (wherein the sulfurization provides a modified product composition including a plurality of modified products each independently comprising a P=S moiety), or a post-modification capping step (wherein at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the modified product compositions include a chiral center and have the same composition). % of the oligomeric compounds share the same stereochemical configuration at the chiral center); or a post-modification capping step and a coupling reagent system comprising a chiral partner compound comprising a monomeric unit of the oligomeric compound (wherein the chiral partner compound comprises a chiral atom that is not within the monomeric unit); or a coupling step immediately preceding the pre-modification capping step (wherein the pre-modification capping reagent system of the pre-modification capping step does not comprise an esterification catalyst or does not comprise a strong nucleophile).

[0095] As described herein, in some embodiments, the oligomeric compound is an oligonucleotide. In some embodiments, the composition comprising a plurality of oligomeric compounds is an oligonucleotide composition comprising a plurality of oligonucleotides. In some embodiments, the coupling step is a coupling step as described herein with respect to oligonucleotide synthesis. In some embodiments, the deblocked compound is a deblocked oligonucleotide, e.g., an oligonucleotide after a deblocking step in an oligonucleotide synthesis cycle. In some embodiments, the deblocked monomer unit is a deblocked 5'-terminal nucleoside unit. In some embodiments, the free linking group is a free 5'-hydroxyl group. In some embodiments, the coupling reagent system is a coupling reagent system in an oligonucleotide synthesis cycle. In some embodiments, the partner compound is a phosphoramidite as described herein with respect to oligonucleotide synthesis. In some embodiments, the coupling product is an oligonucleotide formed after coupling in oligonucleotide synthesis. In some embodiments, the bond connecting the linking group of the deblocked monomer unit to the monomer unit of the partner compound is an internucleotide bond formed during the coupling step. In some embodiments, the pre-modification capping step is a capping step in oligonucleotide synthesis as described herein. In some embodiments, the pre-modification capping reagent system is a pre-capping reagent system in oligonucleotide synthesis as described in the present disclosure. In some embodiments, the pre-modification capping product composition is a composition after the pre-modification capping step in oligonucleotide synthesis. In some embodiments, the pre-modification capping product is a product formed after the pre-modification capping step in oligonucleotide synthesis. In some embodiments, the modification step is a modification step as used in oligonucleotide synthesis.In some embodiments, the modification step as demonstrated in the oligonucleotide synthesis described in this disclosure modifies an internucleotide bond. In some embodiments, the modified product composition is an oligonucleotide composition provided after the modification step in oligonucleotide synthesis. In some embodiments, the modified product is an oligonucleotide provided after the modification step in oligonucleotide synthesis. In some embodiments, the post-modification capping step is a capping step in oligonucleotide synthesis as described in this disclosure. In some embodiments, the post-modification capping reagent system is a post-capping reagent system in oligonucleotide synthesis as described in this disclosure. In some embodiments, the post-modification capping product composition is a composition after the post-modification capping step in oligonucleotide synthesis. In some embodiments, the post-modification capping product is a product formed after the post-modification capping step in oligonucleotide synthesis. In some embodiments, the deblocking step is a deblocking step as described in the oligonucleotide synthesis described in this disclosure. In some embodiments, the non-linking group is an amino group. In some embodiments, the chiral center of the chiral control is a chiral center of the chiral control. In some embodiments, the chiral partner compound that contains a chiral atom that is not in a monomer unit is a phosphoramidite that contains a chiral center that is not in its nucleoside unit and is not P. In some embodiments, the reagent system is free of an esterification catalyst, free of DMAP, and free of NMI. [Brief explanation of the drawings]

[0096] [Figure 1] FIG. 1 is a crude UPLC chromatogram for B6. [Figure 2] FIG. 2 is a crude UPLC chromatogram for B19. [Figure 3] FIG. 3 is a crude UPLC chromatogram for B56. [Figure 4A]FIG. 4(A) is a crude UPLC chromatogram (post-NAP) for B110. [Figure 4B] FIG. 4(B) is the crude UPLC chromatogram for B110 (before NAP). DETAILED DESCRIPTION OF THE INVENTION

[0097] 1.Definition As used herein, the following definitions shall apply unless otherwise stated. For purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. In addition, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, Mb and March, J., John Wiley & Sons, New York: 2001.

[0098] Aliphatic: As used herein, "aliphatic" means a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is fully saturated or contains one or more units of unsaturation, or a combination thereof. Unless otherwise specified, an aliphatic group contains 1-100 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-20 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-10 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-9 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-8 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-7 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms. In yet other embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups, and hybrids thereof.

[0099] Alkyl: As used herein, the term "alkyl" is given its ordinary meaning in the art and includes saturated aliphatic groups, including straight-chain alkyl groups, branched alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In some embodiments, an alkyl has 1-100 carbon atoms. In some embodiments, a straight-chain or branched-chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C1-C for straight chain). 20 , C2 to C in the case of branched chains 20) or about 1-10. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure (and such rings are monocyclic, bicyclic or polycyclic) or about 5, 6 or 7 carbons in the ring structure. In some embodiments, alkyl groups can be lower alkyl groups, where the lower alkyl group has from 1-4 carbon atoms (e.g., C1-C4 for a straight chain lower alkyl).

[0100] Aryl: The term "aryl," used alone or as part of a larger moiety such as "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to a monocyclic, bicyclic, or polycyclic ring system having a total of 5 to 30 ring members, wherein at least one ring of the system is aromatic. In some embodiments, an aryl group refers to a monocyclic, bicyclic, or polycyclic ring system having a total of 5 to 14 ring members, wherein at least one ring of the system is aromatic and wherein the rings of the system each contain 3 to 7 ring members. In some embodiments, an aryl group is a biaryl group. The term "aryl" may be used interchangeably with the term "aryl ring." In some embodiments of the present invention, "aryl" refers to an aromatic ring system, including, but not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl, and the like, which may contain one or more substituents. In some embodiments, the term "aryl," as used herein, also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aryl ring.

[0101] Chiral control: As used herein, "chiral control" refers to control of the stereochemical assignment of the chiral linking phosphorus at a chiral internucleotide linkage within an oligonucleotide. In some embodiments, the control is achieved through chiral elements not present in the sugar and base moieties of the oligonucleotide; for example, in some embodiments, the control is achieved by using one or more chiral auxiliaries during the preparation of the oligonucleotide, as exemplified in the present disclosure, which chiral auxiliaries are often part of the chiral phosphoramidites used during the preparation of the oligonucleotide. Those skilled in the art will understand that, in contrast to chiral control, when a chiral internucleotide linkage is formed using conventional oligonucleotide synthesis without a chiral auxiliary, such conventional oligonucleotide synthesis does not provide control over the stereochemistry of the chiral internucleotide linkage. In some embodiments, the stereochemical assignment of each chiral linking phosphorus at a chiral internucleotide linkage within an oligonucleotide is controlled.

[0102] Chirality-controlled oligonucleotide composition: As used herein, the terms "chirality-controlled oligonucleotide composition," "chirality-controlled nucleic acid composition," and the like refer to a composition comprising multiple oligonucleotides (or nucleic acids) that share 1) a common base sequence, 2) a common backbone linkage pattern, and 3) a common backbone phosphorus modification pattern, where the multiple oligonucleotides (or nucleic acids) share the same stereochemistry at one or more chiral internucleotide linkages (chirality-controlled internucleotide linkages), and the level of the multiple oligonucleotides (or nucleic acids) in the composition is non-random / predetermined (e.g., through chirality-controlled oligonucleotide preparation that forms one or more chiral internucleotide linkages). In some embodiments, multiple oligonucleotides in a chirality-controlled oligonucleotide composition independently share the same base sequence, the same nucleobase, sugar, and internucleotide linkage modifications, if present, and the same stereochemistry (Rp or Sp) at the linkage phosphorus chiral center of one or more chirality-controlled internucleotide linkages, although the stereochemistry of a particular linkage phosphorus chiral center may differ. In some embodiments, about 0.1% to 100%, (e.g., about 1% to 100%, 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%, 50% to 90%, or about 5%, 10%, or 20% to 20% of all oligonucleotides in the chiral controlled oligonucleotide composition. %, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) is a plurality of oligonucleotides.In some embodiments, about 0.1% to 100%, (e.g., about 1% to 100%, 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%, 50% to 90%, or About or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% are a plurality of oligonucleotides. In some embodiments, about 0.1% to 100% (e.g., about 1% to 100%, 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%) of all oligonucleotides in a chiral controlled oligonucleotide composition that share a common base sequence, a common backbone bond pattern, and a common backbone phosphorus modification pattern. 00%, 50% to 90% or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% is a plurality of oligonucleotides.In some embodiments, the predetermined level is between about 0.1% and 100%, (e.g., between about 1% and 100%) of all oligonucleotides in a composition, or of all oligonucleotides in a composition (e.g., of multiple oligonucleotides or oligonucleotide types) that share a common base sequence, or of all oligonucleotides in a composition that share a common base sequence, a common backbone linkage pattern, and a common backbone phosphorus modification pattern, or of all oligonucleotides in a composition that share a common base sequence, a common base modification pattern, a common sugar modification pattern, a common internucleotide linkage type pattern, and / or a common internucleotide linkage modification pattern. , 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80 to 100%, 90 to 100%, 95 to 100%, 50% to 90% or approximately 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) are a plurality of oligonucleotides. In some embodiments, the plurality of oligonucleotides share the same stereochemistry at about 1 to 50 (e.g., about 1 to 10, 1 to 20, 5 to 10, 5 to 20, 10 to 15, 10 to 20, 10 to 25, 10 to 30, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) chiral internucleotide linkages.In some embodiments, the plurality of oligonucleotides comprises about 0.1% to 100% (e.g., about 1% to 100%, 5% to 100%, 10% to 100%, 20% to 100%, 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%, 50% to 90%, about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the chiral internucleotide linkages share the same stereochemistry. In some embodiments, each chiral internucleotide linkage is a chiral-controlled internucleotide linkage, and the composition is a completely chiral-controlled oligonucleotide composition. In some embodiments, not all chiral internucleotide linkages are chiral-controlled internucleotide linkages, and the composition is a partially chiral-controlled oligonucleotide composition. In some embodiments, the chiral-controlled oligonucleotide composition comprises a predetermined level of distinct oligonucleotide or nucleic acid types. For example, in some embodiments, a chiral controlled oligonucleotide composition comprises one oligonucleotide type at a predetermined level. In some embodiments, a chiral controlled oligonucleotide composition comprises two or more oligonucleotide types, each independently at a predetermined level. In some embodiments, a chiral controlled oligonucleotide composition comprises multiple oligonucleotide types, each independently at a predetermined level. In some embodiments, a chiral controlled oligonucleotide composition is a composition of oligonucleotides of a certain oligonucleotide type, and the composition comprises multiple oligonucleotides of that oligonucleotide type at a predetermined level.

[0103] Alicyclic: As used herein, the term "alicyclic" refers to a saturated or partially unsaturated aliphatic monocyclic, bicyclic, or polycyclic ring system, e.g., having 3 to 30 ring members, wherein the aliphatic ring system is optionally substituted. Alicyclic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, cycloalkyl has 3 to 6 carbons. The term "alicyclic" can also include an aliphatic ring fused to one or more aromatic or non-aromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring. In some embodiments, a carbocyclic group is bicyclic. In some embodiments, a carbocyclic group is tricyclic. In some embodiments, a carbocyclic group is polycyclic. In some embodiments, "alicyclic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon or C8-C8 ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic. 10 Bicyclic hydrocarbons or C9-C that are fully saturated or contain one or more units of unsaturation but are not aromatic 16 Refers to tricyclic hydrocarbons.

[0104] Halogen: The term "halogen" means F, Cl, Br or I.

[0105] Heteroaliphatic: The term "heteroaliphatic" is given its ordinary meaning in the art and refers to an aliphatic group, as defined herein, in which one or more carbon atoms are replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, etc.).

[0106] Heteroalkyl: The term "heteroalkyl" is given its ordinary meaning in the art and refers to an alkyl group, as described herein, in which one or more carbon atoms are replaced with a heteroatom (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, etc.). Examples of heteroalkyl groups include, but are not limited to, alkoxy, poly(ethylene glycol)-, alkyl-substituted amino, tetrahydrofuranyl, piperidinyl, morpholinyl, and the like.

[0107] Heteroaryl: The terms "heteroaryl" and "heteroal-," used alone or as part of a larger moiety (e.g., "heteroaralkyl" or "heteroaralkoxy"), refer to a monocyclic, bicyclic, or polycyclic ring system having, for example, a total of 5 to 30 ring members, where at least one ring of the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, the heteroatom is nitrogen, oxygen, or sulfur. In some embodiments, a heteroaryl group has 5 to 10 ring atoms (i.e., monocyclic, bicyclic, or polycyclic), and in some embodiments, 5, 6, 9, or 10 ring atoms. In some embodiments, a heteroaryl group has 6, 10, or 14 pi electrons shared within the cyclic array; in addition to the carbon atoms, and having 1 to 5 heteroatoms. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyronyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, a heteroaryl is a heterobiaryl group, such as bipyridyl. The terms "heteroaryl" and "heteroar-," as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic, or heterocyclyl rings, and the bonding group or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic, bicyclic, or polycyclic.The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," all of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, where the alkyl and heteroaryl portions independently are optionally substituted.

[0108] Heteroatom: The term "heteroatom" means an atom that is not carbon or hydrogen. In some embodiments, a heteroatom is oxygen, sulfur, nitrogen, phosphorus, boron, or silicon (any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic or substitutable nitrogen of a heterocycle (e.g., N, as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (such as in the case of N-substituted pyrrolidinyl); and the like). In some embodiments, the heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, or sulfur.

[0109] Heterocyclyl: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic group," and "heterocycle" are used interchangeably and refer to a saturated or partially unsaturated monocyclic, bicyclic, or polycyclic ring moiety (e.g., 3-30 membered) having one or more heteroatom ring atoms. In some embodiments, the heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, or sulfur. In some embodiments, the heterocyclyl group is a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably 1-4, heteroatoms (as defined above). When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in the case of a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen may be N (such as in 3,4-dihydro-2H-pyrrolyl), NH (such as in pyrrolidinyl), or +It can be NR (such as in the case of N-substituted pyrrolidinyl). The heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heteroaliphatic ring. Heterocyclyl groups can be monocyclic, bicyclic, or polycyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl portions independently are optionally substituted.

[0110] Internucleotide linkage: As used herein, the phrase "internucleotide linkage" generally refers to a phosphorus-containing linkage between nucleotide units of an oligonucleotide, which typically joins two adjacent sugar moieties together, and is synonymous with "intersugar linkage" and "phosphorus atom bridge." In some embodiments, the internucleotide linkage is a phosphodiester linkage as found in naturally occurring DNA and RNA molecules (a native phosphate linkage). In some embodiments, the internucleotide linkage is a "modified internucleotide linkage," in which each oxygen atom of the phosphodiester linkage is optionally and independently replaced by an organic or inorganic moiety. In some embodiments, such organic or inorganic moieties include, but are not limited to, =S, =Se, =NR', -SR', -SeR', -N(R'), B(R'). 3、 In some embodiments, the internucleotide linkage is a phosphotriester linkage, a phosphorothioate diester linkage, or a phosphate diester linkage. JPEG2024105256000013.jpg1177 or modified phosphorothioate triester linkages. Those skilled in the art will appreciate that internucleotide linkages may exist as anions or cations at a given pH due to the presence of acid or base moieties in the linkage.

[0111] Bound phosphorus: As defined herein, the phrase "bound phosphorus" is used to refer to the particular phosphorus atom being referenced being a phosphorus atom present in an internucleotide linkage, which corresponds to the phosphorus atom of the phosphodiester of the internucleotide linkage as found in naturally occurring DNA and RNA. In some embodiments, the bound phosphorus atom is in a modified internucleotide linkage, wherein each oxygen atom of the phosphodiester linkage is optionally and independently replaced by an organic or inorganic moiety. In some embodiments, the bound phosphorus atom is represented by P of Formula VII LIn some embodiments, the bound phosphorus atom is chiral. In some embodiments, the bound phosphorus is chiral (e.g., in a natural phosphate bond).

[0112] Oligonucleotide Type: As used herein, the phrase "oligonucleotide type" refers to a specific base sequence, backbone bond pattern (i.e., pattern of internucleotide bond types, e.g., phosphate, phosphorothioate, etc.), backbone chiral center pattern (i.e., pattern of bond phosphorus stereochemistry (Rp / Sp)), and backbone phosphorus modification pattern (e.g., "-XLR" in Formula VII). 5 " group pattern." In some embodiments, oligonucleotides of a common designated "type" are structurally identical, including stereochemically identical, to one another.

[0113] Oligonucleotide: The term "oligonucleotide" refers to a polymer or oligomer of nucleotide monomers containing any combination of nucleobases (natural or unnatural), sugars (natural or unnatural), and internucleotide linkages (natural or unnatural). Oligonucleotides of the present disclosure can be of various lengths. In specific embodiments, oligonucleotides can range from about 2 to about 200 nucleotides in length. In various embodiments, oligonucleotides can range in length from about 4 to about 10 nucleotides, about 10 to about 50 nucleotides, about 20 to about 50 nucleotides, about 15 to about 30 nucleotides, or about 20 to about 30 nucleotides. In some embodiments, oligonucleotides are about 9 to about 39 nucleotides in length. In some embodiments, oligonucleotides are at least 4 nucleotides in length. In some embodiments, oligonucleotides are at least 5 nucleotides in length. In some embodiments, oligonucleotides are at least 6 nucleotides in length. In some embodiments, oligonucleotides are at least 7 nucleotides in length. In some embodiments, oligonucleotides are at least 8 nucleotides in length. In some embodiments, oligonucleotides are at least 9 nucleotides in length. In some embodiments, oligonucleotides are at least 10 nucleotides in length. In some embodiments, the oligonucleotide is at least 11 nucleotides in length. In some embodiments, the oligonucleotide is at least 12 nucleotides in length. In some embodiments, the oligonucleotide is at least 15 nucleotides in length. In some embodiments, the oligonucleotide is at least 20 nucleotides in length. In some embodiments, the oligonucleotide is at least 25 nucleotides in length. In some embodiments, the oligonucleotide is at least 30 nucleotides in length. In some embodiments, the oligonucleotide is a duplex of complementary strands at least 18 nucleotides in length. In some embodiments, the oligonucleotide is a duplex of complementary strands at least 21 nucleotides in length.

[0114] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass groups with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties.

[0115] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in a unit dose amount suitable for administration in a treatment regimen that exhibits a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including: oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as a sterile solution or suspension or sustained-release formulation; topical application, e.g., as a cream, ointment, or controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginal or rectal administration, e.g., as a pessary, cream, or foam; sublingual; intraocular; transdermal; or adapted for the nasal, pulmonary, and other mucosal surfaces.

[0116] Pharmaceutically acceptable: As used herein, the phrase "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit-to-risk ratio.

[0117] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent, that encapsulates a material, involved in the transport or delivery of a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic, compatible substances used in pharmaceutical formulations.

[0118] Pharmaceutically acceptable salts: As used herein, the term "pharmaceutically acceptable salts" refers to salts of such compounds that are suitable for use in pharmaceutical contexts, i.e., salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., and that are commensurate with a reasonable risk-to-benefit ratio. Pharmaceutically acceptable salts are well known. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or formed by other known methods, such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy- Examples of salts include ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate.In some embodiments, pharmaceutically acceptable salts include non-toxic base addition salts, such as, but not limited to, those formed by acidic groups of provided compounds (e.g., phosphate linkage groups of oligonucleotides, phosphorothioate linkage groups of oligonucleotides, etc.) with bases. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, pharmaceutically acceptable salts include ammonium salts (e.g., -N(R)3). + ) In some embodiments, the pharmaceutically acceptable salt is a sodium salt. In some embodiments, pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates.

[0119] Predetermined: Predetermined (or pre-determined) means, for example, intentionally selected, as opposed to occurring randomly or achieved without control. Those skilled in the art will understand, upon reading this specification, that the present disclosure provides techniques that allow for the incorporation of selected specific chemical and / or stereochemical features into oligonucleotide compositions, and further allow for the controlled preparation of oligonucleotide compositions having such chemical and / or stereochemical features. Such provided compositions are "predetermined" as described herein. A composition that may contain a particular oligonucleotide because it has occurred by chance through an uncontrolled process that intentionally generates specific chemical and / or stereochemical features is not a "predetermined" composition. In some embodiments, a predetermined composition is one that can be intentionally reproduced (e.g., through repetition of a controlled process). In some embodiments, a predetermined level of a plurality of oligonucleotides in a composition means that the absolute and / or relative amounts (ratios, percentages, etc.) of the plurality of oligonucleotides in the composition are controlled. In some embodiments, a predetermined level of a plurality of oligonucleotides in a composition is achieved through chiral-controlled oligonucleotide preparation.

[0120] Protecting group: As used herein, the phrase "protecting group" refers to a temporary substituent that protects a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. A "Si-protecting group" is a protecting group containing a Si atom, such as Si-trialkyl (e.g., trimethylsilyl, tributylsilyl, t-butyldimethylsilyl), Si-triaryl, Si-alkyl-diphenyl (e.g., t-butyldiphenylsilyl), or Si-aryl-dialkyl (e.g., Si-phenyldialkyl). Generally, Si-protecting groups are attached to an oxygen atom. The field of protecting group chemistry has been reviewed (Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). Such protecting groups (and related protecting moieties) are described in detail below.

[0121] Protecting hydroxyl groups are well known in the art and are described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Butts, 3 rdedition, John Wiley & Sons, 1999 (incorporated herein by reference in its entirety). Examples of suitable protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, propionates, valerates, crotonates, and benzoates. Specific examples of suitable esters include formates, benzoyl formates, chloroacetates, trifluoroacetates, methoxyacetates, triphenylmethoxyacetates, p-chlorophenoxyacetates, 3-phenylpropionates, 4-oxopentanoates, 4,4-(ethylenedithio)pentanoates, pivalates (trimethylacetates), crotonates, 4-methoxy-crotonates, benzoates, benzyl p-benzoates, and 2,4,6-trimethylbenzoates. Examples of suitable carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonates. Examples of suitable silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether, and other trialkylsilyl ethers. Examples of suitable alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and allyl ethers or derivatives thereof. Examples of alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, β-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether. Examples of suitable arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.

[0122] Protected amines are well known in the art and include those described in detail in Greene (1999). Suitable mono-protected amines further include, but are not limited to, aralkyl amines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (-NHAlloc), benzyloxycarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethylcarbonyl (-NHFmoc), formamide, acetamide, chloroacetamide, dichloroacetamide, trichloroacetamide, phenylacetamide, trifluoroacetamide, benzamide, t-butyldiphenylsilyl, and the like. Suitable di-protected amines include amines substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides such as phthalimide, maleimide, succinimide, etc. Suitable di-protected amines also include pyrroles, such as 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine, and azides.

[0123] Protected aldehydes are well known in the art and include those described in detail in Greene (1999). Suitable protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, etc. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxanes, 1,3-dioxolanes, semicarbazones, and derivatives thereof.

[0124] Protected carboxylic acids are well known in the art and include those described in detail in Greene (1999). Suitable protected carboxylic acids further include, but are not limited to, optionally substituted C 1~6 These include aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, etc. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl esters, each of which is optionally substituted. Further suitable protected carboxylic acids include oxazolines and orthoesters.

[0125] Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioesters, to name a few.

[0126] Substituted: As described herein, compounds of the present disclosure can contain optionally substituted and / or substituted moieties. In general, the term "substituted," whether preceded by the term "optionally," means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group can have a suitable substituent at each of the group's substitutable positions, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituents can be the same or different at all positions. Combinations of substituents contemplated by the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to a compound that remains substantially unchanged when subjected to conditions that permit its production, detection, and, in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein. In some embodiments, exemplary substituents are described below.

[0127] Preferred monovalent substituents are halogen; -(CH2) 0~4 R ○ ;-(CH2) 0~4 OR ○ ;-O(CH2) 0~4 R ○ , -O-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 CH(OR ○ )2;-(CH2) 0~4 Ph(R ○ -(CH2) 0~4 O(CH2) 0~1 Ph(R ○ -CH=CHPh(R ○ -(CH2) 0~4 O(CH2) 0~1 -pyridyl (R ○ -NO2; -CN; -N3; ​​-(CH2) 0~4 N(R ○ )2;-(CH2) 0~4 N(R ○ )C(O)R○ ;-N(R ○ )C(S)R ○ ;-(CH2) 0~4 N(R ○ )C(O)N(R ○ )2;-N(R ○ )C(S)N(R ○ )2;-(CH2) 0~4 N(R ○ )C(O)OR ○ ;-N(R ○ )N(R ○ )C(O)R ○ ;-N(R ○ )N(R ○ )C(O)N(R ○ )2;-N(R ○ )N(R ○ )C(O)OR ○ ;-(CH2) 0~4 C(O)R ○ ;-C(S)R ○ ;-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 C(O)SR ○ ;-(CH2) 0~4 C(O)OSi(R ○ )3;-(CH2) 0~4 OC(O)R ○ ;-OC(O)(CH2) 0~4 SR ○ 、-SC(S)SR ○ ;-(CH2) 0~4 SC(O)R ○ ;-(CH2) 0~4 C(O)N(R ○ )2;-C(S)N(R ○ )2;-C(S)SR ○ ;-SC(S)SR ○ 、-(CH2) 0~4 OC(O)N(R ○ )2;-C(O)N(OR ○ )R ○ ;-C(O)C(O)R ○ ;-C(O)CH2C(O)R ○ ;-C(NOR ○ )R ○ ;-(CH2) 0~4 SSR ○;-(CH2) 0~4 S(O)2R ○ ;-(CH2) 0~4 S(O)2OR ○ ;-(CH2) 0~4 OS(O)2R ○ ;-S(O)2N(R ○ )2;-(CH2) 0~4 S(O)R ○ ;-N(R ○ )S(O)2N(R ○ )2;-N(R ○ )S(O)2R ○ ;-N(OR ○ )R ○ ;-C(NH)N(R ○ )2;-Si(R ○ )3;-OSi(R ○ )3;-P(R ○ )2;-P(OR ○ )2;-P(R ○ )(OR ○ );-OP(R ○ )2;-OP(OR ○ )2;-OP(R ○ )(OR ○ );-P[N(R ○ )2]2-P(R ○ )[N(R ○ )2];-P(OR ○ )[N(R ○ )2];-OP[N(R ○ )2]2;-OP(R ○ )[N(R ○ )2];-OP(OR ○ )[N(R ○ )2];-N(R ○ )P(R ○ )2;-N(R ○ )P(OR ○ )2;-N(R ○ )P(R ○ )(OR ○ );-N(R ○ )P[N(R ○ )2]2;-N(R ○ )P(R ○ )[N(R ○ )2];-N(R ○ )P(OR ○ )[N(R○ )2];-B(R ○ )2;-B(R ○ )(OR ○ );-B(OR ○ )2;-OB(R ○ )2;-OB(R ○ )(OR ○ );-OB(OR ○ )2;-P(O)(R ○ )2;-P(O)(R ○ )(OR ○ );-P(O)(R ○ )(SR ○ );-P(O)(R ○ )[N(R ○ )2];-P(O)(OR ○ )2;-P(O)(SR ○ )2;-P(O)(OR ○ )[N(R ○ )2];-P(O)(SR ○ )[N(R ○ )2];-P(O)(OR ○ )(SR ○ );-P(O)[N(R ○ )2]2;-OP(O)(R ○ )2;-OP(O)(R ○ )(OR ○ );-OP(O)(R ○ )(SR ○ );-OP(O)(R ○ )[N(R ○ )2];-OP(O)(OR ○ )2;-OP(O)(SR ○ )2;-OP(O)(OR ○ )[N(R ○ )2];-OP(O)(SR ○ )[N(R ○ )2];-OP(O)(OR ○ )(SR ○ );-OP(O)[N(R ○ )2]2;-SP(O)(R ○ )2;-SP(O)(R ○ )(OR ○ );-SP(O)(R ○ )(SR ○ );-SP(O)(R ○ )[N(R○ )2];-SP(O)(OR ○ )2;-SP(O)(SR ○ )2;-SP(O)(OR ○ )[N(R ○ )2];-SP(O)(SR ○ )[N(R ○ )2];-SP(O)(OR ○ )(SR ○ );-SP(O)[N(R ○ )2]2;-N(R ○ )P(O)(R ○ )2;-N(R ○ )P(O)(R ○ )(OR ○ );-N(R ○ )P(O)(R ○ )(SR ○ );-N(R ○ )P(O)(R ○ )[N(R ○ )2];-N(R ○ )P(O)(OR ○ )2;-N(R ○ )P(O)(SR ○ )2;-N(R ○ )P(O)(OR ○ )[N(R ○ )2];-N(R ○ )P(O)(SR ○ )[N(R ○ )2];-N(R ○ )P(O)(OR ○ )(SR ○ );-N(R ○ )P(O)[N(R ○ )2]2;-P(R ○ )2[B(R ○ )3];-P(OR ○ )2[B(R ○ )3];-P(NR ○ )2[B(R ○ )3];-P(R ○ )(OR ○ )[B(R ○ )3];-P(R ○ )[N(R ○ )2][B(R ○ )3];-P(OR ○ )[N(R○ )2][B(R ○ )3];-OP(R ○ )2[B(R ○ )3];-OP(OR ○ )2[B(R ○ )3];-OP(NR ○ )2[B(R ○ )3];-OP(R ○ )(OR ○ )[B(R ○ )3];-OP(R ○ )[N(R ○ )2][B(R ○ )3];-OP(OR ○ )[N(R ○ )2][B(R ○ )3];-N(R ○ )P(R ○ )2[B(R ○ )3];-N(R ○ )P(OR ○ )2[B(R ○ )3];-N(R ○ )P(NR ○ )2[B(R ○ )3];-N(R ○ )P(R ○ )(OR ○ )[B(R ○ )3];-N(R ○ )P(R ○ )[N(R ○ )2][B(R ○ )3];-N(R ○ )P(OR ○ )[N(R ○ )2][B(R ○ )3];-P(OR')[B(R')3]-;-(C 1~4 Linear or branched alkylene)ON(R ○ )2; or -(C 1~4 Linear or branched alkylene)C(O)ON(R ○ )2(in the formula, each R ○ may be substituted as defined below and independently represent hydrogen, C 1~20 C having 1 to 5 heteroatoms independently selected from aliphatic, nitrogen, oxygen, sulfur, silicon, and phosphorus 1~20 Heteroaliphatic), -CH2-(C6~14 aryl), -O(CH2) 0~1 (C 6~14 aryl), -CH2- (5- to 14-membered heteroaryl ring), a 5- to 20-membered monocyclic, bicyclic, or polycyclic saturated, partially unsaturated, or aryl ring having 0 to 5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon, and phosphorus, or, despite the above definitions, R ○ two independent occurrences of together with their intervening atoms are 5-20 membered monocyclic, bicyclic or polycyclic saturated, partially unsaturated or aryl rings (which may be substituted as defined below) having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus.

[0128] R 〇 (or R 〇 Suitable monovalent substituents for the ring formed by two independent occurrences of -(CH) together with their intervening atoms are independently halogen, -(CH) 0~2 R · ,-(Halo R · ), -(CH2) 0~2 OH, -(CH2) 0~2 OR · , -(CH2) 0~2 CH(OR · )2;-O(HaloR · ), -CN, -N3, -(CH2) 0~2 C(O)R · , -(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR · , -(CH2) 0~2 SR · , -(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR · , -(CH2) 0~2 NR · 2, -NO2, -SiR · 3. -OSiR · 3. -C(O)SR · , -(C 1~4 Linear or branched alkylene)C(O)OR · or -SSR ·(where each R · is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only) and independently C1-C4 aliphatic, -CH2Ph, -O(CH2) 0~1 Ph or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon, and phosphorus. 〇 Suitable divalent substituents for saturated carbon atoms of include ═O and ═S.

[0129] Preferred divalent substituents are: =O, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O- or -S(C(R * 2)) 2~3 S-, where R * Each independent occurrence of is selected from hydrogen, a C1-C6 aliphatic, or an unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which may be substituted as defined below. Suitable divalent substituents attached to adjacent substitutable carbons of an "optionally substituted" group include -O(CR * 2) 2~3 O-, where R * Each independent occurrence of is selected from hydrogen, a C1-C6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms selected from nitrogen, oxygen and sulfur which may be substituted as defined below.

[0130] R * Suitable substituents for the aliphatic groups of R are halogen, · ,-(Halo R · ), -OH, -OR · , -O(HaloR · ), -CN, -C(O)OH, -C(O)OR · , -NH2, NHR· , -NR · 2 or -NO2 (each R · is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only) and independently C1-C4 aliphatic, -CH2Ph, -O(CH2) 0~1 Ph or independently is a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms selected from nitrogen, oxygen and sulfur.

[0131] In some embodiments, a suitable substituent on a substitutable nitrogen is —R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CHC(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2 or -N(R † )S(O)2R † where each R † are independently hydrogen, C which may be substituted as defined below 1~6 an aliphatic, unsubstituted -OPh or an unsubstituted 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or, notwithstanding the above definitions, R † two independent occurrences of together with their intervening atoms form an unsubstituted 3- to 12-membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0132] R † Suitable substituents on the aliphatic groups are independently halogen, -R · ,-(Halo R · ), -OH, -OR · , -O(HaloR · ), -CN, -C(O)OH, -C(O)OR · , -NH2, -NHR · , -NR· 2 or -NO2, wherein each R · is unsubstituted or, when preceded by "halo", is substituted only with one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph or a 5- or 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0133] Unsaturated: As used herein, the term "unsaturated" means that a moiety has one or more units of unsaturation.

[0134] Unless otherwise specified, salts, e.g., pharmaceutically acceptable acid or base addition salts, stereoisomeric forms, and tautomeric forms of the provided compounds are included. Unless otherwise specified, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "compound" may include a plurality of such compounds.

[0135] 2. Detailed Description of Specific Embodiments Among other things, the present disclosure provides techniques for preparing oligonucleotide compositions, particularly chiral controlled oligonucleotide compositions, with unexpectedly improved crude purity and yield. In some embodiments, the provided techniques can dramatically reduce the cost of goods and, in some embodiments, enable large-scale production of therapeutic oligonucleotides under conditions, e.g., cost, purity, yield, etc., that are commercially acceptable for clinical use and commercialization. As one of skill in the art will appreciate, the provided techniques enable the production of a variety of oligonucleotide compositions independent of base sequence, chemical / stereochemical modifications, mode of activity, chiral auxiliaries, etc. Exemplary embodiments of the provided techniques are described herein.

[0136] Oligonucleotides and Oligonucleotide Compositions In some embodiments, the oligonucleotide compositions of the provided technology, e.g., product oligonucleotide compositions of various steps, final oligonucleotide compositions, etc., are chiral controlled oligonucleotide compositions. In some embodiments, the oligonucleotides of the provided technology, e.g., product oligonucleotides of various steps, final product oligonucleotides, etc., are chiral controlled oligonucleotide compositions. JPEG2024105256000014.jpg2577 or a salt thereof, wherein: R 5s are independently R' or -OR'; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(O and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-; and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P ...O-, or -OP(OR')[B(R')3]O-. L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each ring As is independently an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R s are independently -H, halogen, -CN, -N3, -NO, -NO2, -L s -R', -L s -Si(R)3, -L s -OR', -L s -SR', -L s -N(R')2, -OL s -R', -OL s -Si(R)3, -OL s -OR', -OL s -SR' or -OL s -N(R')2; each t is independently 0 to 20; Each BA independently 3~30 Alicyclic and C 6~30 C having aryl and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 5~30 Heteroaryl and C having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 3~30 an optionally substituted group selected from heterocyclyl, natural nucleobase moieties, and modified nucleobase moieties; Each L P are independently an internucleotide bond; z is 1 to 1000; L 3E -L s -or-L s -L s - and; R 3E -R', -L s -R', -OR' or a support; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; Each R is independently -H or C 1~30C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0137] In some embodiments, the oligonucleotide composition is a chiral controlled oligonucleotide composition.

[0138] In some embodiments, the chiral controlled oligonucleotide composition comprises: 1) common base sequence; 2) common skeletal bonding patterns; 3) independently about 1 to 50 (e.g., about 5 to 50, about 10 to 50, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50, etc.) common stereochemistry at chiral internucleotide linkages ("chiral controlled internucleotide linkages"). an oligonucleotide composition comprising a plurality of oligonucleotides sharing a The composition is chiral controlled in that the level of the plurality of oligonucleotides in the composition is predetermined.

[0139] In some embodiments, the chiral controlled oligonucleotide composition is an oligonucleotide composition comprising a plurality of oligonucleotides, wherein the plurality of oligonucleotides comprises: 1) Nucleotide sequence; 2) skeletal bonding pattern; 3) backbone chiral center pattern; and 4) Backbone phosphorus modification pattern is a specific oligonucleotide type defined by: The composition is chiral controlled in that the level of the plurality of oligonucleotides in the composition is predetermined.

[0140] In some embodiments, the chiral controlled oligonucleotide composition comprises: 1) common base sequence; 2) a common backbone bonding pattern; and 3) Common skeletal chiral center pattern and wherein the composition is a substantially pure preparation of a single oligonucleotide in that a given level of the oligonucleotides in the composition have a common base sequence and length, a common backbone linkage pattern, and a common backbone chiral center pattern.

[0141] In some embodiments, the chiral controlled oligonucleotide composition is an oligonucleotide composition comprising a plurality of oligonucleotides, wherein: The oligonucleotides share the same base sequence; The oligonucleotides share the same backbone linkage pattern; and the plurality of oligonucleotides comprise at least one chiral controlled internucleotide linkage, the internucleotide linkage being chiral controlled in that the plurality of oligonucleotides share the same stereochemical configuration at the chiral linking phosphorus of the internucleotide linkage; At least ((DS)Nc x 100)% of all oligonucleotides sharing the same base sequence in the composition are multiple oligonucleotides, where DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, and Nc is the number of chiral internucleotide linkages.

[0142] In some embodiments, the chiral controlled oligonucleotide composition is an oligonucleotide composition comprising a plurality of oligonucleotides, wherein: The oligonucleotides share the same composition; and the plurality of oligonucleotides comprise at least one chiral controlled internucleotide linkage, the internucleotide linkage being chiral controlled in that the plurality of oligonucleotides share the same stereochemical configuration at the chiral linking phosphorus of the internucleotide linkage; and The (DS) of all oligonucleotides sharing the same base sequence in the composition Nc × 100)% or more are multiple oligonucleotides, where DS is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and Nc is the number of chiral internucleotide linkages.

[0143] In some embodiments, provided oligonucleotides contain 1 to 30 non-natural internucleotide linkages (not -OP(O)(OH)-O- or salt forms thereof). In some embodiments, provided oligonucleotides contain 2 to 30 non-natural internucleotide linkages. In some embodiments, provided oligonucleotides contain 5 to 30 non-natural internucleotide linkages. In some embodiments, provided oligonucleotides contain 10 to 30 non-natural internucleotide linkages.

[0144] In some embodiments, the provided oligonucleotides comprise 1 to 30 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 2 to 30 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 5 to 30 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 10 to 30 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 1 chiral-controlled internucleotide linkage. In some embodiments, the provided oligonucleotides comprise 2 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 3 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 4 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 5 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 6 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 7 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides comprise 8 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotide comprises 9 chirality-controlled internucleotide linkages. In some embodiments, the provided oligonucleotide comprises 10 chirality-controlled internucleotide linkages. In some embodiments, the provided oligonucleotide comprises 11 chirality-controlled internucleotide linkages. In some embodiments, the provided oligonucleotide comprises 12 chirality-controlled internucleotide linkages. In some embodiments, the provided oligonucleotide comprises 13 chirality-controlled internucleotide linkages.In some embodiments, the provided oligonucleotides contain 14 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 15 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 16 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 17 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 18 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 19 chiral-controlled internucleotide linkages. In some embodiments, the provided oligonucleotides have 20 chiral-controlled internucleotide linkages. In some embodiments, about 1-100% of all internucleotide linkages are chiral-controlled internucleotide linkages. In some embodiments, about 1-100% of all chiral internucleotide linkages (including chiral linking phosphorus) are chiral-controlled internucleotide linkages. In some embodiments, the percentage is about 5%-100%. In some embodiments, the percentage is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the percentage is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, each chiral internucleotide linkage is chiral controlled. In some embodiments, some or all of the chirality-controlled internucleotide linkages in a provided oligonucleotide or one or more segments thereof (e.g., the 5'-wing region, core wing, 3'-wing region) are contiguous.In some embodiments, all of the chirality-controlled internucleotide linkages in a provided oligonucleotide or one or more segments thereof (eg, 5'-wing region, core wing, 3'-wing region) are contiguous.

[0145] In some embodiments, provided oligonucleotides contain 1 to 30 natural phosphate linkages (not -OP(O)(OH)-O- or salt forms thereof). In some embodiments, provided oligonucleotides further contain 1 to 30 natural phosphate linkages (not -OP(O)(OH)-O- or salt forms thereof) in addition to natural phosphate linkages or chiral internucleotide linkages or chiral-controlled internucleotide linkages as described herein. In some embodiments, provided oligonucleotides contain 2 to 30 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 5 to 30 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 10 to 30 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 1 chiral-controlled internucleotide linkage. In some embodiments, provided oligonucleotides contain 2 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 3 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 4 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 5 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 6 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 7 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 8 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 9 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 10 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 11 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 12 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 13 natural phosphate linkages. In some embodiments, provided oligonucleotides contain 14 natural phosphate linkages. In some embodiments, provided oligonucleotides have 15 natural phosphate linkages.In some embodiments, provided oligonucleotides have 16 natural phosphate linkages. In some embodiments, provided oligonucleotides have 17 natural phosphate linkages. In some embodiments, provided oligonucleotides have 18 natural phosphate linkages. In some embodiments, provided oligonucleotides have 19 natural phosphate linkages. In some embodiments, provided oligonucleotides have 20 natural phosphate linkages. In some embodiments, about 1-100% of all internucleotide linkages are natural phosphate linkages. In some embodiments, about 1-99% of all internucleotide linkages are natural phosphate linkages and about 1-99% of all internucleotide linkages are non-natural internucleotide linkages (e.g., an internucleotide linkage of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, and a non-natural internucleotide linkage). In some embodiments, about 1-99% of all internucleotide linkages are natural phosphate linkages, and about 1-99% of all internucleotide linkages are chiral internucleotide linkages (e.g., internucleotide linkages of formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or salt forms thereof, and chiral). In some embodiments, about 1-99% of all internucleotide linkages are natural phosphate linkages, and about 1-99% of all internucleotide linkages are chiral controlled oligonucleotide composition internucleotide linkages (e.g., internucleotide linkages of formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or salt forms thereof, and chiral controlled). In some embodiments, the percentage is about 5% to 100%. In some embodiments, the percentage is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%.In some embodiments, the percentage is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, each non-natural internucleotide linkage independently has the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, wherein the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, is a non-natural internucleotide linkage (not -OP(O)(OH)-O- or a salt form thereof). In some embodiments, each chiral linkage independently has the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, wherein the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, is not a naturally occurring phosphate linkage (is not —O—P(O)(OH)—O— or a salt form thereof). In some embodiments, each chiral-controlled phosphate linkage independently has the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, wherein the structure of Formula VII, VII-a-1, VII-a-2, VII-b, VII-c, VII-d, or VII-e, or a salt form thereof, is not a natural phosphate linkage (not -OP(O)(OH)-O- or a salt form thereof). In some embodiments, some or all of the natural phosphate linkages in a provided oligonucleotide or one or more segments thereof (e.g., the 5'-wing region, core wing, 3'-wing region) are contiguous. In some embodiments, all of the natural phosphate linkages in a provided oligonucleotide or one or more segments thereof (e.g., the 5'-wing region, core wing, 3'-wing region) are contiguous.

[0146] In some embodiments, the non-natural internucleotide linkage is a phosphorothioate linkage or a salt form thereof (-OP(O)(SH)-O- or a salt form thereof). In some embodiments, the chiral internucleotide linkage is a phosphorothioate linkage or a salt form thereof (-OP(O)(SH)-O- or a salt form thereof). In some embodiments, the chiral controlled internucleotide linkage is a phosphorothioate linkage or a salt form thereof (-OP(O)(SH)-O- or a salt form thereof).

[0147] In some embodiments, provided oligonucleotides comprise between 5 and 200, 5 and 150, 5 and 100, 5 and 50, 5 and 40, 5 and 35, 5 and 30, 5 and 25, 10 and 200, 10 and 150, 10 and 100, 10 and 50, 10 and 40, 10 and 35, 10 and 30, 10 and 25, 15 and 200, 15 and 150, 15 and 100, 15 and 50, 15 and 40, 15 and 35, 15 and 30, or 15 and 25 nucleobases. In some embodiments, provided oligonucleotides comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50 nucleobases. In some embodiments, provided oligonucleotides comprise at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50 nucleobases. In some embodiments, provided oligonucleotides comprise at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50 nucleobases. In some embodiments, provided oligonucleotides comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50 nucleobases. In some embodiments, provided oligonucleotides comprise at least 15 nucleobases. In some embodiments, provided oligonucleotides comprise at least 16 nucleobases. In some embodiments, provided oligonucleotides comprise at least 17 nucleobases. In some embodiments, provided oligonucleotides comprise at least 18 nucleobases. In some embodiments, provided oligonucleotides comprise at least 19 nucleobases. In some embodiments, provided oligonucleotides comprise at least 20 nucleobases. In some embodiments, provided oligonucleotides comprise at least 21 nucleobases.In some embodiments, the provided oligonucleotides comprise at least 22 nucleobases. In some embodiments, the provided oligonucleotides comprise at least 23 nucleobases. In some embodiments, the provided oligonucleotides comprise at least 24 nucleobases. In some embodiments, the provided oligonucleotides comprise at least 25 nucleobases. In some embodiments, the nucleobases are optionally substituted adenine, cytosine, guanosine, thymine, or uracil, or tautomers thereof.

[0148] In some embodiments, each chiral bonded phosphorus independently has a diastereomeric purity as described herein. In some embodiments, provided compounds have a purity, diastereomeric purity, and / or enantiomeric purity as described herein. In some embodiments, provided compounds have a purity as described herein. In some embodiments, provided compounds have a diastereomeric purity as described herein. In some embodiments, provided compounds have an enantiomeric purity as described herein. In some embodiments, provided compounds have a diastereomeric purity and an enantiomeric purity as described herein.

[0149] In some embodiments, the provided oligonucleotides comprise or are a 5'-wing region-core region-3'-wing region structure. In some embodiments, the provided oligonucleotides comprise or are a 5'-wing region-core region structure. In some embodiments, the provided oligonucleotides comprise or are a core region-3'-wing region structure. In some embodiments, the provided oligonucleotides comprise a 5'-wing region-core region-3'-wing region structure. In some embodiments, the provided oligonucleotides comprise a 5'-wing region-core region structure. In some embodiments, the provided oligonucleotides comprise a core region-3'-wing region structure. In some embodiments, the provided oligonucleotides are in a 5'-wing region-core region-3'-wing region structure. In some embodiments, the provided oligonucleotides are in a 5'-wing region-core region structure. In some embodiments, the provided oligonucleotides are in a core region-3'-wing region structure. In some embodiments, the wing-core-wing (i.e., XYX) motif is numbered, for example, 5-10-4, meaning that the 5'-wing region is 5 bases long, the core region is 10 bases long, and the 3'-wing region is 4 bases long. In some embodiments, the wing-core-wing motif is, for example, any of the following: 2-16-2, 3-14-3, 4-12-4, 5-10-5, 2-9-6, 3-9-3, 3-9-4, 3-9-5, 4-7-4, 4-9-3, 4-9-4, 4-9-5, 4-10-5, 4-11-4, 4-11-5, 5-7-5, 5-8-6, 8-7-5, 7-7-6, 5-9-3, 5-9-5, 5-10-4, 5-10-5, 6-7-6, 6-8-5, and 6-9-2. In certain embodiments, the wing-core-wing motif is 5-10-5. In certain embodiments, the wing-core-wing motif is 7-7-6. In certain embodiments, the wing-core-wing motif is 8-7-5. In some embodiments, the wing-core motif is 5-15, 6-14, 7-13, 8-12, 9-12, etc.In some embodiments, the core-wing motif is 5-15, 6-14, 7-13, 8-12, 9-12, and the like.

[0150] In some embodiments, the wing region comprises a sugar modification that is not present in the core region. In some embodiments, the wing region comprises a 2'-modification. In some embodiments, each nucleotide unit of the wing region independently comprises a 2'-modification. In some embodiments, each nucleotide unit of the wing region independently comprises the same 2'-modification. In some embodiments, each nucleotide unit of the 5'-wing region independently comprises the same 2'-modification. In some embodiments, each nucleotide unit of the 3'-wing region independently comprises the same 2'-modification. In some embodiments, the 2'-modifications of the 5'-wing region are the same. In some embodiments, the 2'-modifications of the 5'-wing region are different. In some embodiments, the 2'-modification is 2'-OR, where R' is not hydrogen. In some embodiments, the 2'-modification is 2'-OR, where R' is an optionally substituted C 1~6 In some embodiments, the 2'-modification is 2'-OR, where R' is an optionally substituted C 1~6 In some embodiments, the 2'-modification is alkyl. In some embodiments, the 2'-modification is 2'-OMe. In some embodiments, the 2'-modification is 2'-OCH2CH2OMe. In some embodiments, the wing region comprises one or more natural phosphate linkages as described herein. Additionally or alternatively, in some embodiments, the wing region comprises one or more non-natural internucleotide linkages, such as phosphorothioate internucleotide linkages. In some embodiments, the core region comprises one or more natural phosphate linkages. In some embodiments, the core region comprises one or more consecutive natural phosphate linkages. In some embodiments, the core region comprises one or more chiral phosphate linkages. In some embodiments, the core region comprises one or more consecutive chiral phosphate linkages. In some embodiments, the chiral phosphate linkages are phosphorothioate linkages. In some embodiments, the chiral phosphate linkages are chiral-controlled.

[0151] The oligonucleotides of the present disclosure may contain a backbone chiral center pattern. In some embodiments, the backbone chiral center pattern of the oligonucleotide or a segment thereof, such as the core region, results in increased stability. In some embodiments, the backbone chiral center pattern unexpectedly results in increased activity. In some embodiments, the backbone chiral center pattern unexpectedly results in increased stability and activity. In some embodiments, the backbone chiral center pattern unexpectedly results in increased binding to a specific protein. In some embodiments, the backbone chiral center pattern unexpectedly results in enhanced delivery. In some embodiments, the backbone chiral center pattern comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, (Sp)p(Rp)n(Sp)m, (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m or (Sp)p(Op)n(Sp)m (5' to 3' unless otherwise specified), where n is 1-10 and each of p and m is independently 0-50. In some embodiments, the backbone chiral center pattern comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, (Sp)p(Rp)n(Sp)m, (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m or (Sp)p(Op)n(Sp)m (5' to 3' unless otherwise specified), where n is 1 to 10 and each of p and m is independently 1 to 50. In some embodiments, the backbone chiral center pattern comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m (5' to 3' unless otherwise specified), where n is 1 to 10 and each of p and m is independently 1 to 50. In some embodiments, the backbone chiral center pattern comprises (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m.In some embodiments, the backbone chiral center pattern is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is a repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is a repeating pattern of (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m (5' to 3'). In some embodiments, the backbone chiral center pattern comprises or is a repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is a repeating pattern of (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m (5' to 3').

[0152] In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, where m > 2. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, where n is 1, p > 1, and m > 2. In some embodiments, m > 3. In some embodiments, m > 4. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, where m > 2. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, where n is 1, p>1, and m>2. In some embodiments, m>3. In some embodiments, m>4. In some embodiments, the backbone chiral center pattern of the oligonucleotide, or a region thereof, comprises or is two or more units independently selected from (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, (Sp)p(Rp)n(Sp)m, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, and (Sp)p(Op)n(Sp)m, where each variable is independently as described in this disclosure. In some embodiments, n is 1. In some embodiments, n is 1, and m of each unit is independently 2 or greater, as described herein. In some embodiments, at least two m's in two units are different. In some embodiments, the backbone chiral center pattern comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 such units. In some embodiments, the backbone chiral center pattern comprises 2, but not more than 2, such units. In some embodiments, the backbone chiral center pattern comprises 3, but not more than 3, such units. In some embodiments, the backbone chiral center pattern comprises 4, but not more than 4, such units.In some embodiments, the backbone chiral center pattern contains five such units, but not more than five. In some embodiments, a region of the oligonucleotide contains such a backbone chiral center pattern. In some embodiments, such a region does not contain 2'-substitutions in its sugar moieties (two 2'-H). In some embodiments, such a region is flanked by a 5'-region containing a sugar modification as described herein (e.g., a 2'-modification as described herein, e.g., 2'-OMe, 2'-MOE, 2'-F, etc.) and / or a 5'-region containing a sugar modification as described herein (e.g., a 2'-modification as described herein, e.g., 2'-OMe, 2'-MOE, 2'-F, etc.).

[0153] In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, (Sp)p(Sp)m, or (Sp)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, and the oligonucleotide comprises one or more 2'-modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, and the oligonucleotide comprises one or more 2'-F modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, and the oligonucleotide comprises one or more 2'-OR modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, and the oligonucleotide comprises one or more 2'-OR modifications, where R is not -H. In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, and each nucleoside unit between internucleotide linkages having the pattern (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m does not comprise a 2'-modification.In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, wherein each nucleoside unit between internucleotide linkages having the pattern (Rp)n(Sp)m, (Sp)p(Rp)n, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m does not contain a 2'-substitution (-CH2- at the 2'-position). In some embodiments, the backbone chiral center pattern comprises or is (Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Rp)n. In some embodiments, the backbone chiral center pattern comprises or is (Np)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises (Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises (Sp)p(Rp)n. In some embodiments, the backbone chiral center pattern comprises (Np)(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern is (Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern is (Sp)p(Rp)n. In some embodiments, the backbone chiral center pattern is (Np)p(Rp)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Sp)m, optionally with n achiral phosphodiester internucleotide linkages and / or stereorandom (chiral uncontrolled) chiral internucleotide linkages between sections having (Sp)p and sections having (Sp)m. In some embodiments, there are n achiral phosphodiester internucleotide linkages therebetween. In some embodiments, there are n stereorandom chiral internucleotide linkages therebetween. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Rp)n(Sp)m.

[0154] In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, (Sp)p(Sp)m, or (Sp)p(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, and the oligonucleotide comprises one or more 2'-modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, and the oligonucleotide comprises one or more 2'-F modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, and the oligonucleotide comprises one or more 2'-OR modifications as described herein. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m or (Sp)p(Op)n(Sp)m, and the oligonucleotide comprises one or more 2'-OR modifications, where R is not -H. In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m or (Sp)p(Op)n(Sp)m, and each nucleoside unit between internucleotide linkages having the pattern (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m or (Sp)p(Op)n(Sp)m does not comprise a 2'-modification.In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, wherein each nucleoside unit between internucleotide linkages having the pattern (Op)n(Sp)m, (Sp)p(Op)n, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m does not contain a 2'-substitution (-CH2- at the 2'-position). In some embodiments, the backbone chiral center pattern comprises or is (Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Op)n. In some embodiments, the backbone chiral center pattern comprises or is (Np)p(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises (Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises (Sp)p(Op)n. In some embodiments, the backbone chiral center pattern comprises (Np)(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern is (Op)n(Sp)m. In some embodiments, the backbone chiral center pattern is (Sp)p(Op)n. In some embodiments, the backbone chiral center pattern is (Np)p(Op)n(Sp)m. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Sp)m, optionally with n achiral phosphodiester internucleotide linkages and / or stereorandom (chiral uncontrolled) chiral internucleotide linkages between sections having (Sp)p and sections having (Sp)m. In some embodiments, there are n achiral phosphodiester internucleotide linkages therebetween. In some embodiments, there are n stereorandom chiral internucleotide linkages therebetween. In some embodiments, the backbone chiral center pattern comprises or is (Sp)p(Op)n(Sp)m.

[0155] In some embodiments, the oligonucleotide, or a region thereof, comprises a backbone chiral center pattern or repeating pattern of (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m (structurally, starting from the first internucleotide linkage and ending with the last internucleotide linkage having a pattern or repeating pattern of (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m, respectively; depending on whether it is a repeat, it is referred to as a "(repeated) (Sp)m(Rp)n region," "(repeated) (Rp)n(Sp)m region," "(repeated) (Np)p(Rp)n(Sp)m region," or "(repeated) (Sp)p(Rp)n(Sp)m region," respectively). In some embodiments, the oligonucleotide, or a region thereof, comprises a backbone chiral center pattern or repeating pattern of (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m (structurally, starting from the first internucleotide linkage and ending with the last internucleotide linkage having a pattern or repeating pattern of internucleotide linkages of (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m, respectively; depending on whether or not there is a repeat, referred to as a "(repeated) (Sp)m(Op)n region," "(repeated) (Op)n(Sp)m region," "(repeated) (Np)p(Op)n(Sp)m region," or "(repeated) (Sp)p(Op)n(Sp)m region," respectively). For example, the (Sp)p(Rp)n(Sp)m region ((Sp)7(Rp)1(Sp)3 in WV-2555): JPEG2024105256000015.jpg1177) does not contain 2'-OR sugar modifications. In some embodiments, each sugar moiety in this region is -CH2- at the 2'-position. In some embodiments, each sugar moiety in this region is an unmodified, native 2'-deoxyribose moiety of DNA. In some embodiments, the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m is adjacent to a 5'-wing region that structurally terminates in a nucleoside moiety that is linked at its 3' end to the first internucleotide bond of the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m. For example, the adjacent 5'-wing region in WV-2555: In some embodiments, the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m is adjacent to a 5'-wing region that structurally terminates with a nucleoside moiety that is linked at its 3' end to the first internucleotide linkage of the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m. In some embodiments, the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m is adjacent to a 3'-wing region that structurally begins with a nucleoside moiety that is linked at its 5' end to the last internucleotide linkage of the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m. For example, the adjacent 3'-wing region in WV-2555: In some embodiments, the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m is adjacent to a 3'-wing region that structurally begins with a nucleoside moiety that is linked at its 5' end to the last internucleotide linkage of the region comprising a backbone chiral center pattern or repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m. In some embodiments, a region comprising a backbone chiral central pattern or repeating pattern that comprises or is (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m is flanked by 5'-end and 3'-wing regions. In some embodiments, a region comprising a backbone chiral central pattern or repeating pattern that comprises or is (Sp)m(Op)n, (Op)n(Sp)m, (Np)p(Op)n(Sp)m, or (Sp)p(Op)n(Sp)m is flanked by 5'-end and 3'-wing regions. In some embodiments, the flanking 5'-wing region and / or 3'-wing region comprises a non-natural internucleotide linkage. In some embodiments, the flanking 5'-wing region and / or 3'-wing region comprises a chiral internucleotide linkage. In some embodiments, the adjacent 5'-wing region and / or the 3'-wing region comprises a chiral controlled internucleotide linkage. In some embodiments, the adjacent 5'-wing region and / or the 3'-wing region comprises a modified internucleotide linkage comprising an Sp-linked phosphorus. In some embodiments, the adjacent 5'-wing region and / or the 3'-wing region comprises an Sp-phosphorothioate linkage. In some embodiments, the adjacent 5'-wing region and / or the 3'-wing region comprises one or more natural phosphate linkages. In some embodiments, the adjacent 5'-wing region and / or the 3'-wing region comprises one or more consecutive natural phosphate linkages.In some embodiments, the adjacent 5' ends contain only one modified internucleotide linkage that is a 5' terminal internucleotide linkage and one or more consecutive natural phosphate linkages (e.g., in WV-2555. In some embodiments, the adjacent 3' termini include only one modified internucleotide linkage that is a 3' terminal internucleotide linkage and one or more consecutive natural phosphate linkages (e.g., in WV-2555, JPEG2024105256000019.jpg1177). In some embodiments, the adjacent 5'-wing region and / or 3'-wing region comprises a 2'-modified sugar unit. In some embodiments, each sugar unit in the 5'-wing region and / or 3'-wing region is independently modified. In some embodiments, each sugar unit in the 5'-wing region and / or 3'-wing region independently comprises a 2'-modification (e.g., m, 2'-OMe:mA in WV-2555). * SmGmCmUmU * SC * ST * ST * SG * ST * SC * SC * RA * SG * SC * SmUmUmUmA * In some embodiments, each sugar unit in the 5'-wing region and / or the 3'-wing region comprises the same 2'-modification. In some embodiments, the 2'-modification is 2'-OR, where R is an optionally substituted C 1~6 In some embodiments, the 2'-modification is aliphatic. In some embodiments, the 2'-modification is 2'-OMe. In some embodiments, the 2'-modification is 2'-MOE. In some embodiments, the 2'-modification is an LNA modification (which includes a type of C2-C4 bridge).

[0156] In some embodiments, n is 1 to 10. In some embodiments, n is 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, n is 1. In some embodiments, n is 2, 3, 4, 5, 6, 7, or 8. In some embodiments, n is 3, 4, 5, 6, 7, or 8. In some embodiments, n is 4, 5, 6, 7, or 8. In some embodiments, n is 5, 6, 7, or 8. In some embodiments, n is 6, 7, or 8. In some embodiments, n is 7 or 8. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.

[0157] In some embodiments, n is 1. In some embodiments, m is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, m is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, p is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, m is at least 2. In some embodiments, p is at least 2. In some embodiments, n is 1. In some embodiments, m is at least 2, p is at least 2, and n is 1. In some embodiments, p is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, each of m and p is independently at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, each of m and p is independently 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, at least one of m and p is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, m is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, p is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0158] In some embodiments, p is 0 to 50. In some embodiments, p is 1 to 50. In some embodiments, p is 1. In some embodiments, p is 2 to 50. In some embodiments, p is 2, 3, 4, 5, 6, 7, or 8. In some embodiments, p is 3, 4, 5, 6, 7, or 8. In some embodiments, p is 4, 5, 6, 7, or 8. In some embodiments, p is 5, 6, 7, or 8. In some embodiments, p is 6, 7, or 8. In some embodiments, p is 7 or 8. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8. In some embodiments, p is 9. In some embodiments, p is 10. In some embodiments, p is 11. In some embodiments, p is 12. In some embodiments, p is 13. In some embodiments, p is 14. In some embodiments, p is 15. In some embodiments, p is 16. In some embodiments, p is 17. In some embodiments, p is 18. In some embodiments, p is 19. In some embodiments, p is 20. In some embodiments, p is 21. In some embodiments, p is 22. In some embodiments, p is 23. In some embodiments, p is 24. In some embodiments, p is 25. In some embodiments, p is at least 2. In some embodiments, p is at least 3. In some embodiments, p is at least 4. In some embodiments, p is at least 5. In some embodiments, p is at least 6. In some embodiments, p is at least 7. In some embodiments, p is at least 8. In some embodiments, p is at least 9. In some embodiments, p is at least 10.In some embodiments, p is at least 11. In some embodiments, p is at least 12. In some embodiments, p is at least 13. In some embodiments, p is at least 14. In some embodiments, p is at least 15. In some embodiments, p is at least 16. In some embodiments, p is at least 17. In some embodiments, p is at least 18. In some embodiments, p is at least 19. In some embodiments, p is at least 20. In some embodiments, p is at least 21. In some embodiments, p is at least 22. In some embodiments, p is at least 23. In some embodiments, p is at least 24. In some embodiments, p is at least 25.

[0159] In some embodiments, m is 0 to 50. In some embodiments, m is 1 to 50. In some embodiments, m is 1. In some embodiments, m is 2 to 50. In some embodiments, m is 2, 3, 4, 5, 6, 7, or 8. In some embodiments, m is 3, 4, 5, 6, 7, or 8. In some embodiments, m is 4, 5, 6, 7, or 8. In some embodiments, m is 5, 6, 7, or 8. In some embodiments, m is 6, 7, or 8. In some embodiments, m is 7 or 8. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, m is 12. In some embodiments, m is 13. In some embodiments, m is 14. In some embodiments, m is 15. In some embodiments, m is 16. In some embodiments, m is 17. In some embodiments, m is 18. In some embodiments, m is 19. In some embodiments, m is 20. In some embodiments, m is 21. In some embodiments, m is 22. In some embodiments, m is 23. In some embodiments, m is 24. In some embodiments, m is 25. In some embodiments, m is at least 2. In some embodiments, m is at least 3. In some embodiments, m is at least 4. In some embodiments, m is at least 5. In some embodiments, m is at least 6. In some embodiments, m is at least 7. In some embodiments, m is at least 8. In some embodiments, m is at least 9.In some embodiments, m is at least 10. In some embodiments, m is at least 11. In some embodiments, m is at least 12. In some embodiments, m is at least 13. In some embodiments, m is at least 14. In some embodiments, m is at least 15. In some embodiments, m is at least 16. In some embodiments, m is at least 17. In some embodiments, m is at least 18. In some embodiments, m is at least 19. In some embodiments, m is at least 20. In some embodiments, m is at least 21. In some embodiments, m is at least 22. In some embodiments, m is at least 23. In some embodiments, m is at least 24. In some embodiments, m is at least 25. In some embodiments, m is greater than at least 25.

[0160] In some embodiments, at least one of m and p is greater than 2. In some embodiments, at least one of m and p is greater than 3. In some embodiments, at least one of m and p is greater than 4. In some embodiments, at least one of m and p is greater than 5. In some embodiments, at least one of m and p is greater than 6. In some embodiments, at least one of m and p is greater than 7. In some embodiments, at least one of m and p is greater than 8. In some embodiments, at least one of m and p is greater than 9. In some embodiments, at least one of m and p is greater than 10. In some embodiments, at least one of m and p is greater than 11. In some embodiments, at least one of m and p is greater than 12. In some embodiments, at least one of m and p is greater than 13. In some embodiments, at least one of m and p is greater than 14. In some embodiments, at least one of m and p is greater than 15. In some embodiments, at least one of m and p is greater than 16. In some embodiments, at least one of m and p is greater than 17. In some embodiments, at least one of m and p is greater than 18. In some embodiments, at least one of m and p is greater than 19. In some embodiments, at least one of m and p is greater than 20. In some embodiments, at least one of m and p is greater than 21. In some embodiments, at least one of m and p is greater than 22. In some embodiments, at least one of m and p is greater than 23. In some embodiments, at least one of m and p is greater than 24. In some embodiments, at least one of m and p is greater than 25.

[0161] In some embodiments, each of m and p is greater than 2. In some embodiments, each of m and p is greater than 3. In some embodiments, each of m and p is greater than 4. In some embodiments, each of m and p is greater than 5. In some embodiments, each of m and p is greater than 6. In some embodiments, each of m and p is greater than 7. In some embodiments, each of m and p is greater than 8. In some embodiments, each of m and p is greater than 9. In some embodiments, each of m and p is greater than 10. In some embodiments, each of m and p is greater than 11. In some embodiments, each of m and p is greater than 12. In some embodiments, each of m and p is greater than 13. In some embodiments, each of m and p is greater than 14. In some embodiments, each of m and p is greater than 15. In some embodiments, each of m and p is greater than 16. In some embodiments, each of m and p is greater than 17. In some embodiments, each of m and p is greater than 18. In some embodiments, each of m and p is greater than 19. In some embodiments, each of m and p is greater than 20.

[0162] In some embodiments, the sum of m and p is greater than 3. In some embodiments, the sum of m and p is greater than 4. In some embodiments, the sum of m and p is greater than 5. In some embodiments, the sum of m and p is greater than 6. In some embodiments, the sum of m and p is greater than 7. In some embodiments, the sum of m and p is greater than 8. In some embodiments, the sum of m and p is greater than 9. In some embodiments, the sum of m and p is greater than 10. In some embodiments, the sum of m and p is greater than 11. In some embodiments, the sum of m and p is greater than 12. In some embodiments, the sum of m and p is greater than 13. In some embodiments, the sum of m and p is greater than 14. In some embodiments, the sum of m and p is greater than 15. In some embodiments, the sum of m and p is greater than 16. In some embodiments, the sum of m and p is greater than 17. In some embodiments, the sum of m and p is greater than 18. In some embodiments, the sum of m and p is greater than 19. In some embodiments, the sum of m and p is greater than 20. In some embodiments, the sum of m and p is greater than 21. In some embodiments, the sum of m and p is greater than 22. In some embodiments, the sum of m and p is greater than 23. In some embodiments, the sum of m and p is greater than 24. In some embodiments, the sum of m and p is greater than 25.

[0163] In some embodiments, n is 1, and at least one of m and p is greater than 1. In some embodiments, n is 1, and each of m and p is independently greater than 1. In some embodiments, m>n and p>n. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)2Rp(Sp)2. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)2Rp(Sp)2. In some embodiments, (Sp)p(Rp)n(Sp)m is SpRp(Sp)2. In some embodiments, (Np)p(Rp)n(Sp)m is (Np)tRp(Sp)m. In some embodiments, (Np)p(Rp)n(Sp)m is (Np)2Rp(Sp)m. In some embodiments, (Np)p(Rp)n(Sp)m is (Rp)2Rp(Sp)m. In some embodiments, (Np)p(Rp)n(Sp)m is (Sp)2Rp(Sp)m. In some embodiments, (Np)p(Rp)n(Sp)m is RpSpRp(Sp)m. In some embodiments, (Np)p(Rp)n(Sp)m is SpRpRp(Sp)m.

[0164] In some embodiments, (Sp)p(Rp)n(Sp)m is SpRpSpSp. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)2Rp(Sp)2. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)3Rp(Sp)3. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)4Rp(Sp)4. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)tRp(Sp)5. In some embodiments, (Sp)p(Rp)n(Sp)m is SpRp(Sp)5. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)2Rp(Sp)5. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)3Rp(Sp)5. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)4Rp(Sp)5. In some embodiments, (Sp)p(Rp)n(Sp)m is (Sp)5Rp(Sp)5.

[0165] In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)2Rp(Sp)2. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)3Rp(Sp)3. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)4Rp(Sp)4. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)mRp(Sp)5. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)2Rp(Sp)5. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)3Rp(Sp)5. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)4Rp(Sp)5. In some embodiments, (Sp)m(Rp)n(Sp)p is (Sp)5Rp(Sp)5.

[0166] In some embodiments, the provided oligonucleotides are blockmirs. In some embodiments, the provided oligonucleotides are altmers. In some embodiments, the provided oligonucleotides are altmers comprising alternating blocks. In some embodiments, blockmirs or altmers can be defined by chemical modifications (presence or absence), such as base modifications, sugar modifications, internucleotide linkage modifications, stereochemistry, etc., or patterns thereof. Exemplary chemical modifications, stereochemistry, and patterns thereof of blocks and / or alternating units include, but are not limited to, those described herein, such as those described for oligonucleotides. In some embodiments, the blockmir comprises a ..SS..RR..SS..RR.. pattern. In some embodiments, the altmer comprises a SRSRSRSR pattern.

[0167] In some embodiments, the backbone chiral center pattern provided comprises repeating (Sp)m(Rp)n, (Rp)n(Sp)m, (Np)p(Rp)n(Sp)m, or (Sp)p(Rp)n(Sp)m units. In some embodiments, the repeating unit is (Sp)m(Rp)n. In some embodiments, the repeating unit is SpRp. In some embodiments, the repeating unit is SpSpRp. In some embodiments, the repeating unit is SpRpRp. In some embodiments, the repeating unit is RpRpSp. In some embodiments, the repeating unit is (Rp)n(Sp)m. In some embodiments, the repeating unit is (Np)p(Rp)n(Sp)m. In some embodiments, the repeating unit is (Sp)p(Rp)n(Sp)m.

[0168] In some embodiments, the oligonucleotides of the present disclosure are those described in U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 19267 9, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, WO 2018 / 098264 (each of which is independently incorporated herein by reference).

[0169] The product oligonucleotides and compositions thereof are useful for many purposes, such as those described in U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, WO 2018 / 098264, and the like. In some embodiments, product oligonucleotides and compositions thereof prepared by the provided technology are those described in U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, WO 2017 / 015555, WO 2017 / 015575, WO 2017 / 062862, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, WO 2018 / 098264, etc. In some embodiments, the product oligonucleotides and compositions thereof can regulate the level and / or function of various products of nucleic acid sequences. In some embodiments, the product oligonucleotides and compositions, particularly chiral controlled oligonucleotides and compositions, are useful for treating various diseases. In some embodiments, the present disclosure provides pharmaceutically acceptable salts of the oligonucleotides. In some embodiments, the oligonucleotide compositions are pharmaceutical compositions.

[0170] In some embodiments, the final product composition is a chiral controlled oligonucleotide composition of WV-887, WV-892, WV-896, WV-1714, WV-2444, WV-2445, WV-2526, WV-2527, WV-2528, WV-2530, WV-2531, WV-2578, WV-2580, WV-2587, WV-3047, WV-3152, WV-3472, WV-3473, WV-3507, WV-3508, WV-3509, WV-3510, WV-3511, WV-3512, WV-3513, WV-3514, WV-3515, WV-3545, or WV-3546. In some embodiments, the final product composition is a chiral controlled oligonucleotide composition of WV-2603, WV-2595, WV-1510, WV-2378, WV-2380, WV-1092, WV-1497, WV-1085, WV-1086, or WV-2623.

[0171] In some embodiments, the provided techniques include labeling oligonucleotides, for example, with isotopes. In some embodiments, the provided oligonucleotides contain increased levels of one or more isotopes. In some embodiments, the provided oligonucleotides are labeled, for example, with one or more isotopes of one or more elements, such as hydrogen, carbon, nitrogen, etc. In some embodiments, the provided oligonucleotides in the provided compositions, for example, the first plurality of oligonucleotides, comprise one or more base modifications, sugar modifications, and / or internucleotide linkage modifications, wherein the oligonucleotides contain enhanced levels of isotopes. In some embodiments, the isotope is deuterium. In some embodiments, a hydrogen in the sugar is replaced with deuterium (e.g., at the 2' position of a 2'-deoxy). In some embodiments, a hydrogen in a base is replaced with deuterium. In some embodiments, a hydrogen in an internucleotide linkage is replaced with deuterium. In some embodiments, the provided oligonucleotides are labeled with deuterium (- 1 H- 2In some embodiments, the oligonucleotide is labeled (by replacing hydrogen with deuterium). In some embodiments, replacing hydrogen with deuterium can improve the stability, activity, bioavailability, ease of use, convenience, efficacy, and / or systemic exposure of the oligonucleotide. In some embodiments, one or more of the oligonucleotides or any moieties conjugated to the oligonucleotide (e.g., targeting moieties, lipids, etc.) can be labeled. 1 H 2 H. Such oligonucleotides can be used in any of the compositions or methods described herein. In some embodiments, oligonucleotides targeting HTT comprise one or more isotopes. In some embodiments, oligonucleotides targeting dystrophin comprise one or more isotopes.

[0172] Chiral Auxiliaries In some embodiments, the provided techniques are particularly useful for preparing chiral-controlled oligonucleotide compositions with high crude purity and / or yield. In some embodiments, chiral-controlled (stereocontrolled / stereoselective) oligonucleotide synthesis typically uses a chiral auxiliary to control the stereochemistry of the resulting linker phosphorus chiral center. In some embodiments, the present disclosure provides compounds that can be used as chiral auxiliary agents for oligonucleotide synthesis, such as compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof.

[0173] In some embodiments, the present disclosure provides a compound of formula I: JPEG2024105256000020.jpg1677, wherein: L is a covalent bond or an optionally substituted C 1~6 alkylene, wherein one or more methylene units are optionally and independently replaced by -L'-; Each L' is independently a covalent bond, an optionally substituted divalent C 1~3 Alkylene, -C(R 3 )(R4 )-, -C(R 3 )(R 4 )-C(R 3 )(R 4 )-, -Cy- or -C(R 3 )[C(R 4 )3]- and; R 1 , R 2 , R 3 , R 4 and R 5 each independently represents -H, -L s -R, halogen, -CN, -NO2, -L s -Si(R)3, -OR, -SR or -N(R)2; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(O and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-; and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P ...O-, or -OP(OR')[B(R')3]O-. L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -CO2R, or -SO2R; R 6 is R'; R 7 is —OH or —SH; R 1 , R 2 , R 3 and R 4 At least one of is not -H; Each R is independently -H or C 1~30 C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0174] In some embodiments, L is a covalent bond. In some embodiments, provided compounds are JPEG2024105256000021.jpg1277 or a salt thereof. 5 and R 1 and R 2 and together with their intervening atoms form an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms. 1 and R 2 One of them is R 5 and together with their intervening atoms form an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms. As broadly described in this disclosure, the ring formed can be a monocyclic, bicyclic, or polycyclic ring of various sizes and can contain various numbers of heteroatoms. In some embodiments, the ring is a 3-membered ring. In some embodiments, the ring is a 4-membered ring. In some embodiments, the ring is a 5-membered ring. In some embodiments, the ring is a 6-membered ring. In some embodiments, the ring is a monocyclic ring. In some embodiments, the ring contains additional ring heteroatoms other than the intervening heteroatoms. In some embodiments, the ring is a 3-membered ring containing one ring heteroatom. In some embodiments, the ring is a 3-membered ring containing two ring heteroatoms. In some embodiments, the ring is a 3-membered ring containing one carbon, one nitrogen, and one oxygen ring atom.

[0175] In some embodiments, L is —C(R 3 )(R 4 In some embodiments, provided compounds have formula Ia: JPEG2024105256000022.jpg1577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula I has the structure of Formula Ia. In some embodiments, the compound provided is JPEG2024105256000023.jpg1477, or a salt thereof, wherein each variable is independently as described in this disclosure;4 and R 5 is not hydrogen.

[0176] In some embodiments, provided compounds have formula (Ia-1): JPEG2024105256000024.jpg1677, or a salt thereof, wherein each variable is independently as described in this disclosure; 4 and R 5 is not hydrogen and R 2 is R 1 In some embodiments, the compound of Formula Ia has the structure of Formula Ia-1.

[0177] In some embodiments, provided compounds have formula (Ia-2): JPEG2024105256000025.jpg1677, or a salt thereof, wherein each variable is independently as described in this disclosure; 4 and R 5 is not hydrogen and R 2 is R 1 In some embodiments, the compound of Formula Ia has the structure of Formula Ia-2.

[0178] In some embodiments, R 6 is —H. In some embodiments, R 6 is -H, and R 4 and R 5 taken together with their intervening atoms form an optionally substituted 3- to 20-membered heterocyclyl ring having 1-5 heteroatoms. 4 and R 5together with their intervening atoms, form an optionally substituted 4-10 membered heterocyclyl ring containing the intervening nitrogen atom as the only ring heteroatom. In some embodiments, the ring formed is a 3-membered ring. In some embodiments, the ring formed is a 4-membered ring. In some embodiments, the ring formed is a 5-membered ring. In some embodiments, the ring formed is a 6-membered ring. In some embodiments, the ring formed is a 7-membered ring. In some embodiments, the ring formed is substituted. In some embodiments, the ring formed is unsubstituted. In some embodiments, the ring formed is a monocyclic ring. In some embodiments, the ring formed is a bicyclic ring. In some embodiments, the ring formed is a polycyclic ring. In some embodiments, the ring formed is saturated. In some embodiments, the ring formed is R 5 has no ring heteroatoms other than the nitrogen to which it is attached.

[0179] In some embodiments, R 1 and R 2 At least one of R is not hydrogen. 1 is hydrogen and R 2 is not hydrogen. 1 is not hydrogen and R 2 is hydrogen. In some embodiments, R 1 and R 2 None of the is hydrogen.

[0180] In some embodiments, R 1 and R 2 One of is -H and the other is R, where R is not hydrogen. 1 and R 2 one of which is -H and the other is optionally substituted C 1~6 In some embodiments, R 1 and R 2 one of which is -H and the other is optionally substituted C 1~4 In some embodiments, R1 and R 2 one of which is -H and the other is optionally substituted C 1~3 In some embodiments, R 1 and R 2 one of which is -H and the other is optionally substituted C 1~2 In some embodiments, R 1 and R 2 one of which is -H and the other is optionally substituted C 1~6 In some embodiments, R is alkenyl. 1 and R 2 One of R is —H and the other is vinyl. 1 and R 2 one of which is -H and the other is optionally substituted C 1~6 In some embodiments, R is alkynyl. 1 and R 2 One of R is -H and the other is ethynyl. 1 and R 2 One of R is -H and the other is optionally substituted benzyl. 1 and R 2 One of R is -H and the other is benzyl, where the phenyl group of the benzyl is optionally substituted. 1 is -H, and R 2 is benzyl. In some embodiments, R 1 is -H, and R 2 is —R, where R is as described in this disclosure and is not hydrogen. 2 is optionally replaced by C 1~6 In some embodiments, R 2 is an optionally substituted -CH-CPhMe. In some embodiments, R 2 is -CH2-CPh2Me. In some embodiments, R 2is optionally substituted phenyl. In some embodiments, R 2 is optionally substituted benzyl. In some embodiments, provided compounds are JPEG2024105256000026.jpg1077 or a salt thereof.

[0181] In some embodiments, R 1 is not -H and R 2 is not —H. In some embodiments, R 1 and R 2 is independently R, wherein R is not —H. In some embodiments, R 1 is optionally replaced by C 1~6 It is aliphatic and R 2 is optionally substituted phenyl. In some embodiments, R 1 is methyl and R 2 is phenyl.

[0182] In some embodiments, R 1 and R 2 One of is R, wherein R comprises a ring moiety. In some embodiments, R is C 3~20 alicyclic, C 6~20 In some embodiments, R is an optionally substituted group selected from aryl, 5-20 membered heteroaryl having 1-5 heteroatoms, and 3-20 membered heterocyclyl having 1-5 heteroatoms. 3~20 In some embodiments, R is an optionally substituted C 3~10 In some embodiments, R is an optionally substituted C 3~10 In some embodiments, R is an optionally substituted C 4~10In some embodiments, R is cycloalkyl. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is optionally substituted cyclohexyl. In some embodiments, R is optionally substituted cycloheptyl. In some embodiments, R is cyclopropyl. In some embodiments, R is cyclobutyl. In some embodiments, R is cyclopentyl. In some embodiments, R is cyclohexyl. In some embodiments, R is cycloheptyl. In some embodiments, R is optionally substituted C 6~20 In some embodiments, R is an optionally substituted 5-20 membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is an optionally substituted 5-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is an optionally substituted 3-20 membered heterocyclyl having 1-5 heteroatoms. In some embodiments, R 1 and R 2 and the other is R, wherein R is not hydrogen. In some embodiments, R is an optionally substituted C 1~6 In some embodiments, R is an optionally substituted C 1~6 In some embodiments, R is C 1~6 In some embodiments, R is alkyl. In some embodiments, R is methyl. In some embodiments, R is substituted methyl. In some embodiments, R is ethyl. In some embodiments, R is substituted ethyl. In some embodiments, R 1 and R 2One of the is an R that includes a cyclic moiety as described in this disclosure, and the other is an alkyl group as described in this disclosure.

[0183] In some embodiments, R 1 and R 2 Each of is independently R, wherein R is an optionally substituted C 1~20 In some embodiments, R is an unsubstituted C 1~20 In some embodiments, R is an optionally substituted C 1~20 In some embodiments, R is an optionally substituted C alkyl. 1~6 In some embodiments, R is a straight chain C alkyl. 1~6 In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~6 alkyl, and the other is optionally substituted C 1~6 In some embodiments, R 1 and R 2 are the same as. In some embodiments, R 1 and R 2 It is different from.

[0184] In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~6 alkyl, and the other is optionally substituted C 1~6 In some embodiments, R is alkenyl. 1 and R 2 One of R is optionally substituted methyl or ethyl, and the other is vinyl. 1 and R 2 One of the groups is methyl and the other is vinyl.

[0185] In some embodiments, R 1 and R 2 One of them is optionally replaced by C1~6 alkyl, and the other is optionally substituted C 1~6 In some embodiments, R is alkynyl. 1 and R 2 One of R is optionally substituted methyl or ethyl, and the other is ethynyl. 1 and R 2 One of these is methyl and the other is ethynyl.

[0186] In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~6 alkyl, and the other is optionally substituted C 1~6 In some embodiments, R 1 and R 2 is replaced with the same optional C 1~6 In some embodiments, R 1 and R 2 is replaced with the same optional C 1~2 alkyl, and R 1 and R 2 contains no more than two carbon atoms. 1 and R 1 and R are both methyl. 1 and R 1 and R are both ethyl. 1 and R 1 and R are both isopropyl. 1 and R 2 One of them is optionally replaced by C 1~3 one being a straight chain alkyl, the other being an optionally substituted C 3~10 In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~3 one being a straight chain alkyl, the other being an optionally substituted C 5~6 In some embodiments, R1 is methyl. In some embodiments, R 2 is cyclopentyl. In some embodiments, R 2 is cyclohexyl. In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~3 and the other is an optionally substituted benzyl. 1 is methyl and R 2 is optionally substituted benzyl. In some embodiments, R 2 is benzyl. In some embodiments, R 2 is p-CH3O-C6H4-CH2-. In some embodiments, R 1 is selected from methyl, ethyl, cyclohexyl, and benzyl optionally substituted at the phenyl. 2 is selected from methyl, ethyl, cyclohexyl, and benzyl optionally substituted at the phenyl. 1 and R 2 wherein each is independently selected from methyl, ethyl, cyclohexyl, and benzyl optionally substituted at the phenyl. In some embodiments, provided compounds are JPEG2024105256000027.jpg2277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000028.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000029.jpg1177 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000030.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000031.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000032.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000033.jpg1177 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000034.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000035.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000036.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000037.jpg1077 or a salt thereof.

[0187] In some embodiments, R 1 and R 2 One of them is optionally replaced by C 1~6 alkyl and the other is optionally substituted phenyl. 1 is methyl and R 2 is optionally substituted phenyl. In some embodiments, R 1 is methyl and R 2 is phenyl. In some embodiments, R 1 is methyl and R 2 teeth, JPEG2024105256000038.jpg1177. In some embodiments, provided compounds are JPEG2024105256000039.jpg1477 or a salt thereof. In some embodiments, provided compounds are selected from JPEG2024105256000040.jpg1577 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000041.jpg1477 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000042.jpg1477 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000043.jpg1477 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000044.jpg1477 or a salt thereof.

[0188] In some embodiments, R 1 and R 2 is independently R, where R is an optionally substituted aryl group. In some embodiments, R 1 and R 2 is independently an optionally substituted phenyl. In some embodiments, R 1 and R 2 is phenyl. In some embodiments, provided compounds are JPEG2024105256000045.jpg1277 or a salt thereof.

[0189] In some embodiments, R 1 and R 2 are taken together with the carbon atoms to which they are attached to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms. 1 and R 2are taken together with the carbon atoms to which they are attached to form an optionally substituted 3- to 7-membered monocyclic ring having no heteroatoms. In some embodiments, the monocyclic ring formed is a 3-membered ring; in some embodiments, a 4-membered ring; in some embodiments, a 5-membered ring; in some embodiments, a 6-membered ring; in some embodiments, a 7-membered ring; in some embodiments, an 8-membered ring; in some embodiments, a 9-membered ring; and in some embodiments, a 10-membered ring. In some embodiments, the ring formed is a monocyclic ring. In some embodiments, the ring formed is a bicyclic ring. In some embodiments, the ring formed is a polycyclic ring. In some embodiments, the ring formed is aliphatic. In some embodiments, the ring formed does not contain unsaturation. In some embodiments, the ring formed is saturated, partially unsaturated, and / or partially aromatic, for example, a bicyclic or polycyclic ring containing fused saturated, partially unsaturated, and / or aromatic moieties. In some embodiments, the ring formed is substituted. In some embodiments, the ring formed is unsubstituted. In some embodiments, R 1 and R 2 The carbon to which R is attached is not chiral. 1 and R 2 and are the same and the carbon to which they are attached is not chiral. 1 and R 2 The ring formed by R together with the carbon atom to which they are attached does not introduce asymmetry, and R 1 and R 2 The carbon atom to which R is attached is not chiral. 1 and R 2 and the carbon to which they are attached is chiral. 1 and R 2 The ring formed by R together with the carbon atom to which they are attached introduces asymmetry, 1 and R 2 is attached is not chiral. JPEG2024105256000046.jpg1477 and salts thereof. In some embodiments, provided compounds are JPEG2024105256000047.jpg1477 and salts thereof. In some embodiments, provided compounds are JPEG2024105256000048.jpg1377 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000049.jpg1377 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000050.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000051.jpg1377 or a salt thereof.

[0190] In some embodiments, R 4 and R 5 together with their intervening atoms, form an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms. In some embodiments, the ring formed is a 3-membered ring. In some embodiments, the ring formed is a 4-membered ring. In some embodiments, the ring formed is a 5-membered ring. In some embodiments, the ring formed is a 6-membered ring. In some embodiments, the ring formed is a 7-membered ring. In some embodiments, the ring formed is an 8-membered ring. In some embodiments, the ring formed is a 9-membered ring. In some embodiments, the ring formed is a 10-membered ring. In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 1-5 heteroatoms. 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R5 In some embodiments, R 3 is -H, and R 4 and R 5 together with their intervening atoms form the nitrogen atom (R 5 In some embodiments, R 4 and R 5 The ring formed by R together with their intervening atoms is substituted. 4 and R 5 The ring formed by R together with their intervening atoms is unsubstituted. 4 and R 5 The ring formed by R together with their intervening atoms is a monocyclic ring. 4 and R 5 The ring formed by R together with their intervening atoms is a bicycle. 1 and R 2 One of the two and R 3 and R 4or one of the rings, together with their intervening atoms, forms an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-5 heteroatoms. In some embodiments, the ring formed is a 3 membered ring. In some embodiments, the ring formed is a 4 membered ring. In some embodiments, the ring formed is a 5 membered ring. In some embodiments, the ring formed is a 6 membered ring. In some embodiments, the ring formed is a 7 membered ring. In some embodiments, the ring formed is substituted. In some embodiments, the ring formed is unsubstituted. In some embodiments, the ring formed is a monocyclic ring. In some embodiments, the ring formed is a bicyclic ring. In some embodiments, the ring formed is a polycyclic ring. In some embodiments, the ring formed has no additional heteroatoms beyond the intervening atoms. In some embodiments, the ring formed has additional ring heteroatoms in addition to the intervening atoms. Exemplary rings that may be formed are described extensively in this disclosure. In some embodiments, provided compounds are JPEG2024105256000052.jpg3777 and salts thereof. In some embodiments, provided compounds are JPEG2024105256000053.jpg1477 and salts thereof. In some embodiments, provided compounds are JPEG2024105256000054.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000055.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000056.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000057.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000058.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000059.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000060.jpg1177 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000061.jpg1477 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000062.jpg1377 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000063.jpg1277 or a salt thereof.

[0191] In some embodiments, R 1 and R 2 One or two of the following are R 3 , R 4 and R 5 together with intervening atoms to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms. 1 and R 2 One or two of the following are R 3 and R 4 together with one or two of the intervening atoms to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms. 1 and R 2 One or two of the following are R 5 and together with the intervening atoms form an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms. 1 and R 2 One or two of the following are R 5 , R 3 and R 4together with one or two of the intervening atoms to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 1-5 heteroatoms. 1 and R 2 One or two of the following are R 5 , R 3 and R 4 together with one or two of the intervening atoms to form an optionally substituted 6- to 20-membered bicyclic or polycyclic ring having 1 to 5 heteroatoms. 1 and R 2 One or two of the following are R 5 , R 3 and R 4 together with one or two of the intervening atoms to form an optionally substituted 8-20 membered bicyclic or polycyclic ring having 1-5 heteroatoms. 1 and R 2 One of them is R 5 , R 3 and R 4 and together with the intervening atoms form an optionally substituted 8-20 membered bicyclic or polycyclic ring having 1-5 heteroatoms. 1 and R 2 One of them is R 5 , R 3 and R 4 and the intervening atoms to form an optionally substituted 8- to 20-membered bicyclic ring having 1-5 heteroatoms. In some embodiments, the ring formed is an 8-membered ring. In some embodiments, the ring formed is a 9-membered ring.

[0192] In some embodiments, R 5 is R 1 and R 2 and together with their intervening atoms form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 1-5 heteroatoms. 5 is R 3 and R4 and their intervening atoms together form an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms. Exemplary rings formed are described extensively in this disclosure. In some embodiments, the ring formed is a 3-membered ring. In some embodiments, the ring formed is a 4-membered ring. In some embodiments, the ring formed is a 5-membered ring. In some embodiments, the ring formed is a 6-membered ring. In some embodiments, R 5 is R 1 , R 2 , R 3 or R 4 and do not together form an optionally substituted ring. 5 is optionally replaced by C 1~6 In some embodiments, R 5 is optionally replaced by C 1~6 In some embodiments, R 5 is the unsubstituted C 1~6 In some embodiments, R 5 is methyl. In some embodiments, R 5 is ethyl. In some embodiments, R 5 is isopropyl.

[0193] In some embodiments, provided compounds are JPEG2024105256000064.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000065.jpg1177 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000066.jpg1277 or a salt thereof.

[0194] In some embodiments, L is -L'-C(R 3 )(R 4In some embodiments, provided compounds have formula Ib: JPEG2024105256000067.jpg1577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula I has the structure of Formula Ib.

[0195] In some embodiments, L' is a covalent bond. In some embodiments, L' is -C(R 3 )(R 4 In some embodiments, provided compounds have formula Ic: JPEG2024105256000068.jpg1577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula I has the structure of Formula Ic.

[0196] In some embodiments, R on C 3 and R 4 One of them is R 5 and together with their intervening atoms form a nitrogen atom (R 5 In some embodiments, R on C3 forms an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 3 and R 4 One of them is R 5 and together with their intervening atoms form a nitrogen atom (R 5 In some embodiments, R on C2 forms an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 3 and R 4 One of the two and R on C3 3 and R 4 and R 1 and R 2 together with their intervening atoms form an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-5 heteroatoms. 3 and R 4together with its carbon atoms form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms. 3 and R 4 together with C2 form an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-5 heteroatoms. 3 and R 4 together with C3 form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms. For example, R 3 / R 4 and R 5 , R 3 / R 4 and R 3 / R 4 Exemplary such ring moieties formed by, etc., are described extensively in this disclosure and can be, for example, 4-membered, 5-membered, 6-membered, 7-membered, monocyclic, bicyclic, polycyclic, substituted, unsubstituted, with additional ring heteroatoms (beyond intervening atoms), with no additional ring heteroatoms, combinations thereof, etc.

[0197] In some embodiments, R on C 3 is hydrogen. In some embodiments, R on C 4 is hydrogen. In some embodiments, R on C 3 is hydrogen. In some embodiments, R on C 4 is hydrogen. In some embodiments, R on C 3 and R 4 and R on C are both hydrogen. 3 and R 4 and R on C2 are both hydrogen. 3 and R 4 Both R on C3 3 and R 4 In some embodiments, one of the R on C is hydrogen. 3 and R 4 Both R on C23 and R 4 One of the atoms is hydrogen.

[0198] In some embodiments, provided compounds are JPEG2024105256000069.jpg1077 or a salt thereof.

[0199] In some embodiments, L is -Cy-. In some embodiments, provided compounds have formula Id: JPEG2024105256000070.jpg1677 or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula I has the structure of Formula Id. In some embodiments, -Cy- is 1,2-divalent. In some embodiments, -Cy- is an optionally substituted cycloalkylene. In some embodiments, -Cy- is an optionally substituted JPEG2024105256000071.jpg877. In some embodiments, -Cy- is optionally substituted JPEG2024105256000072.jpg977.

[0200] In some embodiments, R 1 and R 2 One of the two and R 3 and R 4 is R and, together with their intervening atoms, form an optionally substituted 3-20 membered ring having 1-10 heteroatoms as described in this disclosure, e.g., ring A as described herein. In some embodiments, provided compounds have formula Ie: JPEG2024105256000073.jpg1677, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula I has the structure of Formula Ie.

[0201] In some embodiments, R 1 and R2 One of the two and R 4 taken together with their intervening atoms form an optionally substituted 3- to 20-membered ring having 1-5 heteroatoms. 3 is -H, and R 1 and R 2 One of the two and R 4 taken together with their intervening atoms form an optionally substituted 3- to 20-membered ring having 1-5 heteroatoms. 2 and R 4taken together with their intervening atoms form an optionally substituted ring (e.g., Formula Ie). In some embodiments, the ring formed, e.g., ring A in Formula Ie, is a 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered ring. In some embodiments, the ring formed is a 3-membered ring. In some embodiments, the ring formed is a 4-membered ring. In some embodiments, the ring formed is a 5-membered ring. In some embodiments, the ring formed is a 6-membered ring. In some embodiments, the ring formed is a 7-membered ring. In some embodiments, the ring formed is an 8-membered ring. In some embodiments, the ring formed is a 9-membered ring. In some embodiments, the ring formed is a 10-membered ring. In some embodiments, the ring formed is a monocyclic ring. In some embodiments, the ring formed is a bicyclic ring. In some embodiments, the ring formed is a polycyclic ring. In some embodiments, the ring formed is saturated. In some embodiments, the ring formed is partially unsaturated. In some embodiments, the ring formed does not have a heteroatom. In some embodiments, the ring formed is an optionally substituted 3-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 4-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 5-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 6-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 7-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 8-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 9-membered saturated aliphatic ring. In some embodiments, the ring formed is an optionally substituted 10-membered saturated aliphatic ring.

[0202] In some embodiments, R 3 is -H, and R 1 is optionally replaced by C 1~6 aliphatic or phenyl, R 5is optionally replaced by C 1~6 It is aliphatic and R 6 is —H. In some embodiments, R 3 is -H, and R 1 and R 5 taken together with their intervening atoms form an optionally substituted ring; R 6 is —H. In some embodiments, R 3 is -H, and R 1 and R 5 together with their intervening atoms form an optionally substituted 5- or 6-membered ring; R 6 is —H. In some embodiments, R 3 is -H, and R 1 and R 5 together with their intervening atoms form R 5 forms an optionally substituted 5-membered saturated ring with no heteroatoms other than the nitrogen to which R is attached, 6 is —H. In some embodiments, R 3 is -H, and R 1 and R 5 together with their intervening atoms form R 5 forms an optionally substituted 6-membered saturated ring with no heteroatoms other than the nitrogen to which it is attached, and R 6 is —H. In some embodiments, R 1 and R 5 together form a ring that is unsubstituted.

[0203] In some embodiments, —OH and —N(R 5 )(R 6 ) is trans. In some embodiments, —OH and —N(R 5 )(R 6 ) is cis. In some embodiments, R 1 and the carbon to which —OH is attached is R. In some embodiments, R 1 and the carbon to which —OH is attached is S. In some embodiments, R 1 is hydrogen. In some embodiments, R1 is not hydrogen. 1 is optionally replaced by C 1~6 In some embodiments, R 1 is methyl. In some embodiments, R 1 is phenyl. In some embodiments, R 3 is hydrogen. In some embodiments, R 5 is hydrogen. In some embodiments, R 5 is not hydrogen. 5 is optionally replaced by C 1~6 In some embodiments, R 5 is methyl. In some embodiments, R 5 is phenyl. In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is not hydrogen. In some embodiments, as demonstrated by certain exemplary data, trans —OH and —N(R 5 )(R 6 ) can provide high yields and / or diastereoselectivities. In some embodiments, as demonstrated by certain exemplary data, compounds containing trans -OH and -N(R 5 )(R 6 ) can provide both high yields and diastereoselectivities.

[0204] In some embodiments, provided compounds, e.g., compounds of formula Ie, are JPEG2024105256000074.jpg1177 and salts thereof. In some embodiments, provided compounds are JPEG2024105256000075.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000076.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000077.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000078.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000079.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000080.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000081.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000082.jpg1377 or a salt thereof. In some embodiments, provided compounds are selected from: JPEG2024105256000083.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000084.jpg1077 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000085.jpg977 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000086.jpg1277 or a salt thereof. In some embodiments, provided compounds are JPEG2024105256000087.jpg1277 or a salt thereof.

[0205] In some embodiments, provided compounds have Formula II: JPEG2024105256000088.jpg1477, or a salt thereof, wherein: Ring A is an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; R 1, R 2 , R 3 , R 4 and R 5 each independently represents -H, -L s -R, halogen, -CN, -NO2, -L s -Si(R)3, -OR, -SR or -N(R)2; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6 Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)( and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-, and one or more carbon atoms are optionally and independently replaced by: Cy L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; t is 0 to 20; R 6 is R'; R 8 -LR 7 , -LC(R 1 )(R 2 )-R 7 or -L s -R 7 and; R 7 is —OH or —SH; L is a covalent bond or an optionally substituted C 1~6 alkylene, wherein one or more methylene units are optionally and independently replaced by -L'-; L' is a covalent bond, an optionally substituted divalent C 1~3 Alkylene, -C(R 3 )(R 4 )-, -C(R 3 )(R 4 )-C(R 3 )(R 4 )-, -Cy- or -C(R 3 )[C(R 4 )3]- and; Each R is independently -H or C 1~30C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0206] In some embodiments, provided compounds have formula II-a: JPEG2024105256000089.jpg1577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula II has the structure of Formula II-a.

[0207] In some embodiments, provided compounds of structure II-a have formula II-b: JPEG2024105256000090.jpg1577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula II-a has the structure of Formula II-b.

[0208] In some embodiments, provided compounds of structure II-a have formula II-c: JPEG2024105256000091.jpg1777, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula II-a has the structure of Formula II-c.

[0209] In some embodiments, R 8 is —OH. In some embodiments, R 6 is —H. In some embodiments, R 5 is optionally substituted alkyl. In some embodiments, R 5 In some embodiments, t is 0. In some embodiments, R 3 is optionally substituted alkyl. In some embodiments, R 3 is methyl. In some embodiments, R 3 is optionally substituted phenyl. In some embodiments, R 3 is phenyl. In some embodiments, R 3 is optionally replaced by C 3~10 In some embodiments, R 3 is optionally substituted cyclohexyl. In some embodiments, R 3 is cyclohexyl.

[0210] In some embodiments, ring A is an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, ring A is or includes at least one monocyclic saturated or partially unsaturated monocyclic moiety, optionally as part of a bicyclic or polycyclic system. In some embodiments, ring A is a monocyclic ring. In some embodiments, ring A is a bicyclic or polycyclic ring containing at least one monocyclic saturated or partially unsaturated monocyclic moiety and optionally one or more aromatic monocyclic moieties. In some embodiments, ring A is or includes at least one saturated monocyclic moiety. In some embodiments, R 8 is the sp of ring A 3 In some embodiments, R 8 is the sp of ring A 3 is linked to a carbon ring atom. 3 is the sp of ring A 3 In some embodiments, R 3 is the sp of ring A 3 In some embodiments, —N(R 5 )(R 6 ) is the sp of ring A 3 In some embodiments, —N(R 5 )(R 6 ) is the sp of ring A 3 It is connected to a carbon ring atom.

[0211] In some embodiments, ring A is an optionally substituted C 3~10 In some embodiments, Ring A is optionally substituted cyclohexyl. In some embodiments, Ring A is cyclohexyl. In some embodiments, R 8 and -N(R 5 )(R 6 ) is cis. In some embodiments, R 8 and -N(R 5 )(R 6) is trans. In some embodiments, compounds of formula II are provided JPEG2024105256000092.jpg1877 and salts thereof.

[0212] In some embodiments, the compound provided is compound II-c or a salt thereof. 3 and R 5 is R and taken together to form a ring that is optionally substituted as described in this disclosure. In some embodiments, compounds of formula II are provided that JPEG2024105256000093.jpg1277 and salts thereof.

[0213] In some embodiments, provided compounds, such as compounds of Formula I, have Formula III: JPEG2024105256000094.jpg1477, or a salt thereof, wherein: Ring A' is an optionally substituted 3- to 20-membered monocyclic, bicyclic, or polycyclic ring having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, wherein Ring A' is -N(R 6 )-includes part; R 1 , R 2 , R 3 and R 4 each independently represents -H, -L s -R, halogen, -CN, -NO2, -L s -Si(R)3, -OR, -SR or -N(R)2; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(O and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-; and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P ...O-, or -OP(OR')[B(R')3]O-. L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; t is 0 to 20; R 6 is R'; R 8 -LR 7 , -LC(R 1 )(R 2 )-R 7 or -L s -R 7 and; R 7 is —OH or —SH; L is a covalent bond or an optionally substituted C 1~6 alkylene, wherein one or more methylene units are optionally and independently replaced by -L'-; L' is a covalent bond, an optionally substituted divalent C 1~3 Alkylene, -C(R 3 )(R 4 )-, -C(R 3 )(R 4 )-C(R 3 )(R 4 )-, -Cy- or -C(R 3 )[C(R 4 )3]- and; Each R is independently -H or C 1~30 C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0214] In some embodiments, provided compounds have formula III-a: JPEG2024105256000095.jpg1377, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula III has the structure of Formula III-a.

[0215] In some embodiments, provided compounds have formula III-b: JPEG2024105256000096.jpg1477, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula III-a has the structure of Formula III-b.

[0216] In some embodiments, R 8 is -N(R 6 )-(N 1 ) adjacent to the nitrogen atom (C 2 ) (e.g., Formula III-a, Formula III-b, etc.). In some embodiments, R 8 is C 2 (C 3 ) is attached to the carbon atom adjacent to R 8 is C 2 (C 4 ) not C 3In some embodiments, R 8 is C 3 (C 5 ) not C 4 In some embodiments, R 8 is C 4 (C 6 ) not C 5 is attached to the carbon atom adjacent to

[0217] In some embodiments, R 8 is —OH. In some embodiments, R 6 is —H. In some embodiments, R 5 is optionally substituted alkyl. In some embodiments, R 5 In some embodiments, t is 0. In some embodiments, R 3 is optionally substituted alkyl. In some embodiments, R 3 is methyl. In some embodiments, R 3 is optionally substituted phenyl. In some embodiments, R 3 is phenyl. In some embodiments, R 3 is optionally replaced by C 3~10 In some embodiments, R 3 is optionally substituted cyclohexyl. In some embodiments, R 3 is cyclohexyl.

[0218] In some embodiments, Ring A' is an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, wherein Ring A' is -N(R 6)-moiety. In some embodiments, Ring A' is Ring A as described in this disclosure, wherein Ring A comprises a nitrogen ring atom. In some embodiments, Ring A' is or comprises at least one monocyclic saturated or partially unsaturated monocyclic moiety, optionally as part of a bicyclic or polycyclic system. In some embodiments, Ring A' is a monocyclic ring. In some embodiments, Ring A' is a bicyclic or polycyclic ring comprising at least one monocyclic saturated or partially unsaturated monocyclic moiety and optionally one or more aromatic monocyclic moieties. In some embodiments, Ring A' is or comprises at least one saturated monocyclic moiety. In some embodiments, R 8 is the sp of ring A' 3 In some embodiments, R 8 is the sp of ring A' 3 is linked to a carbon ring atom. 3 is the sp of ring A' 3 In some embodiments, R 3 is the sp of ring A' 3 is linked to a carbon ring atom. 6 The nitrogen to which is bonded is sp 3 is.

[0219] In some embodiments, provided compounds of formula III are JPEG2024105256000097.jpg1277 and salts thereof. In some embodiments, the compound of Formula III provided is selected from the compounds and salts thereof listed in Table 4 below. JPEG2024105256000098.jpg10977JPEG2024105256000099.jpg10677JPEG2024105256000100.jpg9877JPEG2024105256 000101.jpg10877JPEG2024105256000102.jpg10677JPEG2024105256000103.jpg10677JPEG2024105256000104.jpg9877 JPEG2024105256000105.jpg10677JPEG2024105256000106.jpg10277JPEG2024105256000107.jpg10777JPEG2024105256 000108.jpg10077JPEG2024105256000109.jpg10377JPEG2024105256000110.jpg10077JPEG2024105256000111.jpg3577

[0220] In some embodiments, a provided compound is an enantiomer of a compound selected from Table 1 or a salt thereof. In some embodiments, a provided compound is a diastereomer of a compound selected from Table 1 or a salt thereof. JPEG2024105256000112.jpg6377JPEG2024105256000113.jpg10577JPEG2024105256 000114.jpg10077JPEG2024105256000115.jpg10377JPEG2024105256000116.jpg8377

[0221] In some embodiments, a provided compound is an enantiomer or a salt thereof of a compound selected from Table 2. In some embodiments, a provided compound is a diastereomer or a salt thereof of a compound selected from Table 2. JPEG2024105256000117.jpg11077JPEG2024105256000118.jpg6777

[0222] In some embodiments, a provided compound is an enantiomer or a salt thereof of a compound selected from Table 3. In some embodiments, a provided compound is a diastereomer or a salt thereof of a compound selected from Table 3. JPEG2024105256000119.jpg2577JPEG2024105256000120.jpg9877JPEG2024105256000121.jpg10477JPEG20241052560 00122.jpg10277JPEG2024105256000123.jpg10677JPEG2024105256000124.jpg10077JPEG2024105256000125.jpg1277

[0223] In some embodiments, a provided compound is an enantiomer of a compound selected from Table 4 or a salt thereof. In some embodiments, a provided compound is a diastereomer of a compound selected from Table 4 or a salt thereof.

[0224] In some embodiments, provided compounds, such as compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, contain one or more chiral elements. In some embodiments, provided compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, are chiral. In some embodiments, provided chiral compounds, such as compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, have a purity as described in this disclosure. In some embodiments, provided chiral compounds, compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, are stereopurified as described herein. In some embodiments, provided chiral compounds, compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, are diastereomeric purified as described herein. In some embodiments, provided chiral compounds, compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or salts thereof, are enantiomeric purified as described herein. In some embodiments, provided chiral compounds, compounds of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a or III-b, or salts thereof, are of diastereomeric and enantiomeric purity as described herein.In some embodiments, the present disclosure provides a compound made of a compound of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, or a salt thereof, and including a chiral element of a compound of Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, or III-b, such as a compound of Formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, VI-e, VIII, or a salt thereof.

[0225] Methods for preparing chiral auxiliary compounds are widely known in the art and can be utilized in this disclosure. A large number of compounds have been prepared and characterized, including many in this table. Many of the compounds described herein can provide high stereoselectivity and / or purity when used as chiral auxiliaries.

[0226] Phosphoramidites In many embodiments, chiral auxiliaries are used to prepare chirally pure phosphoramidites, which are used to stereoselectively form the linking phosphorus chiral center compared to the absence of the chiral auxiliary. In some embodiments, the present disclosure provides compounds that can be used as phosphoramidites for oligonucleotide synthesis, such as compounds of formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, IVa-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e, or salts thereof. In some embodiments, the product oligonucleotides may contain one or more natural phosphate linkages and / or chiral internucleotide linkages that are not chiral controlled, and such linkages allow for the easy use of phosphoramidites for conventional oligonucleotide synthesis. As those skilled in the art will understand, nucleic acid base can be blocked in phosphoramidite for oligonucleotide synthesis, and can be deblocked after, for example, synthesis cycle.The blocking and deblocking (protection) technology of nucleic acid base is widely known in the art and can be used in the present disclosure.In the present disclosure, the preparation technology of phosphoramidite can be used.Exemplary techniques include those described in U.S. Patent Application Publication No. 2015100197, U.S. Patent No. 9744183, U.S. Patent No. 9605019, U.S. Patent No. 9394333, U.S. Patent No. 8859755, U.S. Patent Application Publication No. 20130178612, U.S. Patent No. 8470987, U.S. Patent No. 8822671, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20170037399, International Publication No. 2017 / 015555, International Publication No. No. 017 / 015575, WO 2017 / 062862, U.S. Pat. No. 9,403,865, WO 2017 / 160741, WO 2017 / 192664, WO 2017 / 192679, WO 2017 / 210647, WO 2018 / 022473, WO 2018 / 067973, WO 2018 / 098264, etc. As indicated, in some embodiments, the phosphoramidite is DPSE-phosphoramidite containing JPEG2024105256000126.jpg977.

[0227] For example, in some embodiments, the present disclosure provides compounds of formula IV: JPEG2024105256000127.jpg1877, or a salt thereof, wherein: P L is P(=W), P or P→B(R')3; W is O, S or Se; L is a covalent bond or an optionally substituted C 1~6 alkylene, wherein one or more methylene units are optionally and independently replaced by -L'-; L' is a covalent bond, an optionally substituted divalent C 1~3 Alkylene, -C(R 3 )(R 4 )-, -C(R 3 )(R 4)-C(R 3 )(R 4 )-, -Cy- or -C(R 3 )[C(R 4 )3]- and; R 1 , R 2 , R 3 , R 4 and R 5 each independently represents -H, -L s -R, halogen, -CN, -NO2, -L s -Si(R)3, -OR, -SR or -N(R)2; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(O and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-; and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P ...O-, or -OP(OR')[B(R')3]O-. L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; L 7 is -O- or -S-; R 1 , R 2 , R 3 and R 4 At least one of is not -H; BA is C 3~30 Alicyclic and C 6~30 C having aryl and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 5~30 Heteroaryl and C having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 3~30 an optionally substituted group selected from heterocyclyl, natural nucleobase moieties, and modified nucleobase moieties; SU is -L s -O- or JPEG2024105256000128.jpg1177, where SU is linked to the phosphorus atom via an oxygen atom; Each R s are independently -H, halogen, -CN, -N3, -NO, -NO2, -L s -R', -L s -Si(R)3, -L s -OR', -L s -SR', -L s -N(R')2, -OL s -R', -OL s -Si(R)3, -OL s -OR', -OL s -SR' or -OL s -N(R')2; t is 0 to 20; Ring A s is an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; R 5s is R s and; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; Each R is independently -H or C 1~30 C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0228] In some embodiments, P L is P(=W). In some embodiments, P L is P. In some embodiments, P L is P→B(R′). In some embodiments, P L In some embodiments, P is chiral. L In some embodiments, P is Rp. LThe P in is Sp.

[0229] In some embodiments, SU is -L s In some embodiments, SU is JPEG2024105256000129.jpg1177, wherein each variable is independently as described in this disclosure. JPEG2024105256000130.jpg1477, R 1s , R 2s , R 3s , R 4s and R 5s Each of the groups independently represents R s In some embodiments, the SU is JPEG2024105256000131.jpg1677, wherein each variable is independently as described in this disclosure. JPEG2024105256000132.jpg1677, wherein each variable is independently as described in this disclosure. JPEG2024105256000133.jpg1677, wherein each variable is independently as described in this disclosure. JPEG2024105256000134.jpg1377, wherein each variable is independently as described in this disclosure. JPEG2024105256000135.jpg1477, where each variable is independently as described in this disclosure.

[0230] In some embodiments, provided compounds, such as compounds of formula IV, have formula IV-a: JPEG2024105256000136.jpg2177 or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of formula IV is provided having the structure of formula IV-a. In some embodiments, L s is -Cy-. In some embodiments, L s is an optionally substituted monocyclic or bicyclic 3- to 20-membered heterocyclyl ring having 1 to 5 heteroatoms. s is an optionally substituted monocyclic or bicyclic 5-20 membered heterocyclyl ring having 1-5 heteroatoms, where at least one heteroatom is oxygen. s is an optionally substituted divalent tetrahydrofuran ring. In some embodiments, L s is an optionally substituted furanose moiety. In some embodiments, BA in formula IV-a is attached to C1 of the furanose moiety, and -O- in formula IV-a is attached to C3.

[0231] In some embodiments, provided compounds, such as compounds of formula IV, have formula IV-b: JPEG2024105256000137.jpg2477, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula IV has the structure of Formula IV-b.

[0232] In some embodiments, provided compounds, such as compounds of formula IV, have formula IV-c-1: JPEG2024105256000138.jpg2577, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula IV has the structure of Formula IV-c-1.

[0233] In some embodiments, provided compounds, such as compounds of formula IV, have formula IV-c-2: JPEG2024105256000139.jpg2477, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula IV has the structure of Formula IV-c-2.

[0234] In some embodiments, provided compounds, e.g., compounds of formula IV, have formula IV-d: JPEG2024105256000140.jpg2477, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula IV has the structure of Formula IV-d.

[0235] In some embodiments, provided compounds, such as compounds of formula IV, have formula IV-e: JPEG2024105256000141.jpg2477, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula IV has the structure of Formula IV-e.

[0236] In some embodiments, a compound of formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, or IV-e can be prepared from a compound of formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. JPEG2024105256000142.jpg1177 is as described for Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. In some embodiments, the compound of Formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, or IV-e is JPEG2024105256000143.jpg1077 has a structure such that it is a compound having the structure of I, Ia, Ia-1, Ia-2, Ib, Ic, Id or Ie, or a salt thereof.

[0237] In some embodiments, the present disclosure provides a compound of formula IVa: JPEG2024105256000144.jpg1777, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the present disclosure provides a compound having the structure of Formula IVa-a: JPEG2024105256000145.jpg1977, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-a. In some embodiments, the present disclosure provides a compound of formula IVa-b: JPEG2024105256000146.jpg2277, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-b. In some embodiments, the present disclosure provides a compound of formula IVa-c-1: JPEG2024105256000147.jpg2477, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-c-1. In some embodiments, the present disclosure provides a compound of formula IVa-c-2: JPEG2024105256000148.jpg2377, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-c-2. In some embodiments, the present disclosure provides a compound of formula IVa-d: JPEG2024105256000149.jpg2377, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-d. In some embodiments, the present disclosure provides a compound of formula IVa-e: JPEG2024105256000150.jpg2477, or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the compound of formula IVa is a compound of formula IVa-e. In some embodiments, L 7 is —O—. In some embodiments, R 1 , R 5 and R 6 each independently represents an optionally substituted C 1~6 In some embodiments, R 5 and R 6 are the same. In some embodiments, P L is P. In some embodiments, -L 7 -R 1 does not contain a chiral element. In some embodiments, —N(R 5 )(R 6 ) does not contain a chiral element. 7 -R 1 and -N(R 5 )(R 6 ) does not contain a chiral element. 7 -R 1 is —O—CHCH—CN. In some embodiments, —N(R 5 )(R 6 ) is -N(i-Pr)2. In some embodiments, the compound of formula IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, or IVa-e, or a salt thereof, is a phosphoramidite for non-chiral controlled oligonucleotide synthesis, e.g., oligonucleotide synthesis using conventional phosphoramidite chemistry. In some embodiments, R 1 and R 5is R and, together with their intervening atoms, forms a ring as described in the present disclosure. In some embodiments, the ring formed contains a chiral element, and compounds of formula IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, or IVa-e, or salts thereof, can be utilized in chiral-controlled oligonucleotide synthesis.

[0238] In some embodiments, the present disclosure provides a compound of formula V: JPEG2024105256000151.jpg1577, wherein: P L is P(=W), P or P→B(R')3; W is O, S or Se; Ring A is an optionally substituted 3-20 membered monocyclic, bicyclic, or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; R 1 , R 2 , R 3 , R 4 and R 5 each independently represents -H, -L s -R, halogen, -CN, -NO2, -L s -Si(R)3, -OR, -SR or -N(R)2; Each L s are independently a covalent bond or C 1~30 C having an aliphatic group and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 and heteroaliphatic groups, wherein one or more methylene units are optionally and independently selected from C 1~6 Alkylene, C 1~6Alkenylene, -C≡C-, a divalent C1-C6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R')2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(O and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR')[B(R')3]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R')3]O-; and one or more carbon atoms are optionally and independently replaced by an optionally substituted group selected from: -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P ...O-, or -OP(OR')[B(R')3]O-. L Replaced by; Each -Cy- is independently C 3~20 Alicyclic ring and C 6~20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each Cy L are independently, C 3~20 Alicyclic ring and C 6~20 an optionally substituted tetravalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; t is 0 to 20; L 8 -LO-, -LC(R 1 )(R 2 )-O- or -L s -O-; L is a covalent bond or an optionally substituted C 1~6 alkylene, wherein one or more methylene units are optionally and independently replaced by -L'-; L' is a covalent bond, an optionally substituted divalent C 1~3 Alkylene, -C(R 3 )(R 4 )-, -C(R 3 )(R 4 )-C(R 3 )(R 4 )-, -Cy- or -C(R 3 )[C(R 4 )3]- and; BA is C 3~30 Alicyclic and C 6~30 C having aryl and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 5~30 Heteroaryl and C having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 3~30 an optionally substituted group selected from heterocyclyl, natural nucleobase moieties, and modified nucleobase moieties; SU is -L s -O- or JPEG2024105256000152.jpg1277, where SU is linked to the phosphorus atom via an oxygen atom; R 5s is R s and; Each R s are independently -H, halogen, -CN, -N3, -NO, -NO2, -L s -R', -L s -Si(R)3, -L s -OR', -L s -SR', -L s -N(R')2, -OL s -R', -OL s -Si(R)3, -OLs -OR', -OL s -SR' or -OL s -N(R')2; Ring A s is an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O)R; Each R is independently -H or C 1~30 C having an aliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 1~30 Heteroaliphatic and C 6~30 Aryl and C 6~30 C having arylaliphatic and 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon 6~30 an optionally substituted group selected from arylheteroaliphatic, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or two R groups optionally and independently join to form a covalent bond, or two or more R groups on the same atom optionally and independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic, or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or Two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3- to 30-membered monocyclic, bicyclic, or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.

[0239] In some embodiments, P Lis P(=W). In some embodiments, P L is P. In some embodiments, P L is P→B(R′). In some embodiments, P L In some embodiments, P is chiral. L In some embodiments, P is Rp. L The P in is Sp.

[0240] In some embodiments, provided compounds, for example compounds of formula V, have the formula Va: JPEG2024105256000153.jpg1677, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula V is provided having the structure of Formula Va.

[0241] In some embodiments, provided compounds, for example compounds of formula V, have formula Vb: JPEG2024105256000154.jpg2077, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula V is provided having the structure of Formula Vb.

[0242] In some embodiments, provided compounds, for example compounds of formula V, have the formula Vc-1: JPEG2024105256000155.jpg2277, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula V has the structure of Formula Vc-1.

[0243] In some embodiments, provided compounds, for example compounds of formula V, have formula Vc-2: JPEG2024105256000156.jpg2177, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula V is provided having the structure of Formula Vc-2.

[0244] In some embodiments, provided compounds, for example compounds of formula V, have formula Vd: JPEG2024105256000157.jpg2177, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula V has the structure of Formula Vd.

[0245] In some embodiments, provided compounds, for example compounds of formula V, have the formula Ve: JPEG2024105256000158.jpg2277, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a compound of Formula V is provided having the structure of Formula Ve.

[0246] In some embodiments, a compound of formula V, Va, Vb, Vc-1, Vc-2, Vd, or Ve can be prepared from a compound of formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. JPEG2024105256000159.jpg1177 is as described for Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. In some embodiments, the compound of Formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, or IV-e is JPEG2024105256000160.jpg1277 has a structure such that it is a compound having structure II, II-a or II-b.

[0247] In some embodiments, the present disclosure provides a compound of formula VI: JPEG2024105256000161.jpg1377, or a salt thereof, is provided, wherein each variable is independently as described in this disclosure.

[0248] In some embodiments, provided compounds, for example compounds of formula VI, have formula VI-a: JPEG2024105256000162.jpg1377 or a salt thereof, wherein ring A' is P L and ring A comprising the ring nitrogen atom bonded to P of formula VI, wherein each variable is independently as described in this disclosure. In some embodiments, the provided compound of formula VI has the structure of formula VI-a.

[0249] In some embodiments, provided compounds, for example compounds of formula VI, have formula VI-b: JPEG2024105256000163.jpg1977, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula VI is provided having the structure of Formula VI-b.

[0250] In some embodiments, provided compounds, for example compounds of formula VI, have the formula VI-c-1: JPEG2024105256000164.jpg2177, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula VI is provided having the structure of Formula VI-c-1.

[0251] In some embodiments, provided compounds, for example compounds of formula VI, have formula VI-c-2: JPEG2024105256000165.jpg2177, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula VI is provided having the structure of Formula VI-c-2.

[0252] In some embodiments, provided compounds, for example compounds of formula VI, have formula VI-d: JPEG2024105256000166.jpg2077, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, the compound of Formula VI is provided having the structure of Formula VI-d.

[0253] In some embodiments, provided compounds, for example compounds of formula VI, have formula VI-e: JPEG2024105256000167.jpg2077, or a salt thereof, wherein each variable is independently as described in this disclosure. In some embodiments, a provided compound of Formula VI has the structure of Formula VI-e.

[0254] In some embodiments, a compound of formula VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e can be prepared from a compound of formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. JPEG2024105256000168.jpg1077 is as described for Formula I, Ia, Ia-1, Ia-2, Ib, Ic, Id, Ie, II, II-a, II-b, III, III-a, III-b, etc. In some embodiments, the compound of Formula VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e is JPEG2024105256000169.jpg1077 has a structure such that it is a compound having structure III, III-a or III-b.

[0255] In some embodiments, the phosphoramidite has the structure of formula IV, IV-a, IV-b, IV-c-1, IV-c-2, IV-d, IV-e, IVa, IVa-a, IVa-b, IVa-c-1, IVa-c-2, IVa-d, IVa-e, V, Va, Vb, Vc-1, Vc-2, Vd, Ve, VI, VI-a, VI-b, VI-c-1, VI-c-2, VI-d, or VI-e, or a salt thereof; Lis P.

[0256] In some embodiments, the phosphoramidite for non-stereocontrolled coupling has the structure JPEG2024105256000170.jpg1777, where each variable is independently as described in this disclosure.

[0257] Nucleic acid bases In some embodiments, the nucleobase, e.g., BA, in the provided oligonucleotide is a natural nucleobase (e.g., adenine, cytosine, guanosine, thymine, or uracil) or a modified nucleobase derived from a natural nucleobase, e.g., adenine, cytosine, guanosine, thymine, or uracil, or a tautomeric form thereof, which is optionally substituted. Examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine, and tautomeric forms thereof, each of which has its amino group protected by one or more protecting groups, e.g., -R, -C(O)R, etc. Exemplary protecting groups are widely known in the art and can be used in the present disclosure. In some embodiments, the protected nucleobase and / or derivative is selected from the nucleobase containing one or more acyl protecting groups, pyrimidine analogues such as 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pseudoisocytosine and pseudouracil, and other modified nucleobases, such as 8-substituted purine, xanthine or hypoxanthine (the latter two are natural degradation products).Exemplary modified nucleobases are also disclosed in Chiu and Rana, RNA, 2003, 9, 1034-1048, Limbach et al. Nucleic Acids Research, 1994, 22, 2183-2196 and Revankar and Rao, Comprehensive Natural Products Chemistry, vol.7, 313.In some embodiments, the modified nucleobase is substituted uracil, thymine, adenine, cytosine or guanine. In some embodiments, the modified nucleobase is a functional replacement for uracil, thymine, adenine, cytosine or guanine, for example, in terms of hydrogen bonding and / or base pairing.In some embodiments, the nucleobase is optionally substituted uracil, thymine, adenine, cytosine, 5-methylcytosine or guanine.In some embodiments, the nucleobase is uracil, thymine, adenine, cytosine, 5-methylcytosine or guanine.

[0258] In some embodiments, the modified base is an optionally substituted adenine, cytosine, guanine, thymine, or uracil. In some embodiments, the modified nucleobases are independently: (1) the nucleobase is modified by one or more optionally substituted groups independently selected from acyl, halogen, amino, azido, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, heteroaryl, carboxyl, hydroxyl, biotin, avidin, streptavidin, substituted silyl, and combinations thereof; (2) one or more atoms of the nucleobase are independently replaced with another atom selected from carbon, nitrogen, or sulfur; (3) one or more double bonds in the nucleobase are independently hydrogenated; or (4) one or more optionally substituted aryl or heteroaryl rings are independently inserted into the nucleobase; The amino acid sequence is adenine, cytosine, guanine, thymine, or uracil modified by one or more modifications such that the amino acid sequence is adenine, cytosine, guanine, thymine, or uracil.

[0259] Compounds represented by the following general formula are also contemplated as modified nucleobases: JPEG2024105256000171.jpg4777In formula, R 8N is an optionally substituted straight or branched group selected from aliphatic, aryl, aralkyl, aryloxylalkyl, carbocyclyl, heterocyclyl, and heteroaryl, each having 1 to 30 carbon atoms and, where applicable, 1 to 10 heteroatoms, including, by way of example only, methyl, isopropyl, phenyl, benzyl, or phenoxymethyl groups; R 9N and R 10N each independently is an optionally substituted group selected from straight-chain or branched aliphatic, carbocyclyl, aryl, heterocyclyl, and heteroaryl, each having 1 to 30 carbon atoms and 1 to 10 heteroatoms.

[0260] Modified nucleobases also include the expanded nucleobases that are added with one or more aryl rings, such as phenyl rings.It is contemplated that the replacement of nucleobases described in Glen Research Catalog (www.glenresearch.com);Krueger AT et al.,Acc.Chem.Res.,2007,40,141-150;Kool,ET,Acc.Chem.Res.,2002,35,936-943;Benner SA,et al.,Nat.Rev.Genet.,2005,6,553-543;Romesberg,FE,et al.,Curr.Opin.Chem.Biol.,2003,7,723-733;Hirao,I.,Curr.Opin.Chem.Biol.,2006,10,622-627 is useful for synthesizing certain provided compounds in the present disclosure. Some examples of such extended size nucleobases are shown below. JPEG2024105256000172.jpg4677

[0261] Modified nucleobases are not considered to be typical nucleobases, but also include structures that are other moieties, such as, but not limited to, corrin-derived rings or porphyrin-derived rings. Porphyrin-derived base replacements are described in Morales-Rojas, H and Kool, ET, Org. Lett., 2002, 4, 4377-4380. The following are examples of porphyrin-derived rings that can be used as base replacements: JPEG2024105256000173.jpg2577

[0262] In some embodiments, the modified nucleobase is any one of the following structures, optionally substituted: JPEG2024105256000174.jpg2677

[0263] In some embodiments, the modified nucleobase is fluorescent. Examples of such fluorescent modified nucleobases include phenanthrene, pyrene, stilbene, isoxanthine, isoxanthopterin, terphenyl, terthiophene, benzoterthiophene, coumarin, lumazine, tethered stilbene, benzo-uracil, and naphtho-uracil, as shown below. JPEG2024105256000175.jpg6777

[0264] In some embodiments, the modified nucleobase is not substituted. In some embodiments, the modified nucleobase is substituted. In some embodiments, the modified nucleobase is substituted so that it contains, for example, a heteroatom, an alkyl group, or a linking moiety that is linked to a fluorescent moiety, a biotin or avidin moiety, or another protein or peptide. In some embodiments, the modified nucleobase is not a nucleobase in the most classical sense, but is a "universal base" that functions in the same way as a nucleobase. One example of such a universal base is 3-nitropyrrole.

[0265] In some embodiments, other nucleosides can be used in the technology disclosed in the present disclosure, including nucleosides incorporating modified nucleobases or nucleobases covalently linked to modified sugars. Some examples of nucleosides incorporating modified nucleobases include 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 2'-O-methylcytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2'-O-methylpseudouridine, β,D-galactosylqueosine, 2'-O-methylguanosine, N-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 2'-O-methylpyr ... 6 -Isopentenyl adenosine; 1-methyl adenosine; 1-methylpseudouridine; 1-methylguanosine; l-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N 7-Methylguanosine; 3-methyl-cytidine; 5-methylcytidine; 5-hydroxymethylcytidine; 5-formylcytosine; 5-carboxylcytosine; N 6 -Methyladenosine;7-Methylguanosine;5-Methylaminoethyluridine;5-Methoxyaminomethyl-2-thiouridine;β,D-Mannosylqueuosine;5-Methoxycarbonylmethyluridine;5-Methoxyuridine;2-Methylthio-N 6 -isopentenyladenosine; N-((9-β,D-ribofuranosyl-2-methylthiopurin-6-yl)carbamoyl)threonine; N-((9-β,D-ribofuranosylpurin-6-yl)-N-methylcarbamoyl)threonine; uridine-5-oxyacetic acid methyl ester; uridine-5-oxyacetic acid(v); pseudouridine; queusine; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2'-O-methyl-5-methyluridine; and 2'-O-methyluridine.

[0266] In some embodiments, nucleosides include 6'-modified bicyclic nucleoside analogs having either (R) or (S) chirality at the 6'-position, and include the analogs described in U.S. Patent No. 7,399,845. In some embodiments, nucleosides include 5'-modified bicyclic nucleoside analogs having either (R) or (S) chirality at the 5'-position, and include the analogs described in U.S. Patent Application Publication No. 20070287831.

[0267] In some embodiments, the nucleobase or modified nucleobase comprises one or more biomolecule-binding moieties, such as, for example, an antibody, an antibody fragment, biotin, avidin, streptavidin, a receptor ligand, or a chelating moiety. In other embodiments, the nucleobase or modified nucleobase is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. In some embodiments, the nucleobase or modified nucleobase is modified by substitution with a fluorescent or biomolecule-binding moiety. In some embodiments, the substituent on the nucleobase or modified nucleobase is a fluorescent moiety. In some embodiments, the substituent on the nucleobase or modified nucleobase is biotin or avidin.

[0268] Representative U.S. patents that teach the preparation of some of the described modified nucleobases as well as other modified nucleobases include, but are not limited to, the above-mentioned U.S. Pat. No. 3,687,808 as well as U.S. Pat. Nos. 4,845,205; 5,130,300; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,457,191; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594 ,121 specification, 5,596,091 specification; 5,614,617 specification; 5,681,941 specification; 5,750,692 specification; 5,750,692 specification; 6,01 Specification No. 5,886; Specification No. 6,147,200; Specification No. 6,166,197; Specification No. 6,222,025; Specification No. 6,235,887; Specification No. 6,3 Nos. 80,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088 (each of which modified nucleobases, sugars, and internucleotide linkages are incorporated by reference).

[0269] In some embodiments, the base, e.g., BA, is an optionally substituted A, T, C, G, or U, wherein one or more -NH2 is independently and optionally -C(-LR 1 )3, and one or more -NH- are independently and optionally replaced by -C(-LR 1 )2-, and one or more =N- are independently and optionally replaced by -C(-LR 1 )-, one or more =CH- are independently and optionally replaced by =N-, and one or more =O are independently and optionally replaced by =S, =N(-LR 1 ) or =C(-LR 1 )2, where two or more -LR 1 are optionally joined together with their intervening atoms to form a 3-30 membered bicyclic or polycyclic ring having 0-10 heteroatoms. In some embodiments, the modified base is an optionally substituted A, T, C, G, or U, wherein one or more -NH2 are independently and optionally -C(-LR 1 )3, and one or more -NH- are independently and optionally replaced by -C(-LR 1 )2-, and one or more =N- are independently and optionally replaced by -C(-LR 1 )-, one or more =CH- are independently and optionally replaced by =N-, and one or more =O are independently and optionally replaced by =S, =N(-LR 1 ) or =C(-LR 1 )2, where two or more -LR 1 are optionally taken together with their intervening atoms to form a 3-30 membered bicyclic or polycyclic ring having 0-10 heteroatom atoms, wherein the modified base is different from natural A, T, C, G, and U. In some embodiments, the base is an optionally substituted A, T, C, G, or U. In some embodiments, the modified base is a substituted A, T, C, G, or U, wherein the modified base is different from natural A, T, C, G, and U.

[0270] The head of the house, the house, the house, the house, the house, the house, the house, the house of Gryazno, ;Chen,J.-KJAm.Chem.Soc.1994,116,3143;Hendrix et al.1997 Chem.Eur.J.3:110;Hyrup et al.1996 Bioorg.Med.Chem.4:5;Jepsen et al.2004 Oligo.14:130-146;Jones et al.J.Org.Chem.1993,58,2983;Koizumi et al.Nucid et al.2003. Res.12:3267-3273;Koshkin et al.1998 Tetrahedron 54:3607-3630;Kumar et al.1998 Bioo.Med.Chem.Let.8:2219-2222;Lauritsen et al.2002 Chem.Comm.53-53;Lauritsen et al.2003; Bioo.Med.Chem.Lett.13:253-256;Mesmaeker et al.Angew.Chem.,Int.Ed.Engl.1994,33,226;Morita et al.2001 Nucl.Acids Res.Supp.1:241-242;Morita et al.2002 Bioo.Med.Chem.Lett.12:73-76;Morita et al.2003 Bioo.Med.Chem.Lett.2211-2226;Nielsen et al.1997 Chem.Soc.Rev.73;Nielsen et al.1997 J.Chem.Soc.Perkins.Trans.343-333; al.1997 Tetrahedron Lett.38(50):8735-8;Obika et al.1998 Tetrahedron Lett.39:5401-5404;Pallan et al.2012 Chem.Comm.48:8195-8197;Petersen et al.2003 TRENDS Biotech. al.1999 Chem.Commun.1395-1396;Schultz et al.1996 Nucleic Acids Res.24:2966;Seth et al.2009 J.Med.Chem.52:10-13;Seth et al.2010 J.Med.Chem.53:8309-8318;Seth et al.2010 J.Org.Chem.75:1569-1581;Seth et al.2012 Bioo.Med.Chem.Lett.22:296-299;Seth et al.2012 Mol.Ther-Nuc.Acids.1,e47;Seth,Punit P;Siwkowski,Andrew;Allerson,Charles R;Vasquez,Guillermo;Lee,Sam;Prakash,Thazha P;Kinberger,Garth;Migawa,Michael T;Gaus,Hans;Bhat,Balkrishen;et al.From Nucleic Acids Symposium Series(2008),52(1),553-554;Singh et al.1998 Chem.Comm.1247-1248;Singh et al.1998 J.Org.Chem.63:10035-39;Singh et al.1998 J.Org.Chem.63:6078-6079;Sorensen 2003 Chem.Comm.2130-2131;Ts'o et al.Ann.NYAcad.Sci.1988,507,220;Van Aerschot et al.1995 Angew.Chem.Int.Ed.Engl.34:1338;Vasseur et al. al. J. Am. Chem. Soc. 1992, 114, 4006; WO 20070900071; WO 20070900071; and WO 2016 / 079181.

[0271] Exemplary nucleobases are also described in U.S. Patent Application Publication No. 20110294124, U.S. Patent Application Publication No. 20120316224, U.S. Patent Application Publication No. 20140194610, U.S. Patent Application Publication No. 20150211006, U.S. Patent Application Publication No. 20150197540, WO2015107425, PCT / US2016 / 043542, and PCT / US2016 / 043598, the nucleobases of each of which are incorporated herein by reference.

[0272] sugar In some embodiments, provided compounds, e.g., oligonucleotides, comprise one or more modified sugar moieties. In some embodiments, the sugar moiety is: JPEG2024105256000176.jpg1177, wherein each variable is independently as described in this disclosure. In some embodiments, the sugar moiety is: JPEG2024105256000177.jpg1177, where L s is -C(R 5s )2-, wherein each R 5s are independently as described herein. In some embodiments, the sugar moiety is JPEG2024105256000178.jpg1477, wherein each variable is independently as described in this disclosure. In some embodiments, the sugar moiety is: JPEG2024105256000179.jpg1477, where each variable is independently as described in this disclosure. s is -CH(R)-, where R is as described in this disclosure. In some embodiments, R is -H. In some embodiments, R is not -H and L s is -(R)-CH(R)-. In some embodiments, R is not -H and is sIn some embodiments, R is -(S)-CH(R)-. ... 1~6 In some embodiments, R is methyl.

[0273] A variety of sugar modifications are known and can be utilized in the present disclosure. In some embodiments, the sugar modification is a 2'-modification. In some embodiments, the 2'-modification is 2'-F. In some embodiments, the 2'-modification is 2'-OR, where R is not hydrogen. In some embodiments, the 2'-modification is 2'-OR, where R is an optionally substituted C 1~6 In some embodiments, the 2'-modification is 2'-OR, where R is an optionally substituted C 1~6 In some embodiments, the 2'-modification is alkyl. In some embodiments, the 2'-modification is 2'-OMe. In some embodiments, the 2'-modification is 2'-MOE. In some embodiments, the 2'-modification is the LNA sugar modification (C2-O-CH2-C4). In some embodiments, the 2'-modification is (C2-OC(R)2-C4), where each R is independently as described in this disclosure. In some embodiments, the 2'-modification is (C2-O-CHR-C4), where R is as described in this disclosure. In some embodiments, the 2'-modification is (C2-O-(R)-CHR-C4), where R is as described in this disclosure and is not hydrogen. In some embodiments, the 2'-modification is (C2-O-(S)-CHR-C4), where R is as described in this disclosure and is not hydrogen. In some embodiments,...

Claims

1. A method for preparing an oligonucleotide comprising one or more cycles, each of said cycles independently comprising the steps of: (1) a coupling step, comprising contacting a deblocked composition (deblocked oligonucleotide composition) comprising a plurality of deblocked oligonucleotides or nucleosides, each of which is independently deblocked in that it comprises a free hydroxyl group, with a coupling reagent system comprising a partner compound comprising a nucleoside unit; The partner compound has the structure IV-d: (In the formula, teeth, The structure of I-a: or a salt thereof, P L is P; -L 7 is -O-; L is -C(R 3 )(R 4 )-; Each of R 1 and R 2 is independently -H, -L s -R, halogen, -CN, -NO 2 , -L s -Si(R) 3 , -OR, -SR, or -N(R) 2 ; R 3 is —H; R 4 and R 5 together with their intervening atoms form an optionally substituted 3- to 20-membered polycyclic ring having 1-5 heteroatoms; R 6 is —H; -NHR 5 is -NR 5 R 6 as shown in formula Ia; Each L S is independently a covalent bond or a divalent optionally substituted linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1 to 10 heteroatoms, where one or more methylene units are optionally and independently selected from C 1-6 alkylene, C 1-6 alkenylene, -C≡C-, a divalent C 1 -C 6 heteroaliphatic group having 1 to 5 heteroatoms, -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR') [B(R') 3 ]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R') 3 ]O-, and one or more carbon atoms are optionally and independently replaced by Cy L ; each -Cy- is independently an optionally substituted divalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; BA is an optionally substituted group selected from natural nucleobase moieties and modified nucleobase moieties; each of R 2s , R 4s , and R 5s is independently -H, halogen, -CN, -N 3 , -NO, -NO 2 , -L s -R', -L s -Si(R) 3 , -L s -OR', -L s -SR', -L s -N(R') 2 , -O-L s -R', -O-L s -Si(R) 3 , -O-L s -OR', -O-L s -SR', or -O-L s -N(R') 2 , or R 2s and R 4s are R and two R groups together with their intervening atoms form an optionally substituted ring; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O) 2 R; each R is independently -H or an optionally substituted group selected from C1-30 aliphatic, C1-30 heteroaliphatic having 1-10 heteroatoms, C6-30 aryl, C6-30 arylaliphatic, C6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms; two R groups optionally and independently combine to form a covalent bond, or two or more R groups on the same atom optionally, and independently, together with that atom form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms in addition to that atom; or two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms in addition to their intervening atoms; and a coupling step having (2) A pre-modification capping step, the pre-modification capping step comprising: contacting the coupling product composition with a pre-modification capping reagent system; and Capping one or more functional groups of said coupling product composition. Equipped with The pre-modification capping step provides a pre-modification capping product composition comprising a plurality of pre-modification capping product oligonucleotides, The pre-modification capping reagent system includes an acylating agent, the acylating agent having the formula R'-C(O)-L S -R S (In the formula, each R S is independently -H, halogen, -CN, -N 3 , -NO, -NO 2 , -L S-R', -L S-Si(R) 3 , -L S-OR', -L S-SR', -L S-N(R') 2 , -O-L S-R', -O-L S-Si(R) 3 , -O-L S-OR', -O-L S-SR', or -O-L S-N(R') 2 ; Each L S is independently a covalent bond or a divalent optionally substituted linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, where one or more of the methylene units are optionally and independently selected from a C 1-6 alkylene, a C 1-6 alkenylene, -C≡C-, a divalent C 1 -C 6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR') [B(R') 3 ]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R') 3 ]O-, and one or more carbon atoms are optionally and independently replaced by Cy L ; each -Cy- is independently an optionally substituted divalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O) 2 R; each R is independently -H or an optionally substituted group selected from C1-30 aliphatic, C1-30 heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, C6-30 aryl, C6-30 arylaliphatic, C6-30 arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; two R groups optionally and independently combine to form a covalent bond, or two or more R groups on the same atom optionally, and independently, together with that atom form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. The a pre-modification capping step, wherein the capping conditions of said pre-modification capping step are selective or specific for amidation over esterification; (3) a modifying step comprising contacting the coupling product composition or the pre-modification capping product composition with a modifying reagent system comprising a modifying reagent, the modifying step comprising sulfurization, the sulfurization comprising converting a -P(-)- bonded phosphorus atom to a -P(=S)(-)- bonded phosphorus atom; (4) a post-modification capping step; (5) a deblocking step; 23. A method comprising:

2. The method of claim 1, wherein each pre-modification capping step after a coupling step and before a next modification step independently does not contain an esterification catalyst or, if it contains one or more esterification catalysts, the amount of each of the one or more esterification catalysts is independently 0.1 equivalents or less relative to the first nucleoside incorporated into the oligonucleotide.

3. The method of claim 1, wherein each coupling step independently comprises a compound represented by formula VII-b: (In the formula, Each of R 1 and R 5 is independently -H, -L S -R, halogen, -CN, -NO 2 , -L S -Si(R) 3 , -OR, -SR, or -N(R) 2 ; Each of X, Y and Z is independently -O-, -S-, -N(-L S -R 1 )- or L S ; Each L S is independently a covalent bond or a divalent optionally substituted linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, where one or more of the methylene units are optionally and independently selected from a C 1-6 alkylene, a C 1-6 alkenylene, -C≡C-, a divalent C 1 -C 6 heteroaliphatic group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR') [B(R') 3 ]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R') 3 ]O-, and one or more carbon atoms are optionally and independently replaced by Cy L ; each -Cy- is independently an optionally substituted divalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O) 2 R; each R is independently -H or an optionally substituted group selected from C1-30 aliphatic, C1-30 heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, C6-30 aryl, C6-30 arylaliphatic, C6-30 arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; two R groups optionally and independently combine to form a covalent bond, or two or more R groups on the same atom optionally, and independently, together with that atom form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to their intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt form thereof.

4. The method of claim 2, wherein the pre-modification capping reagent system further contains a base.

5. The method of claim 1, wherein the pre-modification capping reagent system is a solution of 2,6-lutidine / Ac 2 O.

6. The method according to claim 1, wherein the modifying reagent system is a sulfurizing reagent system comprising one or more sulfurizing reagents, the sulfurizing reagent system comprising a sulfurizing reagent selected from POS (3-phenyl-1,2,4-dithiazolin-5-one), DDTT (((dimethylamino-methylidene)amino)-3H-1,2,4-dithiazoline-3-thione), DTD (dimethylthialum disulfide), xanthan hydride (XH), S-(2-cyanoethyl)methanesulfonothioate (MTS-CNE) or phenylacetyl disulfide.

7. The method of claim 1, further comprising a post-modification capping step for capping multiple hydroxyl groups.

8. The method of claim 1, wherein the post-modification capping reagent system is a solution of 2,6-lutidine / NMI / Ac 2 O.

9. The method according to claim 1, further comprising a deblocking step utilizing a deblocking reagent system including a deblocking reagent, wherein the deblocking reagent is an acid.

10. The method according to claim 9, a cleavage / deprotection step comprising contacting a plurality of oligonucleotides with one or more cleavage / deprotection reagent systems; The method, wherein said cleavage / deprotection step provides a final product composition comprising a plurality of final product oligonucleotides.

11. The method of claim 1, wherein the final product composition comprising a plurality of final product oligonucleotides is a chiral controlled oligonucleotide composition, the oligonucleotides share the same composition; and said plurality of oligonucleotides comprises at least one chiral controlled internucleotide linkage, said internucleotide linkage being chiral controlled in that said plurality of oligonucleotides share the same stereochemical configuration at a chiral linking phosphorus of said internucleotide linkage; The method of claim 1, wherein at least ((DS)Nc x 100)% of all oligonucleotides sharing the same base sequence in said final product composition are said plurality of oligonucleotides, wherein DS is at least 80% and Nc is the number of chiral controlled internucleotide linkages.

12. The method of claim 11, providing a final product composition having a crude purity of at least 40%, said crude purity being % full-length product.

13. The method of claim 3, wherein -XL S -R 5 has the structure H-XL S -R 5 and is represented by formula Ia: (In the formula, Each of R 1 and R 2 is independently -H, -L S -R, halogen, -CN, -NO 2 , -L S -Si(R) 3 , -OR, -SR, or -N(R) 2 ; R 3 is —H; R 4 and R 5 together with their intervening atoms form an optionally substituted 3- to 20-membered heterocyclyl ring having 1-5 heteroatoms; R 6 is —H; Each L S is independently a covalent bond or a divalent optionally substituted linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1 to 10 heteroatoms, where one or more methylene units are optionally and independently selected from C 1-6 alkylene, C 1-6 alkenylene, -C≡C-, a divalent C 1 -C 6 heteroaliphatic group having 1 to 5 heteroatoms, -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, -P(OR') [B(R') 3 ]-, -OP(O)(OR')O-, -OP(O)(SR')O-, -OP(O)(R')O-, -OP(O)(NR')O-, -OP(OR')O-, -OP(SR')O-, -OP(NR')O-, -OP(R')O-, or -OP(OR')[B(R') 3 ]O-, and one or more carbon atoms are optionally and independently replaced by Cy L ; each -Cy- is independently an optionally substituted divalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 alicyclic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; each R' is independently -R, -C(O)R, -C(O)OR, or -S(O) 2 R; each R is independently -H or an optionally substituted group selected from C1-30 aliphatic, C1-30 heteroaliphatic having 1-10 heteroatoms, C6-30 aryl, C6-30 arylaliphatic, C6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms; two R groups optionally and independently combine to form a covalent bond, or two or more R groups on the same atom optionally, and independently, together with that atom form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms in addition to that atom; or two or more R groups on two or more atoms optionally and independently, taken together with their intervening atoms, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms in addition to their intervening atoms; or a salt thereof.

14. The method of claim 13, wherein R 1 is --H and R 2 is --CH 2 --Si(R) 3 , and each R in --Si(R) 3 is independently not --H.

15. The method of claim 13, wherein R 1 is -H, R 2 is -CH 2 -Si(R) 3 , and each R is independently an optionally substituted group selected from C 1-6 aliphatic and phenyl.

16. The method according to claim 13, wherein H-XL s -R 5 is The method according to claim 1, 17. The method of claim 1, wherein R 1 is --H and R 2 is --CH 2 --Si(R) 3 , and each R in --Si(R) 3 is independently not --H.

18. The method of claim 1, wherein R 1 is -H, R 2 is -CH 2 -Si(R) 3 , and each R is independently an optionally substituted group selected from C 1-6 aliphatic and phenyl.

19. The method of claim 1, teeth, The method according to claim 1, 20. The method of claim 1, teeth, The method according to claim 1, 21. The method according to claim 13, teeth, The method according to claim 1,